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Psychomotor stimulant drugs, such as cocaine and amphetamine-type substances, including 
amphetamine and methamphetamine (METH), are potent central nervous system (CNS) 
stimulants with highly addictive potential. They are widely used and abused around the 
world, generating a staggering burden on society and the individual’s family, yet no specific 
medications have been found to safely facilitate detoxification and promote quicker recovery 
from chronic stimulant abuse. The mainstay pharmacological approach for stimulant 
addiction has largely relied on directly altering neurotransmission of the classic monoamines, 
especially dopamine (DA), which is a key mediator of psychostimulant’s effects. However, 
progress has been hindered by the limited efficaciousness and potential non-specific side 
effects associated with direct manipulation of the DA system. The newly discovered trace 
amine-associated receptor 1 (TAAR1) has gained increasing attention as a novel target for the 
pharmacological development of new addiction treatments. TAAR1 belongs to a family of G 
protein-coupled receptors (GPCRs) and is activated by trace amines (TAs), a group of 
endogenous amines that are intimately related to the classic monoamines. TAAR1 shares 
overlapping CNS distribution with the major monoaminergic pathways and is directly 
activated by some psychostimulants including METH. Early evidence from in vitro 
preparations and in vivo transgenic studies indicated an important role of TAAR1 in the 
regulation of DA transmission and psychostimulant action, leading to the hypothesis that 
pharmacological targeting of TAAR1 may present a promising avenue for addiction 
treatment. However, due to the unavailability of highly selective TAAR1 agonists until very 
recently, a direct assessment of this hypothesis has been difficult. The goal of the present 
thesis is to investigate systematically the potential therapeutic effectiveness of TAAR1-based 
agents in clinically-relevant animal models of addiction. Specifically, we will examine the 
ability of newly generated TAAR1 selective partial and full agonists to modulate key 
abuse-related behavioural and neurochemical effects of cocaine and METH. This is 




findings obtained from the current work provide evidence of highly favourable properties of 
TAAR1 agonists, consistent with an efficacious anti-addiction medication, and support the 
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Chapter One  
1 Psychostimulant Addiction  
1.1 Psychomotor Stimulant and Its Addiction - Concept and Definition   
Psychomotor stimulant drugs, such as cocaine and amphetamine-type substances including 
amphetamine and methamphetamine (METH), are central nervous system (CNS) stimulants 
characterized by their ability to increase alertness and awareness, enhance motivation and 
endurance, stimulate motor activity, and suppress fatigue and sleepiness, as well as reduce 
appetite. In the peripheral nervous system, they produce sympathomimetic effects such as 
increased heart rate and blood pressure, increased respiration rate, and raised body 
temperature (Van Rossum, 1970, Koob and Le Moal, 2005). Acute exposure to these 
substances typically leads to an instant and intense feeling of well-being, self-confidence, and 
euphoria (especially when injected or smoked) (American Psychiatric Association, 2013), as 
well as decreased anxiety, accompanied by enhanced interaction with the environment and 
improved performance (Gawin and Ellinwood Jr, 1989, Drevets et al., 2001). Due to the 
initial positive effects on mental functions, some stimulants have been used clinically at 
relatively low doses for medical purpose. For example, amphetamine has been found to be 
effective in treating attention deficit hyperactivity disorder (ADHD), narcolepsy, obesity, 
chronic fatigue syndrome, and anhedonia associated with refractory depression (Van Rossum, 
1970, Arnsten, 2006, Heal et al., 2013). Likewise, METH is prescribed in the USA, but not in 
Europe, for the treatment of ADHD and obesity (Favrod-Coune and Broers, 2010).  
One key feature of psychomotor stimulants is that they serve as rewards or reinforcers, 
mainly due to their hedonic effects as well other positive influence on mental and physical 
activities, which leads to the initiation of drug taking and continuation of repeated drug use 
(Schuster, 1981, Koob et al., 1998, Everitt and Robbins, 2005). Repeated exposure to these 
drugs can produce neuroadaptive changes that underlie the development of addiction or 




interchangeably in this thesis to refer to the same chronically relapsing brain disorder, 
substance use disorder (as currently defined by the DSM-V), that is characterized by 
persistent and compulsive use of drugs, loss of control over drug intake, and continued drug 
use despite significant negative consequences associated with drug use (American Psychiatric 
Association, 2013). The occasional and limited use of an abusable drug is clinically distinct 
from escalated drug use and the emergence of chronic compulsive drug seeking that indicates 
a drug-dependent state (Koob and Volkow, 2010). Tolerance and withdrawal symptoms 
typically occur along the addiction process. Tolerance refers to the need for higher doses of 
the stimulant to achieve intoxication or desired effects, which reflects adjustments to the 
drug-induced homeostatic disturbances and can lead to escalation of drug use (Stewart and 
Badiani, 1993, Koob and Le Moal, 1997, Koob and Volkow, 2010). Withdrawal involves the 
experience of adverse symptoms due to a reduction of drug concentrations in the blood or 
tissue after the cessation of prolonged heavy use of the drug. Opposite to intoxication, 
withdrawal state is characterized by the development of dysphoric mood with concomitant 
physiological changes such as fatigue, insomnia or hypersomnia, increased appetite, and 
psychomotor retardation or agitation. These symptoms can lead to drug craving and 
re-administration aimed at reversing withdrawal reactions (American Psychiatric Association, 
2013). The recurrent compulsive drug seeking and taking aggravate the addiction cycle 
causing further long-lasting neuroadaptations that persist even after protracted abstinence and 
lead to chronic relapse, which is the hallmark of addiction (Koob and Volkow, 2010). In 
addition, a variety of mental problems may develop during the course of acute or long-term 
stimulant use and withdrawal, such as neurotoxicity, psychosis, anxiety, depression, and 
long-lasting neurocognitive disorders (Kalechstein et al., 2003, Kita et al., 2003, Curran et al., 
2004, Favrod-Coune and Broers, 2010).  
1.2 A Worldview of Psychomotor Stimulant Use - Prevalence and Impact 
Psychomotor stimulants are the most widely used and abused psychotropic substance around 
the world with cocaine and amphetamine-type drugs, due to their powerful inherent 




2007, Favrod-Coune and Broers, 2010). The recent New Zealand Health Survey (Ministry of 
Health, 2014) indicated that the prevalence of having used amphetamines-type substances, 
including METH, in 2013/2014 was 1.1 percent among New Zealand population aged 16-64 
years, which equates to about 30600 New Zealanders, although the use of cocaine in New 
Zealand appeared to be less problematic mainly due to its increasingly high price and the 
ready availability of METH as a close substitute. At the global level, the United Nations 
Office on Drugs and Crime (UNODC) estimated that 1.4 percent of the world population 
aged 15-64 used amphetamine-type stimulants and 0.7 percent used cocaine in 2013 
(UNODC, 2015). 
The high magnitude of worldwide stimulant use has become one of the foremost public 
concerns that harm society on multiple levels, given that 1 out of 10 drug users are problem 
drug users (UNODC, 2015). It has been estimated that the social costs due to substance abuse 
exceed $484 billion per year in the USA, which includes health care expenditures, loss of 
earnings, and costs associated with crime and accidents (Rice et al., 1991, Harwood, 2000, 
Bouchery et al., 2001). Data from the World Health Organization (WHO) showed that, in 
1990, mental illness and addiction accounted for almost 11 percent of the total global burden 
of human disease, and this is expected to rise to around 15 percent by 2020 (Mental Health 
Commission, 2011). Many top medical problems have been linked to substance abuse such as 
cancer, heart disease, and HIV/AIDS transmission; and a considerable proportion of deaths 
from these illnesses were attributed to drug use (Rodriguez et al., 1996, Ockene and Miller, 
1997, McGinnis and Foege, 1999, Halkitis et al., 2001). Moreover, the requirement for 
special education and support service is more frequent for children with prenatal drug 
exposure, who are more likely to have low birth weight, low child IQ, and other 
developmental deficits (Lester et al., 2003, Arendt et al., 2004, Singer et al., 2004, Levine et 
al., 2008). Other significant social outcomes related to drug use and misuse include drugged 
driving, homelessness, child abuse, violence, and crime, all of which take a tremendous toll 





1.3 Behavioural Theories of Addiction 
1.3.1 A conceptual framework  
In the psychiatric-motivational framework proposed by Koob and Le Moal (2008a), drug 
addiction is conceptualized as having aspects of both impulse control disorders and 
compulsive disorders. Impulsivity is defined as ‘a predisposition toward rapid, unplanned 
reactions to internal and external stimuli without regard for the negative consequences of 
these reactions to themselves or others’ (Moeller et al., 2001). In impulse control disorders, 
the committing of an impulsive act is preceded by an increasing sense of tension or arousal, 
accompanied by pleasure, gratification, or relief, and may or may not be followed by regret, 
self-approach, or guilt (American Psychiatric Association, 1994). Positive reinforcement 
plays a critical role in impulse control disorders (Koob, 2004, Koob and Volkow, 2010). On 
the other hand, compulsivity is characterized by perseveration of a behavioural response that 
is inappropriate to the situation; often produces undesirable consequences; and has no 
obvious relationship to the overall goal (Dalley et al., 2011). Anxiety and stress signal the 
emitting of a compulsive repetitive behaviour, and performance of the compulsive behaviour 
relieves the stress and anxiety. Thus, compulsive behaviour is largely driven by negative 
reinforcement and automaticity (i.e., occurrence of behaviour without conscious 
intentionality) (Figure 1.1) (Koob and Volkow, 2010). Impulsivity, compulsivity, and 
addiction are intertwined in such a way that drug addiction is conceptualized as a composite 
spiral cycle composed of three stages - binge/intoxication, withdrawal/negative affect, 
preoccupation/anticipation - with the early stages dominated by impulsivity and the later 
stages dominated by compulsivity combined with impulsivity (Koob, 2004, Koob and 
Volkow, 2010). The transition from impulsivity to compulsivity is accompanied by a 
concurrent shift from positive reinforcement to negative reinforcement as the source of drive 
for the motivated behaviour (Koob, 2004). The three stages are not separate, instead they 
progressively feed into each other and intensify each other, forming a spiral that increases in 
amplitude, ultimately leading to the final pathological state of addiction (Figure 1.2) (Koob 




top of the spiral where the first drug use is initiated in susceptible individuals, and progresses 
with increased engagement with drugs (Koob and Volkow, 2010). Section 1.4, which reviews 




Figure 1.1 Stages of impulse control disorder and compulsive disorder related to the sources 
of reinforcement 
Positive reinforcement (pleasure/gratification) is more closely associated with impulse control 
disorders. Negative reinforcement (relief of anxiety or stress) plays a more critical role in driving 






Figure 1.2 The spiralling addiction cycle from the psychiatric-motivational perspective 
Drug addiction is conceptualized as a spiral cycle composed of three stages - binge/intoxication, 
withdrawal/negative affect, preoccupation/anticipation - that progressively feed into each other and 
intensify each other, growing in amplitude and ultimately leading to the pathological state of 
addiction. (Adapted from Koob and Le Moal, 2001). 
 
1.3.2 Motivation and opponent process theory 
Motivational mechanisms are the key to conceptualize drug addiction as a chronic 
compulsive disorder involving loss of control over excessive drug intake (Koob and Volkow, 
2010). Motivation, defined as a ‘tendency of the whole animal to produce organized activity’ 
(Hebb and Donderi, 2013), is an internal state that varies over time and functions to guide 
behaviour according to changes in the internal and external environment (Koob and Le Moal, 
2008a). Early work by Wikler (1952) addressed the importance of changes in the 
motivational state as the foundation of drug dependence, and this idea has been incorporated 
into the opponent process theory of motivation proposed by Solomon and Corbit (1974), 
where motivation has been inextricably linked with hedonic, affective, or emotional states in 
the transition to addiction. According to Solomon and Corbit (1974), there is an affect control 




negative feedback or opponent loop. Any stimulus-evoked affective state is opposed or 
counteracted by CNS-mediated mechanisms to reduce the intensity of these feelings. The 
opponent process is hypothesized to consist of two processes, the a-process and the 
b-process. The a-process represents either positive or negative hedonic responses, varies with 
the duration, intensity, and quality of the stimulus, and takes place immediately after stimulus 
presentation. The b-process, which is hypothesized to oppose the a-process, occurs following 
the termination of the a-process and has a sluggish onset, a slow accumulating rate to reach 
asymptote, and a slow decay rate. While the a-process develops tolerance with repeated drug 
exposure, the b-process gets larger over time, defining the affective dynamics of the opponent 
process where new motives and opportunities are born that drive behaviour (Figure 1.3) 
(Solomon and Corbit, 1974). In the context of drug addiction, the a-process represents the 
positive hedonic response to the initial acute drug effect (euphoria) and is opposed by the 
b-process, manifested as the acute withdrawal state involving aversive negative emotions 
(dysphoria). The initial drug-taking phase is characterized by a strong a-process and a weak 
b-process and drug-taking behaviour is driven by the positive reinforcement of drug-induced 
euphoria. But with repeated drug exposure, the intensity of the a-process diminishes while 
that of the b-process escalates, generating powerful motivation mediated by negative 
reinforcement from exacerbated withdrawal state that leads to compulsive drug use and 





Figure 1.3 The affective dynamics of the opponent process 
The left panel shows the manifestation of the affective response resulting from the summation of 
the underlying opponent processes, a and b, for the first few stimulations. The right panel shows 
the operation of the summing device after many repeated stimulus exposures. (Adapted from 
Solomon and Corbit, 1974). 
 
 
Figure 1.4 The opponent process theory relevant to addiction 
The left panel shows the standard pattern of affective dynamics for the first few drug stimulations 
that are characterized by a strong a-process and a weak b-process, where positive reinforcement 
drives drug-taking. The right panel shows the standard pattern of affective dynamics after frequent, 
repeated drug exposures, where drug-taking is driven by negative reinforcement resulting from a 





1.3.3 Allostatic model 
More recently, an allostatic model of the brain motivational system has been proposed as an 
extension of the opponent process theory to further explain the persistent changes in 
motivation in the transition to addiction. This model takes a physiological perspective and 
addresses neurobiological adaptations at a neurocircuitry level that underlie addiction (Koob 
and Le Moal, 2001, 2008a). A concept of an antireward system was postulated as a brain 
mechanism to oppose excessive activity of the reward system. Both systems are increasingly 
dysregulated, forming a spiralling cycle resulting in negative hedonic states that lead to 
compulsive drug use and long-term vulnerability to relapse (Koob and Le Moal, 2008a). 
Allostasis is a process of re-establishing homeostasis to achieve a more dynamic balance 
(Sterling and Eyer, 1988) and, from the addiction perspective, is designed to maintain the 
apparent stability of reward function through changes in brain mechanisms (Koob and Le 
Moal, 2001). Counteradaptive processes, such as the b-process, which originate as a normal 
homeostatic regulation of reward function, are nevertheless never able to return to the normal 
homeostatic range, resulting in a chronic progressive deviation from the normal operating 
reward set point (Figure 1.5) (Koob and Le Moal, 2001).  
 
Figure 1.5 The allostatic model of drug addiction 
As an extension of the opponent process theory, the allostatic model of drug addiction proposes 
that both the a- and b-process are increasingly dysregulated with frequent, repeated drug use, such 
that the b-process is never able to return to the original homeostatic level before drug-taking begins 
again. This creates a greater and greater allostatic state in the brain reward system and may 





Allostatic change is hypothesized to be mediated by neuroadaptations that occur at two 
neurocircuitry levels: within-system and between-system (Koob and Bloom, 1988). The 
within-system opposing process involves molecular or cellular changes within a given reward 
circuitry, that is in place for natural rewards to shape survival and counteract excessive 
hedonic processing induced by drugs. It is the same cellular and molecular elements that are 
involved in the primary response to drugs that undergo adaptation to neutralize the drug’s 
effect. The opposing effects persist after the drug terminates, leading to a rebound aftereffect 
of cellular overadaptation, contributing to the withdrawal state and decreased reward 
function. In the between-system opposing process, a separable circuitry, that is different from 
the primary response entity directly involved in the positive reinforcing effects of drugs, is 
recruited to provide inhibitory feedback to the reward system, defined as the antireward 
system (Koob and Le Moal, 2001, 2008a). Particularly, the brain stress/emotional circuit is 
triggered by overactivity of the reward system and produces an additional force to reduce 
reward function. With repeated drug exposure, this antireward system becomes dysregulated 
by chronic activation of the reward system. In this fashion, a functional decrement in brain 
reward system and the recruitment of antireward system form the addiction cycle that 
worsens over time, continuously deviating the allostatic state from the normal homeostatic 
level, resulting in increasingly powerful negative reinforcement that drives compulsivity and 
addiction (Koob and Le Moal, 2008a).  
1.3.4 Incentive-sensitization theory  
The incentive-sensitization theory was proposed by Robinson and Berridge (1993) to capture 
the subjective feelings of obsessive drug-wanting and drug-craving that are considered as 
fundamental to addiction and lead to compulsive drug seeking and taking. Robinson and 
Berridge (1993) argue that the motivation that drives compulsive drug taking does not come 
from either the positive reinforcement associated with the hedonic effects of drugs or the 
negative reinforcement linked to removal of withdrawal symptom; instead such a motivation 




The basic thesis of the incentive-sensitization theory is that all potentially abusable drugs 
have the common ability to induce persistent organizational changes in brain regions that are 
involved in processing incentive motivation and reward (Robinson and Berridge, 1993). As a 
result, the brain regions become sensitized and are hypersensitive to drugs and 
drug-associated stimuli. It is further postulated that two distinct psychological components 
are involved in reward: “liking” and “wanting”, which are mediated by different neural 
systems. In this formulation, “wanting” refers to incentive salience, which is a type of 
incentive motivation that determines the value of incentives and the degree of their 
attractiveness, and thus their ability to promote behaviour directed to the goal (Robinson and 
Berridge, 1993). In contrast, “liking” represents the pleasurable or euphoric effects of drugs, 
and should be neurologically and psychologically dissociated from “wanting”. According to 
Robinson and Berridge (1993), the neural systems that are sensitized by drugs are those 
specifically involved in the “wanting”, but not the “liking”, component of reward. Thus, with 
repeated drug use, the incentive salience of drugs and associated stimuli becomes more and 
more enhanced, accompanied with an increasing narrowing of attentional focus towards 
drug-related stimuli, at the expense of natural rewards, through associative pairing of the 
stimuli with drugs’ effects. As a result, drugs become more and more pathologically wanted 
or desired, and the drug-related stimuli gain increasing power to induce craving and trigger 
compulsive drug seeking and taking (Robinson and Berridge, 1993, Robinson and Berridge, 
2000). In contrast, the neural systems mediating “liking” are not sensitized, which may 
account for the increasing “wanting - liking” dissociation as addiction develops, such that 
drugs are often more and more “wanted” even when they are less and less “liked” (Robinson 
and Berridge, 2001). In addition, the sensitization-related neuroadaptations are long-lasting 
so that the drug-associated stimuli retain incentive salience and remain effective in 
precipitating drug-seeking long after drug use is ceased, which explains the persistent 




1.4 Neurobiology of Addiction and the Role of Dopamine (DA) 
Drug addiction has been conceptualized as the endpoint of a transitional process evolving 
from initial voluntary drug use through gradual loss of control over this behaviour and ending 
in habitual and compulsive drug use (Everitt et al., 2008). Psychostimulants produce 
physiological and subjective changes that mediate their initial reinforcing and rewarding 
effects, which act as a major motivational factor that initiates first drug use and maintains 
drug-taking in the early phase of addiction. As drug-taking continues and escalates, 
increasingly broader neural circuits become involved that display ongoing neuroadaptations 
and dysregulation, progressively leading to the final compulsive state (Koob and Le Moal, 
2005, Everitt et al., 2008). This section will briefly review the neurobiological mechanisms 
that underlie acute psychostimulant reinforcement and the protracted transitional process. 
Among the various brain neurotransmitter systems, the DA system is widely believed to play 
the most pivotal role in psychostimulant addiction, although the importance of other 
neurotransmitters, in particular glutamate, has also gained increasing recognition. Because 
the present thesis is specially centred on TAAR1, whose functional interaction with the DA 
system has been most extensively researched in the past 15 years, the following review will 
focus on the role of DA. Nonetheless, as emerging evidence begins to implicate TAAR1 in 
glutamatergic function, the involvement of the glutamate system in stimulant addiction will 
be also discussed in relation to the current findings in later experimental chapters.  
1.4.1 Acute reinforcement/reward of psychostimulants 
Attempts to explore the neurological substrates underlying the reinforcing and rewarding 
effects of drugs of abuse have gained insight from the discovery of electrical brain 
stimulation reward through the method of intracranial self-stimulation (ICSS). ICSS involves 
delivering of electrical stimuli to a specific brain area through chronically implanted 
electrodes that is contingent on lever-press produced by the animal. This procedure allows the 
determination of an ICSS threshold for a certain brain region, defined as the minimal 
stimulation voltage that is required to sustain an ICSS response (Olds and Milner, 1954). 




sensitive neural elements yielding the lowest ICSS thresholds are embedded in the medial 
forebrain bundle (MFB) (Olds and Milner, 1954, Bielajew and Shizgal, 1986, Wise and 
Rompré, 1989, Wise, 2005). The MFB is a complex fibre system that traverses through 
lateral preoptic area and lateral hypothalamus, consisting of both ascending and descending 
fibre pathways of different origins and terminals (Veening et al., 1982), among which the 
trajectories connecting the ventral tegmental area (VTA) and the lateral hypothalamus as well 
as the basal forebrain are most strongly implicated in brain stimulation reward (Olds and 
Milner, 1954, Wise, 2005, Koob and Volkow, 2010). Acute administration of virtually all 
addictive drugs decreases ICSS thresholds indicating an elevation in brain reward function, 
which may in turn facilitate the acquisition and maintenance of drug-taking behaviours due to 
an enhanced sensitivity to the reinforcing effects of drugs (Kornetsky et al., 1979, Kenny and 
Markou, 2006). On the contrary, extended access to drugs gradually increases ICSS 
thresholds which correlates with escalation of intake, suggesting a downward shift from 
hedonic homeostasis that possibly contributes to the development of addiction (Jang et al., 
2013). Increases in ICSS thresholds are also seen during withdrawal from chronic drug 
exposure, reflecting a reduced reward function and a negative emotional and motivational 
state that is believed to lead to craving and drug-taking (Schulteis et al., 1995, Epping-Jordan 
et al., 1998, Ahmed et al., 2002, Miyata et al., 2011).  
Although various monoamine pathways, including norepinephrinergic, serotonergic, and 
dopaminergic pathways, are contained in the MFB, the mesolimbic and mesocortical DA 
pathways, which are together termed the mesocorticolimbic pathway, are most critical for 
brain reward and the acute reinforcing effects of drugs of abuse, especially psychostimulants 
(Koob et al., 1998, Everitt et al., 2008, Carlson, 2010). DA neurons in the mesolimbic system 
originate in the VTA of the midbrain and project their axons to various forebrain regions 
including the nucleus accumbens (NAc), olfactory tubercle, amygdala, and hippocampus. The 
mesocortical system also begins in the VTA but projects to the prefrontal cortex (PFC), the 
limbic cortex, and the hippocampus (Figure 1.6) (Koob et al., 1998, Carlson, 2010). It has 




dopaminergic innervation of the NAc, especially the shell subregion (Everitt and Wolf, 2002, 
Koob and Le Moal, 2005). Cocaine and d-amphetamine, when self-administered 
intravenously, increased extracellular DA concentration in the NAc (Hurd et al., 1989, Pettit 
and Justice Jr, 1989, Di Ciano et al., 1995, Pontieri et al., 1995, Wise et al., 1995, Ranaldi et 
al., 1999), and the increase in DA-dependent signal was time-locked to each drug infusion 
(Pettit and Justice Jr, 1989, Kiyatkin and Stein, 1995). Selective destruction of the 
mesolimbic DA pathway, either at the dopaminergic terminals in the NAc or at DA cell 
bodies in the VTA, abolished previously established self-administration of cocaine (Roberts 
et al., 1980, Roberts and Koob, 1982), and selective lesion of DA neurons in the NAc 
impaired both the acquisition and maintenance of amphetamine self-administration in rats 
(Lyness et al., 1979). Moreover, rats readily self-infused d-amphetamine directly into the 
NAc (Hoebel et al., 1983, Phillips et al., 1994a, Phillips et al., 1994b), and selective 
antagonism of either D1 or D2 DA receptor in the NAc increased response rate, indicating 
that d-amphetamine reinforcement requires activation of NAc DA receptors (Phillips et al., 
1994b). Accordingly, cocaine sustains intracranial self-administration into the NAc, VTA, 
and medial PFC of rats (Goeders and Smith, 1983, McKinzie et al., 1999, Rodd et al., 2005). 
In addition, d-amphetamine, when microinjected directly into the NAc, produced conditioned 
place preference in rats (Carr and White, 1983, 1986). These findings support the critical role 





Figure 1.6 The mesocorticolimbic dopaminergic pathways 
Sagittal section of the rodent brain illustrating the mesolimbic and mesocortical dopaminergic 
pathways. Red arrows represent the mesolimbic pathway (originating in the VTA and projecting to 
various forebrain regions including the NAc, olfactory tubercle, amygdala, and hippocampus) and 
the mesocortical pathway (originating also from the VTA and projecting to the PFC, the limbic 
cortex, and the hippocampus). AC, anterior commissure; AMG, amygdala; ARC, arcuate nucleus; 
BNST, bed nucleus of the stria terminalis; Cer, cerebellum; C-P, caudate-putamen; DMT, 
dorsomedial thalamus; FC, frontal cortex; Hippo, hippocampus; IF, inferior colliculus; LC, locus 
coeruleus; LH, lateral hypothalamus; N Acc., nucleus accumbens; OT, olfactory tract; PAG, 
periaqueductal gray; RPn, reticular pontine nucleus; SC, superior colliculus; SNr, substantia nigra 
pars reticulata; VP, ventral pallidum; VTA, ventral tegmental area. (Adapted from Koob and 
Volkow, 2010). 
 
Several other forebrain regions, possibly through their connections with the NAc, are also 
important contributors to the acute reinforcing effects of psychostimulants. In particular, the 
central nucleus of the amygdala (CeA), which together with the NAc shell constitutes part of 
a neural continuum called the “extended amygdala”, is one of these regions (Robledo and 




directly into the CeA in a dose-dependent fashion (Chevrette et al., 2002), and blockade of 
the D1 DA receptors in the CeA increased cocaine self-administration in rats (McGregor and 
Roberts, 1993, Caine et al., 1995). In addition, the ventral pallidum is a major output region 
for the NAc (Heimer and Wilson, 1975). Lesions of the ventral pallidum impaired cocaine 
self-administration (Hubner and Koob, 1990, Robledo and Koob, 1993), and microinjection 
of cocaine or d-amphetamine into the ventral pallidum produced conditioned place preference 
in rats (Gong et al., 1996). Finally, the olfactory tubercle, extending ventrally to the NAc 
shell, has been implicated in drug reward (Ikemoto, 2007). Cocaine is readily 
self-administered into the olfactory tubercle by rats, and selective blockade of D1 or D2 DA 
receptors disrupted intra-tubercle self-administration of cocaine. Further, injection of cocaine 
into this region induced conditioned place preference (Ikemoto, 2003). Together these 
findings suggest the functional importance of the CeA, ventral pallidum, and olfactory 
tubercle in mediating psychostimulant reinforcement and reward, in addition to the NAc.  
1.4.2 Voluntary drug-seeking 
Through Pavlovian conditioning and Pavlovian-to-instrumental transfer, an environmental 
stimulus that has been repeatedly paired with the drug may become conditioned and its 
presentation subsequently induces drug craving and seeking (Everitt et al., 2001). The 
acquisition and early performance of this initial drug-seeking behaviour are believed to be 
voluntary and goal-directed, that is, it is still under the control of response-outcome 
contingencies and sensitive to outcome devaluation (Everitt et al., 2008). At this stage, the 
NAc core and its afferent input from the basolateral amygdala (BLA) are critically involved 
(Everitt et al., 2008). Selective lesion of either the BLA or the NAc core impaired the 
acquisition of cocaine seeking, assessed with a second-order schedule of self-administration 
in which an initial response on a drug-seeking chain is required for the access to the 
drug-taking chain (Whitelaw et al., 1996, Ito et al., 2004). In contrast, simple drug-taking, 
maintained by a standard schedule of continuous reinforcement, was not affected when neural 
activity in the BLA or NAc core was disrupted (Whitelaw et al., 1996, Ito et al., 2004). 




unilateral antagonist treatments reduced cocaine seeking (Di Ciano and Everitt, 2004). These 
findings support the notion that the initial voluntary drug-seeking maintained by 
response-outcome contingencies requires the integrity of the NAc core and its afferent from 
the BLA (Di Ciano and Everitt, 2004, Everitt et al., 2008).  
1.4.3 Compulsive drug-seeking  
1.4.3.1 The striato-nigro-striatal loop 
With repeated drug exposure, drug-seeking behaviour becomes increasingly automatic and 
habitual, and is triggered and maintained by stimulus-response contingencies (Everitt et al., 
2001, Everitt et al., 2008). Collective evidence has shown that the transition to the habitual 
drug taking represents a shift in the locus of control from ventral to dorsal striatum. This is 
believed to occur through a striato-nigro-striatal loop in which the ventral tiers of the striatum 
influence the dopaminergic innervation of more dorsal tiers by way of a series of ascending 
spiralling connections with the midbrain (Figure 1.7) (Everitt et al., 2008). In particular, DA 
neurons in the NAc shell project to the VTA, which projects both back to the NAc shell and 
more dorsally to the NAc core. The NAc core projects DA neurons in the substantia nigra 
(SNr), which innervates not only the NAc core itself but also the dorsal striatum, including 
the dorsomedial caudate-putamen and the dorsolateral striatum (Haber et al., 2000). 
Behavioural studies have investigated the functional significance of this ventral-dorsal striatal 
organization in the development of habit-like compulsive drug seeking. In rats that have 
established a habit of cocaine seeking, the presentation of a non-response contingent 
cocaine-associated stimulus increased DA level selectively in the NAc core, while the 
presentation of the same stimulus, when made contingent on cocaine-seeking response, 
increased DA only in the dorsal striatum. These findings suggest that the development of 
compulsive or habitual drug seeking is associated with a gradually weakened role of the NAc 
core and a progressive engagement of the dorsal striatum in the control over behaviour (Ito et 
al., 2000, Ito et al., 2002). Moreover, in the elegant study by Belin and Everitt (2008), 
ventral-dorsal striatal disconnection, by unilateral lesion of the NAc core combined with 




cocaine seeking in rats, but did not affect normal sucrose taking. Again, these results reveal a 
shift from ventral to dorsal striatum in the control over drug-seeking behaviour as 
compulsivity develops (Belin and Everitt, 2008). On the other hand, given the potent 
DA-releasing ability of psychostimulant drugs in the striatum, chronic drug exposure may 
reciprocally accelerate or consolidate the ventral-to-dorsal shift (Everitt and Wolf, 2002, 
Everitt et al., 2008). 
 
 
Figure 1.7 The striato-nigro-striatal loop for the transition to compulsive drug seeking 
The alternation of pink and black arrows between the midbrain and ventral and dorsal striatum 
represents the DA-dependent spiralling circuitry that functionally connects the ventral with more 
dorsal regions. The loop starts from the NAc shell (yellow) that projects (black arrow) to regions of 
the VTA (pink) which send DA projections back to the NAc shell (pink arrow) and to more dorsal 
NAc core (soft blue) (bold dotted arrow). Similarly, the NAc core projects to areas of the VTA 
which innervate not only to the NAc core but also to the dorsomedial striatum. The spiral continues 
to encompass more dorsal striatal regions (dark blue) innervated by the more lateral SNr (pink). 
(Adapted from Everitt et al., 2008).  
 
1.4.3.2 The frontostriatal pathway 
In addition to the subregional transition within the striatum, a gradual shift in balance from 




development of compulsive drug use and addiction (Robbins and Everitt, 1999, Everitt et al., 
2008). The PFC is the central source for executive function and inhibitory response control, 
which is important for outcome evaluation and withholding inappropriate, pre-potent (i.e., 
previously conditioned) responses (Dias et al., 1996, Dias et al., 1997, Jentsch and Taylor, 
1999, Bechara et al., 2000, Ridderinkhof et al., 2004). Increasing evidence has linked 
impaired prefrontal cognitive functions with a reduced ability to inhibit drug-seeking 
impulses and make decisions about the drug in human addicts (Dom et al., 2005, 
Schoenbaum et al., 2006, Olausson et al., 2007, Goldstein and Volkow, 2011). Impulsivity, a 
trait closely associated with prefrontal dysfunction, has been considered as a vulnerability 
marker for escalation of drug intake, relapse after abstinence, and compulsive drug use 
(Dalley et al., 2007, Economidou et al., 2007, Belin et al., 2008, De Wit, 2009). Meanwhile, 
chronic drug use was shown to significantly affect prefrontal cognitive functions and increase 
impulsive behaviour, which promotes uncontrolled drug intake and addiction. Indeed, 
prefrontal defects and impulsivity have been postulated as both predisposing factors for 
addiction and consequences of chronic drug exposure (Jentsch and Taylor, 1999, De Wit, 
2009).  
Prefrontal dysregulation has been show to affect striatal processing through corticostriatal 
projections from medial PFC to the caudate nucleus and NAc (Jentsch and Taylor, 1999). It 
has been hypothesized that subcortical DA activity is under tonic inhibitory control by 
cortical DA, whose loss of function may lead to upregulated DA transmission in the striatum 
(Deutch, 1992, Prasad et al., 1999). Thus, a reduced frontal-striatal inhibitory modulation 
may result in an augmentation of striatal DA-mediated drug reinforcement and drug-seeking 
(Jentsch and Taylor, 1999). Evidence shows that rats with DA depletion in the medial PFC 
were supersensitive to the acute reinforcing effects of cocaine (Schenk et al., 1991) and were 
hyper-motivated to seek cocaine in a progressive ratio (PR) schedule of reinforcement 
(McGregor et al., 1996), supporting the notion that impaired prefrontal function underlies a 





Moreover, the incentive-sensitization theory postulates that chronic drug exposure sensitizes 
the DA innervation of the NAc, which is responsible for attributing incentive salience to 
reward-related stimuli. These sensitized DA neurons become over-activated when presented 
with drug-associated cues, leading to an elevated incentive motivational state of drug 
craving/wanting (Robinson and Berridge, 2001, 2008). It has been shown that repeated 
amphetamine treatment sensitized amphetamine-stimulated DA release in the NAc in rats 
(Robinson et al., 1988, Wolf et al., 1993) and in healthy human (Boileau et al., 2006), which 
may provide a neural basis for incentive motivational process (Robinson and Berridge, 2008).  
Collectively, the transition to addiction occurs as a result of an impaired frontal function 
combined with upregulated striatal responses. This frontal-striatal neuroadaptation may lead 
to poor decision-making and loss of inhibitory impulse control, accompanied by sensitized 
incentive motivational states that drive compulsive drug seeking and taking (Olausson et al., 
2007, Everitt et al., 2008).    
1.4.4 Negative withdrawal state  
The negative emotional state associated with drug withdrawal is believed to be an important 
factor that drives drug craving and seeking via a negative reinforcement mechanism (Koob, 
2013). The opponent process theory and the allostatic model postulate that the negative 
withdrawal state progressively worsens with chronic drug exposure, which involves 
neuroadaptations at both a within-system and a between-system level (Koob and Le Moal, 
2008a). In the within-system process, acute withdrawal from psychostimulants leads to 
decreased function of the mesolimbic DA system which is critically implicated in the acute 
reinforcing and rewarding effects of drugs. Reduced basal level of DA in the ventral striatum, 
including the NAc, has been found in rats withdrawn from cocaine or amphetamine 
(Robertson et al., 1991, Rossetti et al., 1992, Weiss et al., 1992, Kuhar and Pilotte, 1996). 
Moreover, human addicts displayed decreased DA D2 receptors in striatal neurons, indicating 
hypodopaminergic function (Volkow et al., 2003). The downregulated mesolimbic DA 




of drug use after acute withdrawal as well as chronic relapse following protracted abstinence 
(Koob and Le Moal, 2008a). On the other hand, the between-system process recruits 
additional brain circuits involved in modulating stress and anxiety-like effects, which 
constitutes the antireward circuitry, which is hypothetically to be localized in connections of 
the extended amygdala and recruit neurotransmitter systems such as the 
corticotropin-releasing factor (CRF), norepinephrine (NE), and dynorphin (Koob and Le 
Moal, 2008a). Rats that were withdrawn from chronic cocaine administration showed intense 
anxiety-like behaviour, accompanied by altered concentration of CRF in the hypothalamus, 
amygdala, and basal forebrain structures; and CRF antagonism completely prevented 
withdrawal-induced anxiety (Sarnyai et al., 1995, Basso et al., 1999). Similarly, blockade of 
dynorphin receptors attenuated cocaine withdrawal-induced anhedonia measured as increased 
ICSS thresholds (Chartoff et al., 2012). Therefore, a compromised mesolimbic DA function 
and a recruitment of extended amygdala-dependent stress system together contribute to the 
negative hedonic effects of withdrawal and provide a powerful drive for the development of 
addiction (Koob and Le Moal, 2008a).  
1.4.5 Summary  
Taking together, while the initial reinforcing and rewarding effects of psychostimulants 
depend primarily on the NAc shell, the integrity of the NAc core and its afferents from the 
BLA is also required for the acquisition and early maintenance of drug seeking driven by 
response-outcome contingencies. However, as drug use escalates, drug-seeking behaviour 
becomes more and more habitual and stimulus-response-driven, which ultimately leads to 
compulsive drug seeking and addiction. The neural mechanism underlying this switch 
involves a gradual transition from ventral to dorsal striatal control over drug-seeking and 
taking as well as a progressive control shift from the PFC to the striatum, through 
DA-dependent processes. In addition, the negative emotional states associated with 
withdrawal, resulting from deficient mesolimbic DA transmission and dysregulated stress 
modulation mediated by the extended amygdala, also promote compulsive drug seeking 





Figure 1.8 Neuroadaptations in the brain circuitry for the three stages of addiction cycle 
The NAc integrates with the BLA to process conditioned reinforcement and with hippocampus to 
recruit contextual information. The transition to compulsive drug use depends on the 
striato-nigro-striatal loop that connects DA neurons with ventral and dorsal striatum through 
spiralling loops. Transition to addiction also involves frontal-striatal neuroadaptations where PFC 
function is compromised and striatal DA is sensitized. The negative withdrawal state is driven by 
an altered DA system and an increased recruitment of the brain stress system including CRF and 
NE. Acb, nucleus accumbens; BNST, bed nucleus of the stria terminalis; SNc, substantia nigra pars 
compacta; GP, globus pallidus (D, dorsal; V, ventral). (Adapted from Koob and Volkow, 2010). 
 
1.5 Current Treatment and Problems 
Psychostimulant addiction is recognized for its treatment challenges. Currently there are no 
medications available that are approved by the US Food and Drug Administration (FDA) 
specifically for psychostimulant dependence (Taylor et al., 2013). The mainstay of treatment 
has been behavioural interventions, including Cognitive-Behavioural Therapy, the 




others (Ciccarone, 2011). These programs are critical for promoting recovery and preventing 
recidivism, but their success has only been limited thus far (Dutra et al., 2008, Phillips et al., 
2014). Whereas several forms of non-specific pharmacology are currently in use, none have 
shown conclusive efficacy in safely facilitating detoxification and preventing long-term 
relapse with tolerable side effects (Ciccarone, 2011, Phillips et al., 2014). The following 
sections will review some major drug classes that have been explored in preclinical models 
and clinical settings which include antidepressants, γ-aminobutyric acid (GABA) agents, and 
dopaminergic drugs such as DA receptor ligands and DA replacement agonists, including DA 
releasers and DA reuptake inhibitors (Taylor et al., 2013). For the sake of brevity, drugs in 
other classes will not be detailed here as no concrete evidence exists for their superiority in 
treating stimulant addiction.  
1.5.1 Antidepressants 
The use of antidepressants in treating psychostimulant dependence is based on the notion that 
negative symptoms experienced during withdrawal and abstinence are associated with 
deficits in monoamine transmission, which can be rescued by antidepressants that are known 
to augment monoamine levels. Thus antidepressants are expected to alleviate abstinence 
symptomatology, relieve dysphoria, and reduce craving (Margolin et al., 1995). However, 
current evidence of antidepressant pharmacotherapies, including heterocyclic, selective 
serotonin reuptake inhibitors (SSRIs), monoamine oxidase (MAO) inhibitors and others, does 
not generally support their efficacy in treating stimulant abuse (Shoptaw et al., 2008b, Pani et 
al., 2011). A study that evaluated the efficacy of bupropion in treating METH dependence 
found no significant effects for bupropion relative to placebo in reducing METH use, 
increasing retention, or reducing METH craving (Shoptaw et al., 2008b). Another study by 
Pani et al. (2011) reviewed 37 randomized controlled clinical trials on METH dependence, 
including 3551 patients and a range of antidepressant agents, reporting disappointing results. 
Although partially positive outcomes on mood were obtained, consistent with the primary 
effect of antidepressants, they were not judged promising in treating stimulant dependence 




1.5.2 DA replacement agonists - releasers 
Agonist replacement therapy involves replacing the abused drug with one that has similar 
positive reinforcing effects but with less addictive potential to treat stimulant dependence. 
One type of such pharmacological therapy is monoamine releasers, such as amphetamine 
analogues, which have shown inconsistent efficacy in treating cocaine or amphetamine 
dependence. Although some human laboratory studies reported a reduction in cocaine’s 
reinforcing effects during d-amphetamine maintenance treatment (Greenwald et al., 2010, 
Rush et al., 2010), others found no effect of d-amphetamine on amphetamine 
self-administration (Stoops et al., 2007). Moreover, a large-scale review study revealed no 
significant effects of psychostimulants, including d-amphetamine and METH, on improving 
cocaine use, maintaining abstinence, or promoting treatment retention in clinical trials 
(Castells et al., 2010), although the opposite conclusion was reached elsewhere (Stoops and 
Rush, 2013). Also, given the inherent risks of misuse and potential abuse of these substitute 
substances, further studies are required to fully assess their therapeutic efficacy for stimulant 
addiction (Mariani and Levin, 2012).   
1.5.3 DA replacement agonists - uptake inhibitors 
Apart from monoamine releasers, replacement agonists also include uptake inhibitors. 
Methylphenidate and bupropion, both of which are dual NE-DA uptake inhibitors, are 
currently available for use in humans. One human laboratory study showed that maintenance 
on methylphenidate decreased the reinforcing effects of cocaine (Collins et al., 2006). 
However, results from clinical trials generally failed to demonstrate the effectiveness of 
methylphenidate in treating cocaine dependence (Grabowski et al., 1997, Schubiner et al., 
2002, Levin et al., 2006). Moreover, studies have shown no effectiveness of methylphenidate 
in reducing amphetamine use, although it has been argued that the negative outcome could be 
attributed to a floor effect in the percentage of basal amphetamine-positive urines in the 




Similar controversial results have been obtained for bupropion. One laboratory study found 
that acute bupropion attenuated cocaine’s rewarding effects in human participants, but 
increased subject-rated positive experience of cocaine (Stoops et al., 2012). Clinical trials 
generally indicated a lack of major effects of bupropion in managing cocaine dependence 
(Margolin et al., 1995, Levin et al., 2006, Shoptaw et al., 2008a), yet suggested that 
combination with cognitive behavioural therapy may increase its efficacy. Moreover, the 
ability of bupropion in reducing METH dependence has been argued to be limited to light 
users and those able to achieve abstinence early in treatment (Elkashef et al., 2008, Shoptaw 
et al., 2008b, Brensilver et al., 2012, McCann and Li, 2012).  
1.5.4 DA replacement agonists - atypical DA uptake inhibitors  
Because of the limited clinical efficacy and the significant inherent abuse potential of typical 
monoamine reuptake inhibitors and releasers, considerable efforts have been directed towards 
identifying alternative replacing agonists with less abuse liability and increased efficacy to 
treat psychostimulant dependence. Modafinil (Provigil ®) is an atypical dopamine transporter 
(DAT) inhibitor that binds to the same site on the DAT as cocaine but in a distinct manner 
(Federici et al., 2013, Okunola-Bakare et al., 2014, Reith et al., 2015). The behavioural 
effects of modafinil overlap to some extent with those of prototypical stimulants, producing 
discriminative-stimulus effects that partially substitute cocaine in rhesus monkeys and 
humans (Rush et al., 2002a, Newman et al., 2010). It is FDA approved for the treatment of 
narcolepsy and may also be used for ADHD (Turner, 2006, Kumar, 2008). Nonetheless, 
modafinil appears to have minimal abuse potential as it did not support conditioned place 
preference in rats (Deroche-Gamonet et al., 2002) and was not deemed as being positively 
reinforcing in humans (Rush et al., 2002b, Vosburg et al., 2010). Due to these characteristics, 
modafinil has been suggested as a putative alternative agonist replacement therapy. Human 
laboratory studies found that, in frequent drug users, modafinil maintenance reduced the 
reinforcing effect of cocaine (Hart et al., 2008) but not that of METH (De La Garza Ii et al., 
2010). Clinical trials reported limited efficacy of modafinil in cocaine users, preferentially in 




without other substance dependence and those attending counselling (Shearer et al., 2009). 
Taken together, although modafinil possesses a neuropharmacological profile consistent with 
an anti-addiction medication, it produced only modest efficacy in select populations and more 
clinical trials identifying those subpopulations with positive responses are needed.  
Another possible DA replacement approach is based on the benztropine (BZT) class of DAT 
inhibitors. Some of these BZT analogues have high affinity and selectivity for the DAT 
(Newman and Agoston, 1998), exhibit slower rates of DAT occupancy compared with 
cocaine, and provoke long-lasting striatal DA release (Desai et al., 2005, Raje et al., 2005, 
Tanda et al., 2009). Most importantly, several of these compounds appear to be devoid of 
classical cocaine-like stimulating effects such that they did not evoke vigorous 
hyperlocomotion, did not produce conditioned place preference, only partially substituted for 
cocaine in cocaine discrimination tasks, and were less likely to sustain self-administration 
than cocaine (Katz et al., 2001, Desai et al., 2005, Hiranita et al., 2009, Velázquez-Sánchez et 
al., 2009), suggesting low abuse liability. Studies have demonstrated their ability to 
counteract critical abuse-related effects of cocaine and amphetamine-type stimulants in 
animal models. For example, AHN-1055, a N-substituted BZT analogue, was able to block 
cocaine self-administration without affecting responding for natural reward (Ferragud et al., 
2009), reduced cocaine-stimulated locomotor activity, and prevented cocaine-conditioned 
place preference and associated early gene expression in the NAc and dorsomedial striatum 
(Velázquez-Sánchez et al., 2009). Another N-substituted BZT analogue, JHW 007, has also 
been shown to block cocaine-induced conditioned place preference, locomotor hyperactivity, 
and behavioural sensitization (Velázquez-Sánchez et al., 2010). In addition, these two 
compounds were effective in antagonizing hyperlocomotion and self-administration produced 
by amphetamine or METH (Velazquez-Sanchez et al., 2011, Ferragud et al., 2014) and in 
blocking the rewarding and sensitizing effects of amphetamine (Velazquez-Sanchez et al., 
2011). Together, these findings support the novel generation of BZT analogues as lead 




1.5.5 DA receptor ligands  
The direct focus on the DA receptors themselves is based on the well-established central role 
of DA in brain reward regulation and psychostimulant action. Extensive research has been 
carried out in this area, yielding complex results. While D1-like full and partial agonists, as 
well as antagonists, all have been found to attenuate cocaine-induced reinstatement of drug 
seeking (Barrett-Larimore and Spealman, 1996, Self et al., 1996, Barrett-Larimore and 
Spealman, 1997), the discriminative-stimulus effects of cocaine were decreased by a D1-like 
antagonist and a partial agonist but accentuated by full agonists in monkeys (Spealman et al., 
1997). Moreover, several D1-like full and partial agonists were shown to maintain 
self-administration in monkeys and rats (Self and Stein, 1992, Weed and Woolverton, 1995, 
Grech et al., 1996), suggesting that they possess positive reinforcing properties. Although the 
ability of D1-like antagonists to block cocaine self-administration has been demonstrated in 
monkeys and rats, the specificity of this effect has been questioned (Woolverton, 1986, 
Corrigall and Coen, 1991, Caine and Koob, 1994a). Human trials did not produce more 
optimistic results. In spite of the finding that acute pretreatment with a D1-like antagonist, 
ecopipam (SCH 39166), reduced subject-reported euphoria and the desire to take cocaine 
(Romach et al., 1999), a regimen of chronic maintenance on this compound enhanced smoked 
cocaine self-administration and amplified the subjective effects of cocaine, questioning the 
viability of treating cocaine abuse through antagonism of the DA D1 receptors (Haney et al., 
2001).  
Studies on D2-like ligands reported even more complex findings. While D2-like DA receptor 
antagonists have been shown to attenuate cocaine-primed reinstatement of drug seeking in 
monkeys (Spealman et al., 1999, Khroyan et al., 2000), they failed to affect cocaine use or 
cocaine-induced subjective effects including euphoria and post-use craving in humans. In 
addition, they produced clinically significant adverse effects, including dysphoria, anxiety, 




The DA D3 receptor may represent the most promising DA receptor target for anti-addiction 
drug development. Studies have shown that the D3 receptor partial agonist, BP 897, inhibited 
cue-evoked cocaine seeking in rats (Pilla et al., 1999), reduced the discriminative-stimulus 
effect of cocaine and d-amphetamine in mice (Beardsley et al., 2001), and was not 
self-administered by rhesus monkeys (Beardsley et al., 2001). However, extrapyramidal side 
effects have been associated with BP 897 as it produced catalepsy in rats (Pilla et al., 1999) 
and induced a return of MPTP-induced parkinsonian symptoms in monkeys treated with 
L-DOPA (Hadjtahar et al., 1999). In addition, BP 897 produced sedative effects and, at high 
doses, induced ptosis and lethargy in monkeys (Beardsley, 1999). Thus a full assessment of 
its psychopharmacological and side effect profiles is needed and its therapeutic window must 
be carefully monitored (Garcia‐Ladona and Cox, 2003).  
More recent attention has been drawn to D3 receptor antagonists, some of which were 
demonstrated to reverse the elevation of brain stimulation reward produced by cocaine and 
METH without altering reward function by themselves (Vorel et al., 2002, Spiller et al., 
2008), block cocaine-conditioned place preference without producing place conditioning of 
their own (Macdonald et al., 2003, Cervo et al., 2005), and reduce self-administration 
response under PR but not fixed ratio (FR) schedule of reinforcement (Xi et al., 2005, Xi and 
Gardner, 2007), as well as attenuate reinstatement of cocaine seeking induced by cocaine 
challenge (Vorel et al., 2002, Xi et al., 2006, Xi and Gardner, 2007), cocaine-associated cues 
(Gilbert et al., 2005, Gál and Gyertyán, 2006), or stress (Xi et al., 2004). In addition, studies 
have precluded any untoward side effects of D3 receptor antagonists, as these compounds did 
not induce impairments in locomotor, cognitive, and affective function nor displayed abuse 
liability (Heidbreder and Newman, 2010). These preclinical studies have provided incentives 
to advance the discovery and development of novel D3 antagonists with improved 
pharmacokinetics and bioavailability in humans, but such progress appears to be challenging 
and has not yet materialized (Heidbreder and Newman, 2010, Searle et al., 2010, Newman et 




pharmacological profile of candidate compounds, which will ultimately lead to human 
clinical trials to assess their therapeutic efficacy for stimulant dependence.  
1.5.6 GABAergic agents  
Evidence has suggested the possibility that GABAergic drugs may be effective in the 
treatment of stimulant addiction (Brebner et al., 2002, Cousins et al., 2002). Several GABAB 
agonists have been shown to reduce cocaine self-administration in rodents, but the degree of 
effectiveness seems dependent on the reinforcement schedule and the unit dose of cocaine 
(Roberts et al., 1996, Shoaib et al., 1998, Brebner et al., 2000, Roberts, 2005). Among these 
compounds, baclofen (Lioresal®) is the only one available for testing in humans and has 
been found to reduce self-reported craving and cocaine use in human cocaine users 
(Gudeman et al., 1996, Ling et al., 1998, Shoptaw, 2000). However, the short-lived action 
(3-4 h) of baclofen, which requires administration four times per day, poses an obstacle that 
limits outpatient compliance (Brebner et al., 2002). Moreover, baclofen may induce untoward 
side effects such as sedation and motor impairment due to its muscle relaxant and sedative 
properties (Brebner et al., 2002, Roberts, 2005). Together, although there are preclinical and 
clinical data supporting the usefulness of baclofen in addiction pharmacotherapy, problems 
exist that may compromise its efficacy and must be addressed by future investigations. 
1.5.7 Other medications 
The DA system closely interacts with, and is regulated by, various other neurotransmitter 
systems; hence a drug development strategy may be to target these non-dopaminergic circuits 
to indirectly modulate DA activity. These include serotonergic, opioid, glutamatergic, 
GABAergic (as abovementioned), endocannabinoid, and neuropeptide systems. Despite the 
extensive efforts that have been devoted in this field, no compound has yet been shown to be 
definitely effective in addiction management with tolerable side effects.  
1.5.8 Summary 
Currently there is no specific pharmacological therapy with established effectiveness in the 




interventions, which have been proven to be only partially successful. The progress of 
preclinical and clinical research into potential anti-addiction medications was largely 
hampered by their limited efficacy or noticeable adverse side effects. Numerous compounds 
have been explored but a very small portion of them demonstrated favourable therapeutic 
properties. DA D3 receptor antagonists and atypical DA reuptake inhibitors hold the most 
promise. However, direct manipulation of the DA system for treatment purposes is in some 
instances associated with long-term side effects, as evidenced by the debilitating motor 
complications induced by chronic dopaminergic therapies in Parkinson’s disease and 
schizophrenia. In addition, DAT-based replacement medications may have an increased 
abuse liability, although preclinical data has preliminarily precluded this potential risk for 







2 Targeting Trace Amine-Associated Receptor 1 (TAAR1) to 
Treat Psychostimulant Addiction  
Addiction to psychomotor stimulants is a chronic, relapsing disease of the brain for which an 
effective medication is yet to be found. Given the central role of DA in brain reward and 
psychostimulant action, the mainstream pharmacotherapeutic strategies have been to either 
directly or indirectly target the DA system. These approaches have generally been hindered 
by limited efficacy or potential non-specific side effects, although some promising results 
have been reported (see chapter one). During the on-going search for more efficacious 
medications in stimulant addiction, the trace amine (TA) transmitter system, a secondary 
amine system intimately related to the DA system, has attracted increased attention in recent 
years. TAs belong to a group of endogenous amines whose neurobiological functions were 
largely neglected until the breakthrough discovery of a group of G protein-coupled receptors 
(GPCRs), the so-called trace amine-associated receptors (TAARs), by two independent 
research groups in 2001 (Borowsky et al., 2001, Bunzow et al., 2001). Research conducted in 
the past 15 years has concentrated primarily on TAAR1, as the only member in this receptor 
family that is both responsive to TAs and phylogenetically conserved in the mammalian brain 
(Borowsky et al., 2001, Lindemann et al., 2005). TAAR1 has proved to be an important 
modulator of DA and has been implicated in psychostimulant action, giving rise to the 
suggestion that it may serve as a target for anti-addiction medicinal development. The general 
aim of the present thesis is to systematically investigate the therapeutic potential of 
TAAR1-based agents in stimulant addiction. This chapter will firstly summarize the latest 
advancements in understanding the pharmacological and neurochemical role of the TA 
system in mammalian CNS followed by a detailed review of in vitro and in vivo evidence 
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demonstrating the important implication of TAAR1 in psychostimulant addiction. Next, the 
rationale and the specific objectives of the current work will be stated, incorporating an 
outline of the subsequent experimental chapters (chapters three-five).  
2.1 Trace Amines 
TAs, including ρ-tyramine, m-tyramine, β-phenylethylamine (β-PEA), m-octopamine, 
ρ-octopamine, tryptamine, and synephrine, are a group of endogenous amines found in both 
invertebrate and vertebrate species (Berry, 2004). TAs have well-documented roles in 
invertebrates as major neurotransmitters, with octopamine believed to be the sympathetic 
nervous system counterpart of NE in vertebrates (Robertson and Juorio, 1976, Evans and 
O'Shea, 1977, Roeder, 1999). By contrast, although the existence of TAs in the vertebrate 
central and peripheral nervous systems has long been recognized, their functions were largely 
unknown due to the apparent lack of identified receptors specific for TAs, which prompted 
their description as “false neurotransmitters” (Berry, 2004). TAs are structurally similar to, 
and share same biosynthetic and metabolic pathways with, the classic monoamines (Berry, 
2004, Ledonne et al., 2011). Initial studies postulated that TAs exerted sympathomimetic 
actions in the vertebrate peripheral nervous system, linking them to blood pressure regulation 
and electrolyte homeostasis (Barger and Dale, 1910, Podder et al., 1979). This notion can be 
traced back to the clinical observation of the so-called “cheese reaction”, a hypertensive crisis 
experienced by sensitive patients treated with MAO inhibitor class of antidepressant drugs 
and exposed to aged cheese and other types of processed food enriched in ρ-tyramine 
produced through bacteria decarboxylation during fermentation (Blackwell and Mabbitt, 
1965, Boulton et al., 1970, Rice et al., 1976, Stratton et al., 1991, Anderson et al., 1993). It 
has been shown that peripheral tyramine releases endogenous NE from peripheral stores, 
which in turn stimulates adrenergic nerves, a process responsible for its indirect sympathetic 
action (Crout et al., 1962, Tapper et al., 1981). 
In the CNS, TAs are present at low nanomolar concentrations at a range that is several 




extremely rapid turnover rate and a very short half-life of around 30 seconds (Burden and 
Philips, 1980, Berry, 2004). TAs exhibit a heterogeneous distribution that closely parallels 
the classic monoaminergic projection pathways, with enhanced expression in the nigrostriatal 
and mesolimbic dopaminergic pathways (Philips, 1984). Evidence suggests that some TAs, 
including ρ-tyramine, β-PEA, and tryptamine, are synthesized within nigrostriatal DA 
neurons while ρ-octopamine is synthesized within adrenergic neurons (Berry, 2004). 
However, as indicated previously, TAs were regarded for a considerable time as mere 
metabolic by-products of other neurotransmitters and having little neurophysiological 
significance in their own right. In subsequent studies, TAs were classified as endogenous 
neuromodulators that regulated, and were themselves susceptible to regulation by, co-existing 
neurotransmitters (Berry, 2004). Indeed, ample evidence has demonstrated an intimate 
functional inter-regulation between TAs and the classic monoamines, especially DA. First, 
changes in monoamine activity were able to alter TA levels. For example, while reductions in 
striatal levels of β-PEA (Juorio et al., 1991b) and ρ-tyramine (Jones et al., 1983) were found 
to follow an increased DA release triggered by electrical stimulation of the SNr, inhibition of 
DA neurotransmission led to an elevated accumulation rate of β-PEA in the striatum (Juorio 
et al., 1991a). Reciprocally, TAs appeared to potentiate the efficacy of synaptic transmission 
of these monoamines (Philips, 1984, Burchett and Hicks, 2006). For instance, administration 
of MAO-B inhibitors, which increased β-PEA levels above their physiological range, 
enhanced striatal neuronal response to DA (Berry et al., 1994) and DA agonists (Paterson et 
al., 1991). Moreover, iontophoretic application of β-PEA elicited a potentiated cortical 
neuronal response to NE (Paterson and Boulton, 1988, Paterson, 1993). Similarly, 
iontophoretic administration of ρ-tyramine, m-tyramine, and β-PEA applied at weak currents 
increased cortical neuronal response to DA (Jones and Boulton, 1980). Likewise, application 
of octopamine through weak iontophoretic currents enhanced both inhibitory and excitatory 
neuronal responses mediated by NE (Jones, 1982a). The effect of tryptamine on serotonin 
(5-HT) neurotransmission appeared to be more complex as both a depression and potentiation 




biphasic effects of 5-HT itself on cortical neuron activity (Jones, 1982b). Taken together, 
these findings suggest that TAs are likely to serve as a fine-tuning mechanism that keeps a 
balanced monoaminergic tone by responding to endogenous- or exogenous-induced 
monoamine fluctuations, a process that may be partly mediated through interaction with 
specific receptors for TAs (Berry, 2004).  
Given the abovementioned reciprocal relationship between TAs and monoamines, it is not 
surprising that dysfunction of TA signalling has been historically associated with a broad 
spectrum of neurological pathologies that involve changes in monoamine function, including 
ADHD (Baker et al., 1991), depression (Sandler et al., 1979, Wolf and Mosnaim, 1983, 
Sabelli et al., 1995), bipolar affective disorder (Karoum et al., 1982), and schizophrenia 
(Potkin et al., 1979, Buckland et al., 1997). Most importantly, of particular interest to the 
present thesis, ample evidence has implicated TAs in psychostimulant action and brain 
reward (Greenshaw, 1984, Janssen et al., 1999), suggesting their potential role in drug 
addiction.  
Firstly, β-PEA has been found to bear close structural and pharmacological similarity with 
amphetamine (Tinklenberg et al., 1978, Janssen et al., 1999). At concentrations that were 
several orders of magnitude above its normal physiological range, β-PEA induced 
amphetamine-like effects in rodents and monkeys, including hyperactivity (Dourish, 1985) 
and stereotypic behaviour (Borison et al., 1977, Tinklenberg et al., 1978). This evidence led 
to the characterization of β-PEA as brain “endogenous amphetamine” (Janssen et al., 1999). 
Moreover, β-PEA activity is altered by exogenous application of d-amphetamine. Acute 
application of d-amphetamine resulted in an initial decrease and a subsequent increase in 
brain levels of β-PEA in rabbits (Borison et al., 1975). Also, chronic administration of 
amphetamine in rats downregulated aromatic L-amino acid decarboxylase (AADC) mRNA 
levels, which could in turn lead to decreased β-PEA activity (Buckland et al., 1996). On the 




levels as depletion of brain β-PEA blocked the motor-stimulating effect of d-amphetamine in 
mice and rabbits (Borison et al., 1975). 
Furthermore, consistent with its hypothesized role as “endogenous amphetamine”, β-PEA 
was shown to possess reinforcing properties, a defining feature that underlies the abuse 
liability of psychostimulants. β-PEA was as effective as amphetamine in its ability to produce 
conditioned place preference in rats (Gilbert and Cooper, 1983) and was readily 
self-administered by dogs that had a stable history of amphetamine or cocaine 
self-administration (Risner and Jones, 1977, Shannon and Thompson, 1984). Moreover, high 
concentrations of β-PEA dose-dependently maintained responding in monkeys that were 
previously trained to self-administer cocaine, and pretreatment with a MAO-B inhibitor, 
which delayed β-PEA deactivation, further increased response rates (Bergman et al., 2001).  
On the other hand, more variable influences on brain reward have been reported for other 
TAs. In rats that responded at threshold levels for ICSS of the lateral hypothalamus, 
tryptamine antagonists not only caused dose-related increases when given alone but also 
potentiated the brain reward-facilitating effects of amphetamine (Silveira Filho and Graeff, 
1977). Conversely, systematic application of tryptamine decreased ICSS in both the medial 
raphe nucleus and the lateral hypothalamus (Broadbent and Greenshaw, 1985). Moreover, in 
sharp contrast to the conditioned place preference produced by β-PEA, tryptamine induced 
conditioned taste aversion to a novel saccharin solution in rats (Fletcher, 1986). These 
findings suggest an inhibitory regulation of reward function via tryptamine-mediated 
pathways. In addition, while little is known about the role of octopamine in brain reward in 
vertebrates, the functional contribution of octopamine to reward-associated learning has been 
well-noted in insects (Hammer, 1997, Unoki et al., 2006, Perry and Barron, 2013). Also, 
studies conducted in Drosophila suggest that tyramine is essential for the development of 
cocaine sensitization (McClung and Hirsh, 1999), a phenomenon thought to share similar 
underlying neuroadaptive mechanisms to those mediating craving and relapse (Kalivas et al., 




In summary, these findings underscore the important implications of TAs in 
psychostimulants-mediated effects and in brain reward processing, which, together with their 
widely documented interaction with the classic monoamines, strongly suggest a potential 
involvement of the TA system in the neurological adaptations underlying drug addiction. 
However, due to the apparent absence of specialized receptors for TAs and the lack of 
knowledge of their signalling mechanisms, research interest in their neurobiological functions 
and neuropathological implications was largely discouraged for a considerable time.  
2.2 Identification of TAAR Family  
Progress in the characterization of the neurobiological functions of TAs has been hampered 
by the difficulty in identifying their specific receptor targets. Although saturable high-affinity 
binding sites distinct from the amine transporters and receptors had been identified in the 
mammalian brain (Kellar and Cascio, 1982, Brüning and Rommelspacher, 1984, McCormack 
et al., 1986, Nguyen and Juorio, 1989), it was at the beginning of the twenty-first century that 
two research groups independently reported the cloning and identification of a novel family 
of mammalian GPCRs (Borowsky et al., 2001, Bunzow et al., 2001). Such receptors, 
including several orphan receptors, shared an unusually high degree of sequence homology, 
and some were directly activated by TAs. The discovery of receptors for TAs supported their 
role as bona fide neurotransmitters, that is, as molecules able to trigger cellular events 
directly, and led to a renewed interest in the TAs and their biological functions. In subsequent 
studies, Lindemann and collaborators proposed a uniform nomenclature for this newly 
discovered GPCR family, together with closely related receptors, as TAARs, acknowledging 
the fact that some members are unresponsive to TAs (Lindemann et al., 2005). Further work 
by the same group completed the identification of all members of this GPCR family in rats, 
mice, chimpanzees, and humans, demonstrating remarkable differences in the number of 
receptor genes and the proportion of pseudogenes amongst the four species (Lindemann et 
al., 2005). There are nine TAAR genes in human including three pseudogenes; nine genes in 
chimpanzee including six pseudogenes; 19 and 16 in rat and mouse with two and one being 




subfamilies were identified based on phylogenetic relationships and pharmacophore 
similarities, which remained consistent across all of the four species (Lindemann et al., 
2005). The three subfamilies consist of TAARs 1-4, TAAR5, and TAARs 6-9, with each 
subgroup represented by at least one functional TAAR gene. Not surprisingly, the only two 
receptors that are activated by TAs, namely TAAR1 and TAAR4, both belong to the first 
subfamily, supporting a functional basis for the classification (Lindemann et al., 2005). While 
TAAR1 is sensitive to all TAs and the TAAR1 gene is phylogenetically conserved in all the 
studied species including human, TAAR4 is a pseudogene in the human genome and rat 
TAAR4 responds only to β-PEA and tyramine, although to a much lesser degree than 
TAAR1 (Borowsky et al., 2001, Bunzow et al., 2001, Lindemann et al., 2005). As a result, 
TAAR1 has received by far the most attention over the past decade and it is the best 
characterized receptor of the class (Lindemann and Hoener, 2005).  
2.3 Expression, Signalling, and Pharmacology of TAAR1 
TAAR1 couples to a Gαs G protein and, upon stimulation, triggers accumulation of 
intracellular cAMP via adenylyl cyclase activation and stimulates G protein-coupled 
inwardly-rectifying K+ channel (GIRK) (Borowsky et al., 2001, Bunzow et al., 2001, Miller 
et al., 2005, Xie et al., 2007, Bradaia et al., 2009). TAAR1 activation can also lead to PKA 
and PKC phosphorylation and upregulation of the transcription factors, CREB and NFAT 
(Panas et al., 2012). TAAR1 also signals via a G protein-independent, β-arrestin2-dependent 
pathway involving the protein kinase B (AKT)/glycogen synthase kinase 3 (GSK3) β 
signalling cascade, an important player in many DA-mediated actions (Harmeier et al., 2015) 
(Figure 2.1). Among the TAs, β-PEA and tyramine are the most potent activators at TAAR1, 
with β-PEA being more potent than tyramine at human and mouse TAAR1, with the opposite 
being true at rat TAAR1 (Bunzow et al., 2001, Grandy, 2007, Wainscott et al., 2007). 
Strikingly, in addition to TAs as principal binding ligands, TAAR1 is also activated by a vast 
variety of endogenous and exogenous molecules, including the major catecholamines, DA, 
NE, and 5-HT, and some of their metabolites, amphetamine-like compounds including 




derivatives including lysergic acid diethylamide (LSD), and several adrenergic ligands 
(Bunzow et al., 2001), as well as certain thyroid hormones derivatives (Hart et al., 2006). 
Studies aiming at determining TAAR1 distribution in the mammalian system have 
consistently reported a widespread and unique pattern of TAAR1 mRNA or protein 
expression in the central and peripheral nervous system in human, mouse, rat, and rhesus 
monkey. In the brain, TAAR1 mRNA has been detected throughout the limbic system and in 
regions associated with the major monoaminergic pathways, including the VTA, SNr, locus 
coeruleus, raphe nucleus, caudate nucleus, putamen, NAc, hippocampus, hypothalamus, and 
amygdala (Borowsky et al., 2001, Bunzow et al., 2001, Miller et al., 2005, Xie et al., 2007, 
Lindemann et al., 2008, Espinoza et al., 2015a). In addition to subcortical areas, TAAR1 is 
also expressed in cortical regions, especially in layer V pyramidal neurons of the PFC 
(Espinoza et al., 2015b). The cellular distribution of TAAR1 is predominantly intracellular, 
with diffuse expression within the perikaryon and along axonal processes, and sparse 
membrane-associated neuronal expression (Bunzow et al., 2001, Xie et al., 2007). Therefore, 
it has been postulated that the intracellular TAAR1 might recruit an accessory protein for 
translocation to the plasma membrane (Bunzow et al., 2001) or indeed might signal 
intracellularly, given the accessibility of several TAAR1 endogenous ligands within the 
cytoplasm and the ability of intracellular GPCRs to exert downstream effects (Xie et al., 
2007, Lam et al., 2015). Remarkably, TAAR1 is co-localized with DAT in a subset of DA 
neurons, and/or expressed in neurons that are in close apposition to DAT-expressing neurons 
in mouse and rhesus monkey SNr (Xie et al., 2007). There is also evidence suggesting 
co-expression of TAAR1 with the NE transporter in adrenergic neurons in the rhesus monkey 
locus coeruleus, as well as co-localization with 5-HT transporter in serotonergic neurons in 
the mouse dorsal raphe nucleus (Lindemann et al., 2008, Xie et al., 2008). The 
neuroanatomical distribution of TAAR1 in relation to the major monoamine systems suggests 
that TAAR1 might be in a position to regulate monoaminergic transmission through direct 
interactions with monoamine transporters and presynaptic autoreceptors co-expressed with 




monoaminergic neurons. The next section will review evidence from different research lines 
in support of such fundamental neurochemical interactions. 
 
 
Figure 2.1 Signalling of trace amine-associated receptor 1 (TAAR1) at a DA synapse 
Amphetamines enter the presynaptic neurons through competitive reuptake inhibition of the DA 
transporter (DAT) (1) and by diffusion through presynaptic membranes, causing release of DA by 
way of vesicular monoamine transporter-mediated exocytosis (2) and reverse transport through the 
DAT (3). Both amphetamines and endogenous TAs activate TAAR1, leading to adenylyl cyclase 
activation and downstream stimulation of PKA/PKC (4). TAAR1 also signals via G 
protein-independent, β-arrestin2-dependent pathway involving the protein kinases B 
(AKT)/glycogen synthase kinases 3 (GSK3) β signalling cascade. D2 receptor activation through 
β-arrestin2 dephosphorylates AKT, resulting in AKT inactivation and increased GSK3β signalling 
(5). TAAR1 interacts with both presynaptic D2s and postsynaptic D2 receptor through formation of 
heterodimeric complexes, leading to reduced TAAR1-stimulated cAMP accumulation (6, 
postsynaptic process not show). Interaction of TAAR1 with D2 receptor also shifts β-arrestin2 
recruitment from D2 receptor to TAAR1, resulting in reduced GSK3β activation (7). In addition, 
phosphorylation of the DAT through TAAR1-stimulated activation leads to DAT internalization, 





2.4 Functional Interaction of TAAR1 with Brain Monoamine Systems 
Studies with heterologous expression systems and brain synaptosomes have revealed a 
complex tripartite relationship between TAAR1, monoamine transporters, and monoamine 
autoreceptors in vitro. First, in such in vitro preparations, TAAR1 activation by agonist 
ligands, including TAs, the classic biogenic amines, and drugs of the amphetamine-class, was 
shown to be markedly enhanced by co-transfecting TAAR1 with monoamine transporters 
(Miller et al., 2005, Xie et al., 2007). Since these TAAR1 agonists are also substrates at 
monoamine transporters, it has been hypothesized that the monoamine transporters might 
serve as conduits for the entry of TAAR1 agonists into the synaptic terminal such that 
activation of intracellular TAAR1 can occur (Miller et al., 2005, Xie et al., 2007, Miller, 
2011). Alternatively, the transporter-mediated agonist uptake might trigger trafficking of 
TAAR1 into the plasma membrane (Xie et al., 2007). Additionally, such in vitro assays have 
revealed that TAAR1 activation functionally downregulates the activity of monoamine 
transporters. In cells co-transfected with both TAAR1 and one of the main aminergic 
transporters, TAAR1 activation by DA, NE, or 5-HT led to functional inhibition of the 
co-expressed transporter, reducing uptake and increasing efflux of the associated 
neurotransmitter (Xie et al., 2008). 
Moreover, further evidence suggests that both TAAR1 and monoamine autoreceptor 
activation modulate monoamine transporter function reciprocally by way of opposing 
interactions on aminergic transmission (Xie et al., 2008). While TAAR1 activation promotes 
efflux of monoamines through their transporter proteins, autoreceptor activation leads to 
increases in the uptake of classical biogenic amines in monkey and wild-type mouse striatal 
and thalamic synaptosomes, with this effect being absent in synaptosomes from TAAR1 
knockout (KO) mouse (Xie et al., 2008). When the DA, NE, and 5-HT transporters were 
co-transfected with D2s, α2A, or 5-HT1B autoreceptors, uptake of the respective amine 
transmitter was significantly enhanced. Conversely, NE and 5-HT reduced retention of the 
preloaded neurotransmitter in the presence of the specific autoreceptor antagonist in both 




TAAR1-dependent monoamine efflux has been attributed to reversed transport of 
monoamines through their corresponding transporters resulting from TAAR1-mediated 
intracellular cAMP accumulation and substrate phosphorylation (Xie et al., 2008). Together, 
these findings indicate that the classical biogenic amines interact with both TAAR1 and 
monoamine autoreceptors to regulate transporter function. Thus, a concept of presynaptic 
receptor balancing has been proposed whereby TAAR1 and monoamine autoreceptors 
equilibrate monoamine activity, with the former inhibiting uptake and the latter facilitating it 
(Xie et al., 2008, Xie and Miller, 2009b).  
More recent evidence from both in vitro and in vivo studies suggests a direct interaction of 
TAAR1 with monoamine autoreceptors that may underlie the presynaptic receptor balancing 
previously proposed. First, TAAR1 and D2s receptors, when co-expressed in cells, were able 
to form constitutive heterodimers in plasma membrane, thus allowing functional regulation of 
these two GPCRs and/or other cellular substrates (Espinoza et al., 2011). Indeed, both total 
and membrane expression level of TAAR1 was decreased by co-expressing it with D2s in the 
same cells (Espinoza et al., 2011). Such interactions between TAAR1 and D2s receptors are 
in part mediated by receptor heterodimerization. Previously, it was shown that co-transfecting 
D2s, α2A or α2B, or 5-HT1A or 5-HT1B along with TAAR1 attenuated TAAR1 
activation-induced intracellular cAMP in response to DA, NE, or 5-HT, respectively (Xie et 
al., 2008). Thus, the facilitating effects of autoreceptor activation on monoamine transporter 
function could result from either direct enhancement or suppression of TAAR1-mediated 
inhibition of transporter function. Importantly, more recent studies indicated that TAAR1 
activation may also potentiate D2s-mediated inhibition of monoamine transmission, an effect 
that is lacking in TAAR1 KO mice (Leo et al., 2014). Similarly, previous findings indicated 
that activating TAAR1 with specific agonists increased agonist potency at 5-HT1A receptors 
whereas selective blockade of TAAR1 produced the opposite effects (Revel et al., 2011). 
Collectively, these findings suggest that TAAR1 stimulation may have dual effects on 
monoaminergic activity. While TAAR1’s direct inhibition of the monoamine transporter may 




monoamine autoreceptors may lead to enhanced transporter function and depressed 
monoamine transmission.  
Therefore, it would appear that the relative activation of TAAR1 and D2s receptors by 
endogenous or exogenous ligands critically determines the net output of monoaminergic 
systems through key effects on transporter regulation (Xie and Miller, 2009b). Unlike the 
common biogenic amines, which activate both types of receptors, the endogenous TAs are 
agonists at TAAR1 only. Consequently, selective TAAR1 stimulation by TAs or specific 
agonists is distinct from TAAR1 activation by classical monoamines in that these trigger 
inhibitory modulation of TAAR1 through autoreceptor co-stimulation. Not surprisingly, in 
vitro, the co-expression of monoamine autoreceptors with TAAR1 attenuated TAAR1 
signaling in response to common monoamines, but not to β-PEA (Xie and Miller, 2008). In 
agreement with these findings, while the common biogenic amines significantly enhanced 
uptake in cells co-transfected with the respective monoamine autoreceptors and transporters, 
β-PEA did not (Xie and Miller, 2008). 
Further accentuating the complexity of TAAR1 molecular interactions at monoamine 
synapses, recent studies have unveiled regulatory effects of TAAR1 signaling on postsynaptic 
D2 receptors. While TAAR1 KO mice had impaired striatal presynaptic D2s-mediated 
autoinhibition (Leo et al., 2014), they also exhibited upregulation of striatal postsynaptic D2 
receptors mRNA and overactivity of D2 receptor-mediated G protein/cAMP-independent, 
β-arrestin2-dependent signaling pathway (Espinoza et al., 2015a). D2 receptor activation 
through β-arrestin2 has been shown to dephosphorylate AKT and its downstream target 
GSK3β, leading to inhibited AKT activity and subsequent increase in GSK3β signaling 
(Beaulieu et al., 2011). Decreased phosphorylation of AKT with concomitant elevation of 
GSK3β is associated with excessive dopaminergic stimulation, as produced either by indirect 
DA agonists including psychostimulants, such as amphetamine and cocaine, or by DAT 
deletion (Beaulieu et al., 2004, Li and Gao, 2011). Conversely, pharmacological or genetic 




psychostimulants (Beaulieu et al., 2004, Beaulieu et al., 2005, Li and Gao, 2011). Therefore, 
the finding that striatal D2 receptors and associated AKT/GSK3β signaling pathway are 
upregulated in TAAR1 KO mice suggests that TAAR1 activation may counteract DA 
signaling at postsynaptic sites, although this effect is likely to be indirect. A recent study 
reported that the formation of heteromeric complexes between TAAR1 and D2 receptors not 
only reduces TAAR1-stimulated cAMP accumulation, but also shifts β-arrestin2 recruitment 
from activated D2 receptors to activated TAAR1 (Harmeier et al., 2015). Interestingly, 
TAAR1-mediated β-arrestin2 signaling leads to increased phosphorylation of AKT and 
GSK3β, indicating an enhanced AKT activation and a silencing of GSK3β activity, opposite 
to the known effect of β-arrestin2 on its downstream target (Harmeier et al., 2015) (Figure 
2.1). 
This complementary evidence suggests that TAAR1 may be able to downregulate DA 
transmission not only by potentiating D2s-mediated presynaptic autoinhibition but also 
through inhibiting D2 receptor-mediated postsynaptic signaling. In support of this notion, 
mice with TAAR1 depletion exhibited greater locomotor activity compared to wild-type 
counterparts when challenged with quinpirole, a D2-like receptor agonist that is known to 
inhibit locomotion at low doses via stimulating presynaptic D2s and enhance locomotion at 
high doses by activating postsynaptic D2-like receptors, suggesting that TAAR1 deletion may 
induce supersensitivity of postsynaptic D2-like receptors (Espinoza et al., 2015a). 
Taken together, these findings suggest that multidirectional interactions occur between 
TAAR1 and monoamine molecular targets at both pre- and post-synaptic sites. However, 
knowledge derived from analysis at cellular and molecular levels raises the question as to the 
ultimate functional outcome of these complex interactions and the exact neurophysiological 
role of TAAR1. Inspection of the neurological and behavioral adaptations exhibited by 
transgenic mice with TAAR1 modifications provides additional insight into this question. 
Compared to wild-type littermates, TAAR1 KO mice exhibited no differences in general 




2008), but displayed deficits in pre-pulse inhibition of acoustic startle, a DA-dependent 
response, indicating impaired sensorimotor gating (Wolinsky et al., 2007). Moreover, these 
KO mice had elevated spontaneous firing frequency and depolarized resting membrane 
potential of DA neurons in the VTA (Lindemann et al., 2008), amplified spontaneous spike 
rate of 5-HT neurons in the dorsal raphe nucleus (Revel et al., 2011), and increased 
extracellular DA in the NAc (Leo et al., 2014). Moreover, they showed enhanced sensitivity 
to amphetamine-induced locomotor activity and increase in extracellular DA, NE, and 5-HT 
levels in the striatum (Wolinsky et al., 2007, Lindemann et al., 2008), and METH-induced 
conditioned place preference (Achat-Mendes et al., 2012). When challenged with MDMA, 
the wild-type mice displayed dose-dependent, biphasic thermoregulatory responses with early 
hypothermia followed by hyperthermia, but TAAR1 KO mice only showed long-lasting 
hyperthermia accompanied by supersensitivity to MDMA-stimulated locomotor activity and 
release of DA and 5-HT in the NAc and dorsal striatum, and of DA in the frontal cortex (Di 
Cara et al., 2011). By contrast, mice engineered to overexpress TAAR1 showed unaltered 
spontaneous locomotor activity but hyposensitivity to amphetamine-induced psychomotor 
activity and catecholamine release in the NAc (Revel et al., 2012a). Taken together, these 
findings suggest that TAAR1 may be constitutively active or tonically activated by ambient 
levels of endogenous amines to exert an inhibitory influence on monoaminergic 
neurotransmission; and that TAAR1 activation may restrain the potentiation of monoamine 
transmission elicited by stimulant drugs. Actually, it has been suggested that TAAR1 may be 
recruited by amphetamine-class drugs, such as MDMA and METH, which are themselves 
agonists at TAAR1, to modulate their neurochemical and behavioural actions (Lindemann et 
al., 2008, Di Cara et al., 2011, Miller, 2011).  
2.5 Target TAAR1 to Treat Stimulant Addiction  
The very recent engineering of the highly selective TAAR1 agonists and antagonists has 
provided the first direct tools to investigate the functional role of this receptor in monoamine 
transmission. It has been shown that the selective TAAR1 antagonist, EPPTB, increased the 




the idea that TAAR1 is constitutively active or tonically activated by ambient levels of 
amines to downregulate DA tone. Moreover, while the selective TAAR1 full agonists, 
RO5166017 and RO5256390, decreased the firing frequency of DA neurons in the VTA and 
of 5-HT neurons in the dorsal raphe nucleus, the partial agonists, RO5203648 and 
RO5263397, enhanced the firing rate of these same neurons, acting in the similar manner as 
the selective antagonist, further confirming the constitutive activity or tonic activation status 
of TAAR1 such that partial agonism results in an antagonistic-like effect (Revel et al., 2011, 
Revel et al., 2012b, Revel et al., 2013). Further, the full agonist, RO5166017, has been 
recently reported to reduce electrically evoked DA release in both the dorsal striatum and 
NAc in slices of mouse brain, whereas the antagonist, EPPTB, increased DA release in the 
NAc (Leo et al., 2014), demonstrating homogenous inhibitory effects of TAAR1 at 
dopaminergic cell bodies and terminals. In addition, these findings provide evidence that full 
activation of TAAR1 is capable of actively suppressing DA signalling and DA release.  
As a result, the critical hypothesis arises that targeting TAAR1 pharmacologically may 
provide a therapeutic means to modulate the characteristic aberrant DA transmission that 
hallmarks the addictive process, and may present a novel avenue for medicinal development 
in psychostimulant addiction. Early in vivo studies with the highly selective TAAR1 agonists 
have offered preliminary evidence supporting this possibility. Firstly, an important 
behavioural manifestation of psychostimulant-induced increase in mesocorticolimbic DA 
transmission in rodents is locomotor hyperactivity and, at high doses, stereotypies, which are 
repetitive, invariant behavioural patterns with no obvious goal or function, consisting of 
repetitive head bobbing, gnawing, sniffing, licking, and biting (Fog, 1969, Schuster, 1981, 
Mason, 1991, Nakagawa et al., 2011). It has been shown that, the full agonists, RO5256390 
and RO5166017, and the partial agonists, RO5263397 and RO5203648, reduced cocaine- or 
d-amphetamine-stimulated hyperlocomotion or stereotypies in mice or rats, with little or no 
effect on locomotor activity when administered alone (Revel et al., 2011, Revel et al., 2012b, 
Revel et al., 2013). In addition, mutant mice that lack the Slc6a3 gene encoding the DAT 




and the partial agonist, RO5203648, reduced the spontaneous hyperactivity in these mice 
(Revel et al., 2011, Revel et al., 2012b). Together, these observations suggest that full or 
partial TAAR1 activation is sufficient to counteract behavioural abnormalities induced by 
excessive DA transmission, and highlight the remarkable potential of TAAR1-based 
compounds to modulate the pathological neuroadaptations that abused drugs produce on the 
DA system.  
In particular, the use of partial agonists may be more advantageous than full agonists in 
situations where drug-induced neurochemical imbalance leads to insufficient or excessive 
TAAR1 stimulation, providing a means to “stabilize” TAAR1 activity. In turn, this 
bidirectional regulation on TAAR1 activation level through partial agonism allows a 
state-dependent modulation of DA neurotransmission which fluctuates across different stages 
in the addiction cycle. As previously described, the acute euphoria effect of the drug that 
positively reinforces drug taking at early stages is mediated by large increases in DA 
transmission in the NAc, while the negative hedonic affective state marking the withdrawal 
stage is caused by a reduced mesolimbic DA function that progressively worsens with 
chronic drug use (Koob and Le Moal, 2008a, b). In addition, an activation of DA 
transmission is involved in the reinstatement of drug seeking induced by re-exposure to 
drug-associated cues (Ito et al., 2000, Weiss et al., 2000) or drug itself (Stewart, 2000, Di 
Ciano et al., 2001). For instance, in a typical cocaine or d-amphetamine self-administration 
session, response during the initial “loading” phase, which is characterized by rapid 
accumulation of drug infusions, is accompanied by elevation in extracellular DA 
concentration in the NAc until a peak DA level is reached. During the subsequent 
“maintenance” phase where response is well-spaced with relatively uniform inter-response 
intervals, DA level remains tonically elevated but displays phasic fluctuations that are 
time-locked to the periodic lever pressing (Kiyatkin and Stein, 1995, Wise et al., 1995, 
Ranaldi et al., 1999). By contrast, DA concentration gradually declines in an acute extinction 
session despite increased lever pressing, with the period of highest responding rate marked by 




single non-contingent drug infusion or drug-paired stimulus causes an immediate increase in 
DA level in the NAc and a recovery of lever pressing (Ranaldi et al., 1999, Weiss et al., 
2000).  
Thus, partial activation of TAAR1 may attenuate acute drug reward and drug-taking by 
suppressing drug-stimulated DA overactivity, reduce withdrawal-associated anhedonia and 
drug-craving by compensating for diminished DA, and prevent cue- or drug-induced 
reinstatement of drug seeking through inhibiting hyperdopaminergic response to the cue or 
drug itself. On the other hand, full activation of TAAR1 may have a more general inhibitory 
influence on the DA system, which is more beneficial in situations where DA transmission is 
potentiated by psychostimulants such as during drug intoxication and relapse. In the long 
term, the disrupted DA system is expected to gradually become stabilized and “normalized” 
under TAAR1 regulation, allowing for a longer period of or even lifetime abstinence, which 
is the final goal of an efficacious anti-addiction treatment.  
However, due to the unavailability of highly selective TAAR1 agonists until very recently, 
early attempts to directly test the hypothesis that TAAR1 activation may be effective in 
reducing neurochemical and behavioural markers of psychostimulant addiction are extremely 
scarce. The abovementioned studies where several TAAR1 agonists reversed cocaine- or 
d-amphetamine-induced motor response are informative because an increase in extracellular 
DA levels in the mesolimbic pathway, especially the NAc, has been postulated as a common 
mechanism for the acute motor-stimulating and reinforcing effects of psychostimulants 
(Vezina, 2004). A recent study assessed the effects of the partial TAAR1 agonist, 
RO5203648, on cocaine self-administration in rats. The results showed a dose-dependent 
reduction of response rate for cocaine (Revel et al., 2012b). Recent neurochemical data has 
showed that RO5203648 effectively reduced cocaine-induced DA overflow in the NAc in rat 
brain slices (Pei et al., 2014), which may at least partially account for TAAR1’s regulation of 




confirmation of the anti-addiction properties of TAAR1 agonists and paved the way for 
further investigations2.  
2.6 The Present Work  
The general aim of the present thesis was to test the hypothesis that TAAR1 may present a 
novel target for therapeutics in stimulant addiction. This was achieved by means of a 
systematic investigation of the functional regulation by TAAR1 of key behavioural aspects 
associated with psychostimulant action as well the physiological mechanisms underlying the 
effects of TAAR1. We utilized well-validated animal models of addiction that are associated 
with specific elements of the addiction process. The selective partial agonists, RO5203648, 
RO5263397, and compound M, were used as the primary pharmacological tools for this 
investigation. The full agonist, RO5256390, was also tested in some models for comparison 
purposes. The overarching goal was to provide a step-by-step assessment of the potential 
therapeutic-like effectiveness of TAAR1 agonists in relevant models of stimulant addiction, 
and to understand the underlying physiological mechanisms. This was accomplished across 
three sets of experiments (10 experiments in total described in chapters three to five). The 
below sections describe the rationale and objectives of each experiment.  
2.6.1 Experiment set one 
The first set of experiments (experiments 1-2) investigated the effect of TAAR1 partial 
agonism on the locomotor-activating effects of METH and explored the neurobiological basis 
for this effect (chapter three). Acute cocaine or amphetamine produces hyperlocomotion in 
rodents, and repeated exposure to these drugs leads to behavioural sensitization, which is a 
progressive increase in their ability to elicit locomotor activity. When established, 
behavioural sensitization is enduring as animals may remain hypersensitive to the 
motor-activating effects of drugs for months or years after the discontinuation of drug 
treatment (Robinson and Berridge, 1993, Robinson and Berridge, 2001, Vezina, 2004). 
                                                 
2 During the three-year PhD, new findings have been reported with those selective TAAR1 ligands. To avoid 
confusions about the presented rationale which is based on earlier evidence, these newer findings will be 




Although hyperlocomotion and behavioural sensitization are not common phenomena in 
human addicts, they are of the most typical behavioural effects observed in rodents and, as 
previously mentioned, both have been related to addiction processes because the neural 
substrates underlying these effects at least partially overlap with those responsible for drug 
reward and the transition to addiction (Wise and Bozarth, 1987, Robinson and Berridge, 
2001). In particular, the acute ability of psychostimulants to increase extracellular levels of 
DA in the NAc has been critically associated with both their locomotor-activating effects and 
reinforcing efficacy (Robinson and Berridge, 2001, Vezina, 2004). Moreover, the long-term 
neuroadaptations produced by repeated drug exposure that underlie behavioural sensitization 
and escalation of drug use both involve sensitized dopaminergic responses in the NAc to the 
drug (Vezina, 2004). Also, the long-lasting potentiation of DA neuronal responsiveness 
caused by chronic drug exposure has been linked to prolonged relapse vulnerability after 
cessation of drug use (Shaham and Hope, 2005). For these reasons, one of the 
pharmacotherapeutic strategies for stimulant addiction is to develop medications that are able 
to reverse neurobiological changes induced by acute and chronic drug exposure, which can be 
assessed in models that produce hyperactivity and behavioural sensitization after specific 
drug treatment regimens. Therefore, one of the objectives of the present work is to study the 
ability of TAAR1 agonists to modulate psychostimulant-induced locomotor changes as an 
initial step in the evaluation of their therapeutic potential in stimulant abuse.  
Although this question has been addressed to some degree previously (Revel et al., 2011, 
Revel et al., 2012b, Revel et al., 2013), these studies did not provide a full picture on the 
ability of TAAR1 to regulate the psychomotor-activating effects of stimulants. Thus, 
experiments 1-2 further explored this issue. Briefly, the ability of TAAR1 partial activation to 
modulate locomotor activity produced by acute (experiment 1) and repeated (experiment 2) 
METH was assessed with the selective TAAR1 partial agonists, RO5203648 (experiment 1) 
and compound M (experiment 2). Experiment 2 also examined how compound M influenced 
the effects of chronic METH on the inducibility of the immediate early genes (IEGs), c-fos 




methyl CpG binding protein 2 (MeCP2), in brain areas important for addiction in order to 
gain insight into the underlying neurobiological mechanisms.  
2.6.2 Experiment set two 
The second set of experiments (experiments 3-6) examined the effect of partial and full 
TAAR1 activation on the reinforcing efficacy of psychostimulants (chapter four). 
Psychostimulants are characterized by their powerful intrinsic reinforcing and rewarding 
properties, which is one of the major contributors to the initiation and maintenance of drug 
taking in human addicts and critically underlies their ability to sustain self-administration in 
animals. The reinforcing efficacy of a drug has been suggested to correlate positively with its 
actual abuse liability (Schuster, 1981). Thus, the ability of a medication to decrease the 
reinforcing effects of psychostimulants may be indicative of anti-addiction potential (Mello 
and Negus, 1996). In this regard, animal models of self-administration, which closely mimic 
human drug taking, afford a valuable approach for the preclinical evaluation of new 
pharmacotherapies for addiction (Mello and Negus, 1996, Pierce and Kumaresan, 2006).  
There is only one existing study that has examined the influence of a TAAR1 agonist on 
cocaine self-administration behaviour in rats, which showed a decrease in cocaine responding 
(Revel et al., 2012b). However, only a single dose of cocaine (0.5 mg/kg/infusion) was 
examined in this study, making interpretation of the results problematic. It has been 
consistently reported that, within the range of doses that sustain self-administration, animals 
adjust their response as a function of the unit injection dose of the drug. For drugs like 
cocaine and METH, the dose-response function typically displays an inverted U-shaped curve 
characterised by an ascending limb, where increases in unit doses of the drug result in 
increased self-administration until a peak level is reached, and a descending limb, where 
further increases of drug dose lead to decreased self-administration (Nader and Reboussin, 
1994, Mello and Negus, 1996, Shippenberg and Koob, 2002, Clemens et al., 2006, Sharpe et 
al., 2014). A treatment medication may affect the dose-response curve in three possible ways, 




an antagonism, potentiation, or complete blockade of the reinforcing effects of the drug. The 
ideal therapeutic outcome is a downward shift which results in decreased drug-taking across 
all of the drug doses. Shifting the curve to the right is less satisfactory because it decreases 
responding rate at some unit doses but simultaneously increases responding at other doses, 
representing a simple change in drug potency that can be compensated by self-adjusting the 
amount and frequency of drug intake (Mello and Negus, 1996). Therefore, a complete 
dose-effect function for drug self-administration should be constructed to evaluate the 
treatment effectiveness of a medication (Mello and Negus, 1996, Shippenberg and Koob, 
2002). Hence, in order to extend the previous study that examined a single dose of cocaine, 
experiment 3 explored the effect of full and partial TAAR1 activation on the dose-response 
function for cocaine self-administration, with the use of the full agonist, RO5256390, and the 
partial agonist, RO5203648.  
In addition, the PR schedule has been widely adopted by self-administration studies to 
investigate the reinforcing property of a drug and to assess the effectiveness of 
pharmacological pretreatment (Arnold and Roberts, 1997). Under the PR schedule, the 
number of responses required to obtain each subsequent drug infusion systematically 
increases, and the final response ratio in the series at which responding ceases is defined as 
the breaking point (BP), which reflects the maximum effort that an animal will expend to 
earn a drug infusion and thus provides a measure of motivation to take the drug (Richardson 
and Roberts, 1996, Arnold and Roberts, 1997). Here, to gain further insight into TAAR1’s 
regulation of the reinforcing efficacy of psychostimulants, we tested the effects of the 
selective partial TAAR1 agonists, RO5203648 (experiment 4) and RO5263397 (experiment 
5), on the self-administration of cocaine or METH, respectively, under a PR schedule of 
reinforcement. Besides, to control for potential side effects of TAAR1 agonists on non-drug 
related behaviour, such as motor function and motivation for natural reinforcers, the influence 





The last experiment in this chapter aimed to gain insight into the neuronal mechanism 
involved in TAAR1’s regulation of psychostimulant action. It was recently reported that 
RO5203648 blocked cocaine-induced DA release in the NAc in rat brain slice as measured by 
fast-scan cyclic voltammetry (FSCV) (Pei et al., 2014), which is consistent with the 
hypothesized counteracting effects of TAAR1 on DA transmission. Experiment 6 extended 
this finding by measuring the influence of RO5263397 on METH-evoked DA overflow in the 
NAc core using FSCV. The NAc core was chosen because it is a major action site for 
psychostimulants and critically mediates the transition to compulsive drug use and addiction. 
Given the rich expression of TAAR1 in the NAc, local application of RO5263397 within this 
region was expected to attenuate the DA augmentation produced by METH.  
2.6.3 Experiment set three 
As will be described in detail in the following experimental chapters, the results obtained 
from experiment sets one and two provided evidence on the ability of TAAR1 to modulate 
several important effects of psychostimulants. The third set of experiments was designed to 
further explore TAAR1’s anti-addiction properties by assessing the therapeutic-like potential 
of TAAR1 agonists in relapse, which is one of the core features of addiction and represents a 
major obstacle in addiction treatment (chapter five). Experiment 7 employed a model of 
context-induced renewal of drug-seeking after prolonged abstinence without extinction, 
which approximates human situations where re-experiencing the environment associated with 
past drug-taking behaviour triggers relapse of drug seeking after a long drug-free period 
(Fuchs et al., 2006, Ferragud et al., 2009). It has been shown that DA transmission in the 
mesolimbic pathway plays a role in context-induced reinstatement (Crombag et al., 2008), 
and elevation of DA concentrations by drug-associated stimuli has been reported in the dorsal 
striatum (Volkow et al., 2006) and the NAc (Fontana et al., 1993). Thus, given the known 
ability of TAAR1 to dampen DA activity, pharmacological activation of TAAR1 was 
expected to attenuate context-induced renewal of drug-seeking. Experiment 7 tested this 
hypothesis in cocaine relapse with the full agonist, RO5256390, and the partial agonist, 




examined in order to control for their non-specific effects on general motoric and appetitive 
functions.  
Another model that has been widely used to study relapse is the extinction-reinstatement 
model, in which animals undergo extinction training until response rate decreases to a set 
criterion and reinstate drug seeking when challenged with the drug itself, drug-associated 
cues, or stressors (Shalev et al., 2002, Shaham and Hope, 2005). The neurobiological 
mechanisms underlying the three types of reinstatement have been found to be partially 
dissociable. Whereas both drug- and cue-induced reinstatement largely involve DA-mediated 
processes that differ to some degree in pharmacology and neuroanatomy, stress-induced 
reinstatement seems to rely more on the CRF and the NE systems (Shalev et al., 2002). 
Because the functional modulation by TAAR1 has been much better characterized for DA 
compared to other neurotransmitter systems, stress-induced reinstatement was not assessed in 
the current thesis. Moreover, the effects of re-exposure to drug-paired cues after extinction 
may be to certain degree analogous to the effects of re-exposure to drug-associated context 
after abstinence (experiment 7), as both processes involve learned associations between 
drug-associated cues, including both discrete cues and contextual cues, and the drug’s 
pharmacological effects (Bossert et al., 2013). For this reason, cue-induced reinstatement was 
not examined in the present thesis, but further studies are warranted given the limited overlap 
in the neuronal substrates for drug seeking after extinction versus abstinence (Fuchs et al., 
2006). Therefore, experiments 8 and 9 investigated the ability of TAAR1 activation to 
suppress cocaine (experiment 8) or METH (experiment 9) reinstatement induced by a prime 
injection of the previously self-administered drug. As our findings (from experiment 7) 
indicated a more desirable profile of the partial TAAR1 agonist than that of the full agonist, 
only the partial agonists, RO5203648 (experiment 8) and RO5263397 (experiment 9), were 
tested in this model.  
The last experiment (experiment 10) aimed to determine the potential abuse liability of 




self-administration paradigm, due to its high level of face and predictive validity, has been 
regarded as the gold standard for preclinical abuse liability screening of novel medications 
(Haney and Spealman, 2008, Carter and Griffiths, 2009). A typical method is the substitution 
procedure where a dose of the test compound is substituted for a dose of a reinforcing drug 
that is already maintaining a high level of self-administration. The response rate for the test 
compound obtained at different doses is compared with that of the initial reinforcing drug and 
vehicle, which serve as a positive and negative control, respectively (Ator and Griffiths, 2003, 
Carter and Griffiths, 2009). In experiment 10, the partial agonist, RO5263397, was 







3 TAAR1 Activation Modulates Psychostimulant-Induced 
Locomotor Activity and Neuronal Plasticity 
3.1 Introduction  
It is well-established that acute psychostimulant treatment produces locomotor hyperactivity, 
an effect that is mediated by an increased mesolimbic DA transmission. With repeated 
exposure, the mesolimbic DA pathway is gradually sensitized, displaying augmented 
responsiveness to further drug challenges. This translates into behavioural sensitization, 
which is a progressively enhanced ability of psychostimulants to elicit locomotor activity 
(Robinson and Berridge, 2001, Vezina, 2004). It has been suggested that the short- and 
long-term neurobiological changes involved in the locomotor-activating effects of 
psychostimulants are also involved in drug reward, escalation of drug use, and propensity to 
relapse (Robinson and Berridge, 2001, Vezina, 2004, Shaham and Hope, 2005, Pierce and 
Kumaresan, 2006). Thus, pharmacological manipulations that counteract the locomotor 
effects of psychostimulants could have therapeutic implications in addiction.  
Previous studies examining the influence of TAAR1 selective agonists on the acute 
locomotor-enhancing effects of psychostimulants have generally reported a blockade of 
cocaine- or d-amphetamine-induced hyperactivity in rats or mice (Revel et al., 2011, Revel et 
al., 2012b, Revel et al., 2013). However, in these studies, locomotor activity was monitored 
only for a short period (30 min) and reported as total distance travelled, providing limited 
data as to the magnitude and duration of TAAR1’s effects. Thus, experiment 1 aimed to 
investigate TAAR1’s regulation of acute METH-induced locomotor activity over an extended 
period of time (3-h) during which locomotor fluctuations were examined across time3. 
                                                 
3 Published paper. Experiment 1 has been published in the following paper: Cotter R, Pei Y, Mus L, Harmeier 




Because the effects of METH on locomotion and DA activity may subside in the later phase 
of the prolonged test, a partial agonist (RO5203648) was chosen given its potential ability to 
bidirectionally influence TAAR1 activation and therefore state-dependently regulate DA 
transmission. 
In addition, the effects of selective TAAR1 agonists on METH-induced behavioural 
sensitization have not yet been tested. Thus, experiment 2 explored this question with another 
partial agonist, compound M. In order to gain insight into the underlying neuronal 
mechanisms of TAAR1’s modulatory effects, the associated changes in the brain expression 
of c-Fos, Arc, and MeCP2 were examined following the last METH challenge in the final 
probe test.  
3.2 Materials and Methods 
3.2.1 Subjects 
Male Long Evans rats (n = 35, for experiment 1) and male Lister hooded rats (n = 32, for 
experiment 2) were sourced from the University of Canterbury and the University of 
Leicester, respectively. Rats were around 8 weeks-old when experiments began and were 
housed in a temperature and humidity controlled colony room with a 12-h light/dark cycle 
(lights off at 8 a.m.). Water and standard laboratory rat chow was given ad libitum at all times. 
Experiments were conducted in compliance with the New Zealand Animal Welfare Act 1999, 
and approved by the University of Canterbury Animal Ethics Committee, and with 
appropriate project and personal license authority granted by the UK Home Office under the 
Animals (Scientific Procedures) Act 1986.  
3.2.2 Pharmacological agents 
METH hydrochloride was obtained from BDG Synthesis (Wellington, New Zealand) and 
Sigma-Aldrich (UK) and dissolved in 0.9% physiological saline for intraperitoneal (i.p.) 
injection. RO5203648 and compound M were synthesized at F. Hoffmann-La Roche Ltd. 
                                                                                                                                                        





(Switzerland) and dissolved in 10% dimethylsulfoxide in 0.9% physiological saline or 2% 
Tween20 in distilled water for i.p. injection. All drugs were prepared fresh on the day.  
3.2.3 Apparatus 
Locomotion test was conducted in a set of four open field boxes made of black Perspex (50 × 
40 × 35 cm for experiment 1; 50 × 50 × 30 cm for experiment 2). Locomotor activity was 
monitored and measured with a video tracking system and image analysis software 
(Viewpoint 2.5, Champagne au Mont D’Or, France for experiment 1; ANYMAZE software 
for experiment 2) that provided automatic measures of travelled distance, trajectory, and 
velocity of the subjects.   
3.2.4 Behavioural procedures (experiments 1 and 2) 
In experiment 1, six groups of rats (n = 5-6 per group) were habituated in the open field for 
10 min for two consecutive days. During the test, rats were given a pretreatment of 
RO5203648 (0, 5, or 10 mg/kg, i.p.) followed 15 min after by METH (0 or 0.75 mg/kg, i.p.). 
10 min after METH treatment, rats were placed into the open field and locomotor activity 
was measured for 3 h. Four rats were tested concurrently in four separate open fields. 
Locomotor activity was estimated as distance travelled and recorded in 20 min bins.  
In experiment 2, six groups of rats were habituated in the open field for 20 min for two 
consecutive days. During the 10-day sensitization period, rats received daily treatment of 
compound M (0, 10, or 20 mg/kg, i.p.) followed 15 min after by METH (0 or 1.25 mg/kg, i.p.) 
and were allowed to freely explore the open field for 60 min. Four rats were tested 
concurrently in four separate open fields. Locomotor activity was estimated as distance 
travelled and recorded in 10 min bins. After the sensitization period, rats underwent 
withdrawal from all pharmacological treatments for ten consecutive days. The group of rats 
that received vehicle pretreatment followed by saline injection was further divided into a 
Vehicle-Saline group and a control group with similar mean locomotor measures. This 
resulted in seven groups in total (n = 4-5 per group). On day 21, all rats received a challenge 




group which received a saline injection. Locomotor activity was monitored for 60 min and 
recorded in 10 min bins in the probe test.  
3.2.5 Immunohistochemistry and microscopy (experiment 2 cont.) 
All rats from experiment 2 were deeply anesthetized with sodium pentobarbitone (100 mg/kg) 
3 h after the challenge injection of METH or saline in the final probe test. Rats were perfused 
transcardially first with 0.9% saline followed by 4% paraformaldehyde (pH 7.4, dissolved in 
0.1 M phosphate buffer, PB). Brains were removed and submerged in 4% paraformaldehyde 
for 24 h at 4 °C, and then transferred into 15% sucrose (in 0.1 M phosphate buffered saline, 
PBS) for 48 h, and finally to 30% sucrose (in 0.1 M PBS) at 4 °C until tissue sank. Brains 
were then fast frozen with isopentane and dry ice and stored at -80 °C until sectioning. Brains 
were coronally sectioned at 30 µm thickness using a cryostat. Sections were collected 
through the PFC to the striatum, six parallel series per brain, and stored in 0.1 M PB 
containing 0.1% sodium azide at 4 °C prior to immunohistochemical staining.  
The first three parallel series of each brain were selected for immunohistochemical staining 
of c-Fos, Arc, and MeCP2, respectively. For c-Fos staining, free floating sections were rinsed 
three times with 0.1 M PBS for 5 min, treated 10 min with 3% H2O2 in PBS, and washed 
three times with PBS containing 1% Triton X-100 (PBS-Tx) for 5 min. The sections were 
then incubated with 5% normal goat serum (Biorbyt, UK) in PBS for 30 min, washed three 
times with PBS for 5 min, and incubated for 48 h with gentle rotation at 4 °C in a rabbit 
polyclonal anti-Fos primary antibody (Insight Biotechnology, UK) at 1:2000 in PBS-Tx with 
1% normal goat serum. After three rinses in PBS for 5 min, sections were incubated with 
secondary biotinylated Goat Anti-Rabbit IgG Antibody (Vector Laboratories, UK) at 1:500 in 
PBS with 1% normal goat serum, and washed in PBS for 5 min three times. This was 
followed by 1-h incubation in ABC mix from VECTASTAIN Elite ABC Kit (Standard*) 
(Vector Laboratories, UK) at 1:200 in PBS and three times wash in 0.1M PB for 5 min. 
Sections were then reacted with nickel-enhanced 3,3’-diaminobenzidine (DAB, composition 




5 min and washed three times in 0.1 M PB for 5 min. The process for staining MeCP2 and 
Arc was identical to that of c-Fos, except that sections were incubated for 48 h at 4 °C in a 
rabbit polyclonal anti-MeCP2 primary antibody (Merck Millipore, UK) or a rabbit polyclonal 
anti-Arc primary antibody (SYSY, Germany), respectively, at 1:2000 in PBS-Tx with 1% 
normal goat serum.  
The brain regions of the prelimbic cortex, the NAc core, and the NAc shell were selected for 
the quantification of immunoreactivity of c-Fos, Arc, and MeCP2 protein as an index of 
expression of each protein. Photomicrographs containing one of the selected areas (4-6 
photographs per site) were taken at 40 × magnification with a digital Panasonic camera (17 
megapixels) attached to a Zeiss microscope. The number of immunoreactive neurons for each 
protein was counted manually and averaged for each selected area. Results were expressed as 
cell density (number of stained neurons per mm2).  
3.2.6 Statistical analysis 
Data were analysed by analysis of variance (ANOVA) with repeated measures when a 
within-subjects design was in use. Post hoc comparisons were conducted with the method of 
Newman-Keuls (N-K) using the sampling error from the overall ANOVA as denominator or 
with Fisher’s PLSD test. Statistical significance was set at α = 0.05. Statistical analyses were 
performed using StatView 5.0 (SAS Institute, NC, USA).  
3.3 Results and Summary  
3.3.1 Experiment 1 results  
RO5203648 altered METH-induced locomotor activity in a time-dependent fashion, 
producing an early attenuation followed by a striking late potentiation. A repeated measure 
ANOVA for locomotor activity in 20 min bins across the 3-h test showed a significant effect 
of treatment (F5, 29 = 15.80, p < .0001) and time (F8, 232 = 15.94, p < .0001), as well as a 
significant interaction between these factors (F40, 232 = 8.35, p < .0001) (Figure 3.1). METH 
produced high levels of locomotor activity in the first 20 min that decreased gradually over 




during the first h at both the low and the high doses (p < .01 for the 1-3rd bins, by N-K tests). 
However, as the effect of METH treatment alone slowly subsided, RO5203648 potentiated 
METH’s effect by maintaining locomotor activity at moderately high levels, which were 
significantly higher than that produced by METH alone at both the low dose (p < .05 for the 
6th bin, p < .01 for the 7-9th bins, by N-K tests) and the high dose (p < .05 for the 5th bin, p 
< .01 for the 6-9th bins, by N-K tests) of RO5203648.  
 
 
Figure 3.1 RO5203648 time-dependently modulated METH-induced locomotion 
METH produced robust increases in locomotor activity compared with control treatment. 
RO5203648 time-dependently modulated METH-stimulated locomotor response characterized by 
an early attenuation and a late potentiation when METH’s effect began to subside. 5 RO = 5 mg/kg 
RO5203648, 10 RO = 10 mg/kg RO5203648, MA = methamphetamine. 
 
3.3.2 Experiment 1 summary  
To examine TAAR1 modulation of the locomotor-activating effects of acute METH, 
RO5203648 (0, 5, or 10 mg/kg, i.p.) was given 15 min prior to METH (0 or 0.75 mg/kg, i.p.) 




METH-induced hyperlocomotion in the early phase of the test, but potentiated it in the later 
phase when METH’s effects began to decay, indicating a time-dependent interaction between 
METH and the partial agonist.   
3.3.3 Experiment 2 results  
During the 10-day sensitization phase, compound M administered 15 min prior to METH had 
no significant effects on METH-induced hyperlocomotion at either the low or the high dose. 
When given on its own, compound M did not alter baseline locomotor behaviour at either 
dose compared with the saline treatment.  
Following the sensitization phase, rats underwent a 10-day withdrawal period with no 
pharmacological exposure. Behavioural sensitization was tested by giving a METH challenge 
on day 21 to all the rats except for the control group which received saline. A repeated 
measure ANOVA for locomotor activity from the 2nd 10 min bins revealed a significant main 
effect of treatment (F6, 25 = 4.57, p < .005) and time (F4, 100 = 4.46, p < .005). Post hoc 
comparisons showed that previous repeated METH treatment significantly enhanced the 
locomotor response to the METH challenge compared with repeated saline treatment (p < .05, 
by Fisher’s PLSD), demonstrating the expression of behavioural sensitization, which 
persisted after a prolonged withdrawal period. This expression of METH sensitization was 
not altered by previous compound M pretreatment at either dose. Repeated treatment with 
compound M alone had no significant effects on subsequent METH-induced locomotor 
response relative to saline treatment, but the high dose group showed a significantly higher 
level of locomotion compared with the low dose group (p < .05, by Fisher’s PLSD), with the 





Figure 3.2 Compound M altered subsequent locomotor response to a METH probe 
On the final probe test, previous chronic METH treatment significantly increased METH-probed 
locomotor response comparing to previous saline treatment, which was not altered by compound M 
concurrent administration with METH. However, previous compound M treatment alone produced 
a dose-dependent effect on locomotor response to the METH challenge. * p < .05. Veh = vehicle, 
10M = 10 mg/kg compound M, 20M = 20 mg/kg compound M, MA = methamphetamine. 
 
Immunohistochemistry was performed to examine the effects of compound M on the 
expression of c-Fos, Arc, and MeCP2 in the NAc core and shell, and the prelimbic cortex 
after the final METH challenge. One-way ANOVA revealed a significant effect of treatment 
on the expression of c-Fos in the NAc core (F6, 25 = 29.99, p < .0001) and shell (F6, 25 = 13.89, 
p < .0001), and the prelimbic cortex (F6, 25 = 12.74, p < .0001); on the induction of MeCP2 in 
the NAc core (F6, 25 = 4.69, p < .005) and shell (F6, 25 = 6.15, p < .001); and on Arc expression 
in the NAc core (F6, 25 = 7.64, p < .0001) and shell (F6, 25 = 5.16, p < .005), and the prelimbic 
cortex (F6, 25 = 5.75, p < .001). Post hoc comparisons with Fisher’s PLSD test showed that a 
history of repeated METH exposure significantly increased METH-probed expression of 
c-Fos, Arc, and MeCP2 in the NAc core and shell, but not in the prelimbic cortex, relative to 
previous saline treatment (p < .05). Compound M, at the high dose, when co-administered 
with METH, enhanced chronic METH-induced c-Fos elevations in the NAc core (p < .05) 




c-Fos inducibility in the NAc core at both the low and the high doses relative to saline 




Figure 3.3 Compound M modulated the effects of repeated METH on brain gene inducibility 
A history of repeated METH exposure significantly elevated subsequent METH-inducible c-Fos (a 
and b), MeCP2 (d and e), and Arc (g and h) in the NAc core and shell. Compound M at the high 
dose potentiated METH-induced increase in c-Fos inducibility in the NAc core (a) and prelimbic 
cortex (c). Previous compound M treatment alone also increased METH-probed c-Fos expression 
in the NAc core at both doses (a). * p < .05 significantly different from previous saline treatment; # 
p < .05 significantly different from previous repeated METH treatment. Veh = vehicle, 10M = 10 
mg/kg compound M, 20M = 20 mg/kg compound M, MA = methamphetamine. 
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3.3.4 Experiment 2 summary 
Compound M pretreatment had no effect on METH-induced locomotor activity during the 
sensitization phase or on the expression of METH behavioural sensitization on the probe test 
at either the high or the low dose. When applied singly, compound M at both doses did not 
affect locomotor behaviour during the acquisition phase or on the probe test after METH 
challenge. However, compound M alone produced a dose-dependent effect on 
METH-induced locomotion in the final test, with the saline group between the high and the 
low dose groups.  
Immunohistochemistry showed that previous chronic METH treatment significantly 
increased METH-evoked expression of c-Fos, Arc, and MeCP2 in the NAc core and shell, 
but not in the prelimbic cortex. Previous daily pretreatment with compound M potentiated 
METH-induced changes in c-Fos inducibility in the NAc core and prelimbic cortex. Repeated 
exposure to compound M alone also increased METH-induced c-Fos in the NAc core. 
3.4 Discussion  
METH is well known for its ability to potently increase extracellular DA levels by acting at 
the DAT, where it competes with DA for reuptake, causes transporter internalization, and 
promotes transporter-mediated efflux (reverse transport) (Sandoval et al., 2001, Elliott and 
Beveridge, 2005). METH also interferes with vesicular monoamine transporter-2, depleting 
DA vesicular storage and increasing cytosolic DA availability for reverse transport by the 
DAT (Sulzer et al., 2005, Fleckenstein et al., 2009). The potent DA-releasing capacity of 
METH is thought to critically underlie its motor-stimulating and rewarding effects, and 
contribute to its abuse liability (Howell and Kimmel, 2008). In addition, as abovementioned, 
METH is a potent full agonist at TAAR1. TAAR1 stimulation by METH triggers a series of 
cellular phosphorylation cascades, leading to reduced DA uptake, enhanced DA efflux, and 
DAT internalization, that partially contribute to the known DA-releasing effects of METH, 
although these findings were obtained in vitro (Xie and Miller, 2009a). Therefore, it has been 




abuse-related behavioural and neurophysiological effects of METH. The findings described 
in chapter one provided preliminary evidence for this concept by demonstrating complex 
interacting effects between METH and two TAAR1 selective partial agonists, RO5203648 
and compound M, on locomotor activity and brain gene expression.  
Experiment 1 showed that RO5203648 pretreatment time-dependently modulated the 
locomotor-activating effects of acute METH, characterized by an early attenuation followed 
by a late potentiation during a 3-h extended test session. This bidirectional modulation of 
METH’s effects by TAAR1 appears to be consistent with the previously proposed 
state-dependent regulation of DA transmission by TAAR1 partial agonism. The onset of 
METH’s effects is rapid and extracellular DA levels are expected to rise sharply at the 
beginning of the test, which corresponded with the period of strongest locomotor activity. In 
this phase the effect of RO5203648 was to increase TAAR1 activation, potentially leading to 
reduced DA transmission and suppressed locomotion. On the contrary, as METH’s effects 
started to decay in the late phase of the test, which may have been accompanied by a gradual 
return of extracellular DA concentrations, RO5203648 may have become more 
antagonistic-like at TAAR1, maintaining DA and locomotion at moderately high levels. 
Alternatively, or complementarily, the attenuation effect at the early phase may be explained 
by a direct competition of RO5203648 with METH, which blocked the TAAR1-dependent 
pathway of METH-induced DA release. Indeed, the present study could be linked to an in 
vivo microdialysis study by Cotter et al. (2015) that measured the regulation of 
METH-stimulated DA overflow in the NAc by the same partial agonist. This study tested the 
effects of TAAR1 activation on DA overflow in the NAc during a 3-h test period and 
reported a similar temporal biphasic modulation whereby METH-induced DA accumulation 
was transiently depressed early in the session but elevated afterwards, although the late 
potentiation effect did not reach statistical significance (Cotter et al., 2015). This suggests 
that mechanisms other than net DA transmission at NAc synapses are likely to contribute to 
the complex regulation of METH-induced behavioural hyperactivity by TAAR1. In addition, 




METH-mediated DA efflux and uptake inhibition, suggesting that RO5203648’s influence on 
METH’s behavioural effects is unlikely to depend exclusively on direct, local actions at the 
DAT. As those authors suggested, the discrepancy between the findings from their in vitro 
synaptosomal preparations and in vivo microdialysis measures could be explained by the 
different concentrations used in each experiment and a broader network effect of systemic 
TAAR1 activation (Cotter et al., 2015). As described previously, the VTA appears a critical 
action site for TAAR1 where TAAR1 full agonists inhibit the firing rate of DA neurons and 
partial agonists produce the opposite effect. It is possible that TAAR1’s regulation on the 
terminal release of DA in the NAc derives from TAAR1-induced alterations in the discharge 
rate of midbrain DA neurons that send projections to the NAc.  
Moreover, apart from DA as the chief mediator, the glutamate system also appears to be 
importantly engaged in psychostimulants actions, partially via glutamate-DA interactions 
within the mesocorticolimbic circuits (Burns et al., 1994, Wang and McGINTY, 1999, 
Tzschentke, 2001). For example, while blockade of NMDA receptors in the medial PFC 
facilitated the locomotor-stimulating effect of METH (Han et al., 2012), 
intra-cerebroventricular injection of NMDA receptor agonists prevented it (Atsushi et al., 
1991), suggesting a potential involvement of cortical glutamatergic hypofunction in 
METH-induced hyperactivity. Critically, studies have established a regulatory role of 
TAAR1 in glutamate transmission. Mice with TAAR1 depletion exhibited altered subunit 
composition and deficient functionality of the NMDA receptors in the PFC (Espinoza et al., 
2015b). Furthermore, the selective TAAR1 full agonists, RO5256390 and RO5166017, and 
the partial agonist, RO5263397, were shown to inhibit hyperlocomotion induced by NMDA 
receptor blockers (Revel et al., 2011, Revel et al., 2013). Therefore, it may be reasonable to 
assume that TAAR1 modulation of the motor-stimulating effects of METH also involves 
interference with the glutamatergic system, possibly through an upregulation of glutamate 
activity, whose hypofunction has been implicated in METH-induced hyperlocomotion. 




Following repeated administration, METH produces long-lasting neuroadaptations in the 
mesolimbic DA system, characterized by a progressive augmentation of METH-induced DA 
efflux, which translates into an increased locomotor response to METH treatment, known as 
behavioural sensitization. To examine the effects of TAAR1 on METH-induced long-term 
behavioural and neuronal adaptations, compound M, another selective partial TAAR1 agonist, 
was applied 15 min prior to METH for ten consecutive days. Following a 10-day withdrawal 
period, locomotor response and brain gene expression induced by a METH challenge were 
examined. Our results showed that daily pretreatment with compound M had no effects on 
METH-induced hyperlocomotion during the acquisition phase or the subsequent expression 
of METH behavioural sensitization on the probe test. This finding is inconsistent with a 
recent study by Cotter et al. (2015) where daily treatment of RO5203648 prior to METH 
blocked both the early induction and the later expression of METH-induced behavioural 
sensitization. Actually, as experiment 1 indicated, RO5203648 effectively blocked the 
locomotor-stimulating effects of acute METH before METH’s effect subsided, and produced 
a decrease in METH-stimulated DA overflow. Thus, the inhibition by RO5203648 of METH 
behavioural sensitization could be explained by the ability of RO5203648 to attenuate the 
increase in DA transmission elicited by METH exposure (Cotter et al., 2015). Moreover, in a 
similar paradigm, another partial TAAR1 agonist, RO5263397, attenuated the development 
and expression of cocaine sensitization (Thorn et al., 2014b). Thus the lack of effects of 
compound M on METH behavioural sensitization is an unexpected finding and might be 
explained by a different pharmacological profile of compound M. No existing published 
study has used compound M and information about its pharmacology is scarce. In addition, 
our choice of 10 and 20 mg/kg dosage of compound M might have fallen outside its 
therapeutic window. It is possible that an inhibition by compound M of METH’s effects 
would become evident at its therapeutically effective doses. Moreover, we know that this 
compound has been developed by Hoffmann-La Roche Ltd for human clinical trials, and 




An interesting finding is that, while daily treatment of compound M alone did not affect 
baseline locomotor activity during the acquisition phase, it appeared to have an impact on the 
subsequent response to METH. On the probe test, previous repeated compound M exposure 
produced a dose-dependent effect such that METH-probed locomotor response was 
significantly higher for the high dose group than the low dose group, although the differences 
between saline and the two compound M groups did not reach statistical significance. This 
dose-dependent effect of compound M might have important functional implications because 
it suggests that chronic TAAR1 partial agonism with compound M might produce 
long-lasting neuroadaptations resulting in altered sensitivity to METH with the high dose 
enhancing it and the low dose reducing it. One possibility is that, through regulating the 
spontaneous firing rate of midbrain DA neurons, repeated compound M may induce 
persistent structural and functional plasticity of these neurons that influence their sensitivity 
to DA agonists, leading to increased or decreased DA releasability upon exposure to METH. 
Alternatively, intermittent compound M stimulation of TAAR1 may produce 
neuroadaptations of this receptor, resulting in altered responsiveness of TAAR1 to 
endogenous and exogenous ligands. Thus, given that METH direct interaction with TAAR1 
partially contributes to METH’s DA-releasing properties, compound M might regulate 
METH-induced DA release and the ensuing locomotor response by interfering with this 
TAAR1-mediated pathway.  
Actually, this dose-dependent effect of compound M could be linked to Cotter et al. (2015)’s 
finding that RO5203648 at the high dose cross-sensitized with METH, suggesting that 
chronic TAAR1 partial activation has the potential to cause neuroadaptive changes in a 
manner similar to METH. On the other hand, the low dose of the TAAR1 partial agonist did 
not cross-sensitize with METH in the Cotter et al. (2015)’s study, and a low dose of 
compound M showed a tendency to desensitize rats to METH treatment. These data, together 
with the acute interaction between METH and RO5203648 in experiment 1, further 
emphasize the complex regulation of psychostimulant actions by TAAR1. Moreover, these 




chronic administration in clinical settings due to the risk of developing long-term METH-like 
neuroadaptations. In this regard, one direction for future research is to characterize the 
pharmacological and behavioural effects of chronic compound M treatment, as is the 
characterization of other selective TAAR1 agonists, to determine the optimal dosages that 
may be used in human. 
To gain insight into the underlying neurological process that may mediate the effects of 
compound M, the expression of c-fos, arc and MeCP2 was examined following the last 
METH challenge. The induction of c-Fos protein has been considered as an immediate 
marker of neuronal activation and is believed to play a role in stimulant-induced structural 
plasticity (Zhang et al., 2006, Jedynak et al., 2012). Similarly, Arc is rapidly activated by 
plasticity-producing stimulation and is specifically localized in the stimulated synaptic sites 
(Plath et al., 2006). Arc expression has been critically linked to the induction and 
maintenance of the neuronal plasticity that underlies learning and memory (Kodama et al., 
1998, Czerniawski et al., 2011). Studies have shown that the induction of c-Fos and Arc by 
stimulants, including cocaine and METH, is at least partially dependent on the NMDA 
receptor (Torres and Rivier, 1993, Ohno et al., 1994, Kodama et al., 1998), consistent with 
the central role of NMDA receptor-dependent long-term potentiation in synaptic adaptations 
that critically underlie reward-related learning and behavioural modifications associated with 
drug addiction (Malenka and Bear, 2004, Jones and Bonci, 2005, Zweifel et al., 2008). On the 
other hand, MeCP2 acts as a key transcriptional repressor and activator by binding to 
methylated DNA to exert epigenetic control over gene expression (Chahrour et al., 2008, 
Cohen et al., 2008). MeCP2 is important for neuronal maturation and the functional 
regulation of synaptic activity such as the formation of long-term potentiation and synaptic 
plasticity (Asaka et al., 2006, Moretti et al., 2006, Smrt et al., 2007). Evidence has 
demonstrated the involvement of MeCP2 in psychostimulant-induced behavioural and 
neuronal effects, including self-administration, conditioned place preference, locomotor 
hyperactivity and sensitization, and changes in neuronal excitability, as well as the expression 




Deng et al., 2014). Therefore, alterations in the activity of these genes or proteins might be 
part of the long-lasting neuroadaptations that underlie psychostimulant sensitization and, 
more broadly, the development of compulsivity of drug addiction.  
The present experiment showed that a history of repeated METH exposure significantly 
altered the inducibility of all the three genes upon a METH challenge, which is consistent 
with the notion that chronic psychostimulants induce enduring synaptic plastic changes. In 
particular, we found an enhanced METH-probed expression of c-Fos, Arc, and MeCP2 in the 
NAc core and shell, but not in the prelimbic cortex, in rats that were previously treated with 
METH compared to those treated with saline. Previous studies examining 
sensitization-associated changes in c-Fos and Arc have yielded inconsistent results. Some 
studies showed a blunting effect of repeated psychostimulants treatment on IEG expression in 
the PFC, striatum, and NAc (Hope et al., 1992, Persico et al., 1993, Renthal et al., 2008, 
McCoy et al., 2011). However, other studies have reported an increase in drug-probed c-Fos 
in the NAc following repeated amphetamine or cocaine exposure and withdrawal (Crombag 
et al., 2002b, Mattson et al., 2007). Yet, evidence elsewhere showed a region-specific 
sensitization of c-Fos inducibility after chronic METH exposure, which was observed in the 
dorsal striatum but not in the NAc (Jedynak et al., 2012). In the case of Arc, previous studies 
showed that chronic METH pre-exposure had no effect on METH challenge-induced Arc 
expression in the striatum, orbital cortex, and cingulate cortex, but increased it in the frontal 
cortex and the parietal cortex (Kodama et al., 1998, McCoy et al., 2011). On the other hand, 
Arc expression in the frontal cortex was downregulated following repeated METH treatment 
without withdrawal (Cheng et al., 2015) but increased by repeated cocaine administration 
(Freeman et al., 2002). Several factors might contribute to the different results found in those 
previous and the present studies including the withdrawal duration, the environmental context, 
the dose of the challenge drug, and the specific subregions that were studied. For example, it 
has been suggested that cocaine sensitization is associated with time-dependent anatomical 
neuroadaptations such that repeated cocaine administration decreased c-Fos expression in the 




challenged after a 2-day withdrawal, but had no effect on these areas when the challenge was 
given after a 2-week withdrawal, instead increasing c-Fos protein in the intermediate zone of 
the NAc shell (Todtenkopf et al., 2002, Brenhouse and Stellar, 2006). Moreover, Renthal et al. 
(2008) examined the influence of chronic amphetamine on subsequent c-Fos inducibility in 
the striatum across a 1-10 day withdrawal period and found a suppressant effect only during 
the first five days of withdrawal, suggesting that varying the withdrawal length can affect the 
results. Furthermore, it has been shown that the experimental context (i.e., the home cage or a 
novel environment) and drug history interact to regulate c-Fos expression induced by 
amphetamine challenge (Ostrander et al., 2003), and that the environmental context 
modulates the effects of acute amphetamine on Arc expression in multiple brain regions 
especially the NAc shell (Klebaur et al., 2002). Finally, Crombag et al. (2002b) found that the 
ability of past cocaine exposure to enhance subsequent c-Fos induction in the NAc was 
critically dependent on the dose of the cocaine challenge. Therefore, our finding of a 
sensitized c-Fos and Arc response in the NAc core and shell by repeated METH treatment 
might reflect effects specific to the treatment procedures adopted in the present experiment.  
The observation that the inducibility of MeCP2 was simultaneously enhanced by previous 
METH treatment suggests that MeCP2-mediated transcriptional regulation of new gene 
products may contribute to the altered activity of c-Fos and Arc. Studies have shown that 
psychostimulant induces MeCP2 phosphorylation in a specific neuronal subset within the 
NAc and disruption of MeCP2 phosphorylation led to enhanced sensitivity to 
amphetamine-induced behavioural sensitization and the associated changes in Fos response in 
those NAc neurons (Deng et al., 2010, Deng et al., 2014). Similarly, mice with dysfunctional 
MeCP2 gene were hypersensitive to cocaine-induced locomotor hyperactivity and exhibited 
enhanced inducibility of Arc in the striatum (Su et al., 2012). These observations led to the 
suggestion that MeCP2 might be recruited by psychostimulants to limit their effects on the 
neuronal and behavioural plasticity that is associated with the development of 
psychostimulant addiction (Deng et al., 2014). The present experiment showed that repeated 




by a sensitized reactiveness of c-Fos and Arc, which paralleled the expression of behavioural 
sensitization, implying a rather complex mechanism of psychostimulant-triggered 
transcriptional regulation of IEGs that might involve additional regulatory events beyond 
MeCP2-mediated epigenetic modifications.   
We showed that daily concurrent administration of compound M with METH potentiated 
METH-induced increase in the subsequent inducibility of c-Fos in a region- and dose-specific 
manner, suggesting that partial TAAR1 agonism with compound M is able to modulate the 
long-term neuronal plasticity produced by repeated METH exposure. The expression of c-Fos 
was enhanced by compound M in both the prelimbic cortex and the NAc core, suggesting that 
compound M’s regulation of METH occurs at both striatal and prefrontal cortical levels. This 
process may involve TAAR1’s modulation of both DA- and glutamate-mediated pathways 
because evidence has suggested a role for both neurotransmitters in psychostimulant-induced 
IEG expression (Graybiel et al., 1990, Young et al., 1991, Torres and Rivier, 1993, Drago† et 
al., 1996, Carta et al., 2000, Amano et al., 2002, Ujike et al., 2002, Zhang et al., 2004, Deng 
et al., 2010, Mao et al., 2011). In addition, these data also suggest that the regulation of 
METH-induced behavioural and neuronal adaptations by compound M may be dissociable 
given the lack of effects of compound M on METH locomotor sensitization.   
Moreover, our results showed that repeated compound M treatment alone changed 
subsequent METH-inducible c-Fos expression in the NAc core, further supporting the idea 
that chronic partial TAAR1 activation may cause neuroadaptations, mainly in the striatum, 
that alter neuronal sensitivity to psychostimulants. This TAAR1-mediated regulation of brain 
early gene activity highlights some of the neural mechanisms that may underlie the 
dose-dependent effect of compound M on METH-probed locomotor behaviour in the current 
experiment and the cross-sensitization of RO5203648 with METH in the Cotter et al. 
(2015)’s study.  
In summary, the findings from the first set of experiments demonstrated complex interactions 




gene expression. These data suggest that partial TAAR1 activation has the ability to modulate 
acute and repeated METH-induced behavioural and neuronal plasticity that is associated with 
the development of compulsive drug use, and that TAAR1 may serve as a potential 






4 TAAR1 Activation Reduces the Reinforcing Efficacy of 
Psychostimulants 
4.1 Introduction  
Psychostimulants act as reinforcers, which by definition increase the likelihood of repeated 
drug taking, a precondition necessary for the escalation of drug intake, the transition to 
compulsive drug use, and the ultimate development of addiction (Breiter et al., 1997). Indeed, 
the addictive potential of a drug has been positively related to its reinforcing efficacy 
(Schuster, 1981). The powerful reinforcing effects of psychostimulants rely primarily on their 
ability to potently increase mesolimbic DA transmission (Marona-Lewicka et al., 1996, 
Howell and Kimmel, 2008). As previously described, amphetamine-like drugs, such as 
METH, are known as DA releasers through interference with the DAT and the vesicular 
monoamine transporter-2, causing DA accumulation at the synapse (Heal et al., 2013). The 
magnitude of amphetamine-induced DA release in the ventral striatum has been positively 
correlated with subjective experience of euphoria (Drevets et al., 2001, Oswald et al., 2005) 
and self-reported drug wanting in humans (Leyton et al., 2002). Likewise, although via a 
different mechanism, cocaine acts as a DAT blocker that inhibits reuptake of DA from the 
extracellular fluid into presynaptic terminals through the DAT, which also leads to 
augmented extracellular concentrations of DA (Pettit and Justice Jr, 1991). In human cocaine 
abusers, a greater degree of DAT occupancy by cocaine was associated with a higher rating 
of self-reported “high” produced by intravenous (i.v.) cocaine (Volkow et al., 1997). In 
animals, the reinforcing efficacy of a drug is best characterized in the self-administration 
paradigm which has been widely used to model key features and patterns of human drug 
abuse (Richardson and Roberts, 1996). Studies have consistently demonstrated an increased 
level of extracellular DA in the striatum, including the NAc, in rats that self-administered 




DA depletion in the NAc markedly decreased self-administration of these drugs (Lyness et al., 
1979, Roberts et al., 1980, Caine and Koob, 1994b). Moreover, in rats that were trained to 
self-administer cocaine, increases in the unit dose of cocaine led to proportional increases in 
both total amount of cocaine intake and extracellular level of DA in the NAc that was 
maintained throughout the self-administration session, suggesting that the stronger 
reinforcing efficacy of a larger unit dose of cocaine is associated with a greater ability to 
elevate DA levels in the NAc (Pettit and Justice Jr, 1991). Therefore, given the hypothesized 
ability of TAAR1 to prevent DA hyperactivity, TAAR1 activation is expected to 
downregulate self-administration of psychostimulants by reducing their reinforcing efficacy 
through counteracting their potentiating effects on mesolimbic DA transmission.  
As mentioned before, the only study (by the time the current thesis started) that tested 
TAAR1 selective agonists in psychostimulants self-administration used a FR1 schedule of 
reinforcement and a single unit dose of the drug (Revel et al., 2012b). The present chapter 
aimed to more comprehensively investigate TAAR1 regulation of the reinforcing properties 
of psychostimulants by assessing the ability of the partial agonist, RO5203648, and the full 
agonist, RO5256390, to shift the dose-response function of cocaine self-administration 
(experiment 3)4, and the effects of RO5203648 (experiment 4)5 and another partial agonist, 
RO5263397 (experiment 5)6, on the BP for cocaine or METH self-administration, 
respectively, under a PR schedule of reinforcement. Additionally, experiments 4 and 5 also 
examined the influence of the two partial agonists on food self-administration under the same 
                                                 
4 Published paper. Experiment 3 has been published in the following paper: Pei Y, Mortas P, Hoener MC, 
Canales JJ (2015) Selective activation of the trace amine-associated receptor 1 decreases cocaine's reinforcing 
efficacy and prevents cocaine-induced changes in brain reward thresholds. Progress in 
Neuro-Psychopharmacology and Biological Psychiatry 63:70-75. 
5 Published paper. Experiment 4 has been published in the following paper: Pei Y, Lee J, Leo D, Gainetdinov 
RR, Hoener MC, Canales JJ (2014) Activation of the trace amine-associated receptor 1 prevents relapse to 
cocaine seeking. Neuropsychopharmacology 39:2299-2308. doi: 10.1038/npp.2014.88.   
6 Published paper. Experiment 5 and 6 have been published in the following paper: Pei Y, Asif‐Malik A, 
Hoener M, Canales JJ (2016) A partial trace amine‐associated receptor 1 agonist exhibits properties consistent 




PR schedule in order to control for their potential non-specific effects. Finally, in order to 
account for TAAR1’s behavioural regulation at the physiological level, experiment 6 
explored the effects of the partial agonist, RO5263397, on METH-induced DA overflow in 
the NAc core in rat brain slices by way of FSCV6. A recent report indicated that RO5203648 
effectively blocked cocaine-stimulated DA release in the NAc (Pei et al., 2014). A similar 
result was expected for experiment 6.  
4.2 Materials and Methods 
4.2.1 Subjects 
Male Long Evans rats were sourced from the University of Canterbury and the University of 
Leicester and were 10-12 weeks-old when experiments began. All animals were housed in 
temperature and humidity controlled colony rooms with a 12-h light/dark cycle (lights off at 8 
a.m.). Rats were given a maintenance diet and kept at 100% of their weight seven days’ 
post-surgery. Water was given ad libitum at all times. All procedures were approved by the 
Animal Ethics Committee of the University of Canterbury or the University of Leicester.  
4.2.2 Pharmacological agents 
Cocaine was obtained from the National Institute of Drug Abuse (USA) and dissolved in 0.9% 
physiological saline for i.v. self-administration. METH hydrochloride was obtained from 
BDG Synthesis (Wellington, New Zealand) and Sigma-Aldrich (UK) and dissolved in 0.9% 
physiological saline for i.v. self-administration or artificial cerebrospinal fluid (aCSF) for the 
voltammetry experiments. RO5256390, RO5203648, and RO5263397 were synthesized at F. 
Hoffmann-La Roche Ltd. (Switzerland) and dissolved in 10% dimethylsulfoxide in 0.9% 
physiological saline for i.p. injections or in aCSF for the voltammetry assays.  
4.2.3 Catheter implantation surgery 
Rats assigned to cocaine or METH self-administration experiments were operated on to 
implant i.v. catheters. In experiment 4 and 6, animals were anesthetized with ketamine (85 
mg/kg, i.p.) and domitor (medetomidine, 0.35 mg/kg, i.p.). The analgesic carprofen was 




Camcaths, Cambridge, UK) were implanted into the right jugular vein, existing dorsally 
between the scapulae. Analgesic and antiseptic cream was applied to the back and neck 
incision areas following suturing. On completion of surgery, rats were given Antisedan 
(atipamezole, 1.0 mg/kg, i.p.) to reverse the anesthesia. To prevent infection, rats were treated 
with antibiotic (cephalexin, 50 mg/kg, s.c.) 90 min before surgery. Catheters were flushed 
with heparinized saline (0.1 ml, 70 IU/ml) before and after each self-administration session to 
prolong patency. Animals in experiment 5 were anesthetized with 2,2,2-tribromoethanol 
solution (12.5 mg/ml solution in 2.5% tertiary amyl alcohol, 2 ml/100g of body weight) and 
received carprofen (5 mg/kg, i.p.) immediately after surgery. The antibiotic (cephalexin, 25 
mg/kg, s.c.) was given daily pre and post-surgery for seven days. The rest of the surgical 
procedure remained the same as described above.  
4.2.4 Self-administration apparatus 
Twelve self-administration chambers (Med Associates, VT, USA) controlled by software 
(Med-PC IV®) were used. Chambers had two response levers designated as active and 
inactive. Active lever presses resulted in activation of the infusion pump and delivery of 
cocaine or METH, and illumination of a light stimulus for 5 seconds. Presses on the inactive 
lever were recorded but had no programmed consequences. Each experimental chamber was 
enclosed in a sound-attenuating box. The house light was on throughout training and test 
sessions. Rats were connected to a liquid swivel with polyethylene-50 (PE-50) tubing 
protected by a metal spring. In the food self-administration assay, active lever presses 
resulted in delivery of a chocolate-flavored pellet (45 mg, Bio-Serve, NJ, USA) into a food 
magazine situated between the two levers, and illumination of the stimulus light for 5 
seconds.  
4.2.5 Cocaine dose-response training and test (experiment 3) 
Rats (n = 36) were firstly trained to lever press to self-administer cocaine (0.45 
mg/kg/infusion in 100 µl, over 5 seconds) under a FR1 schedule of reinforcement in daily 60 




12 for three consecutive days with less than 20% variance in the last three days), rats were 
randomly assigned to five groups (n = 7-8 per group) that self-administered cocaine either at 
the same dose (0.45 mg/kg/infusion) or at a substitute dose (1.0, 0.2, 0.1, or 0.03 
mg/kg/infusion). The new dose of cocaine was maintained until a criterion of stability was 
met (less than 10% variation in the last three days). The amount of cocaine was limited 
throughout the experiment to a maximum of 20 mg/kg per session to prevent overdose.  
Two experiments were performed that respectively examined the effects of RO5203648 and 
RO5256390 on cocaine dose-response functions. After training, each rat was subjected to five 
cocaine intake tests in which a pretreatment of RO5203648 (3 or 6 mg/kg, i.p.), RO5256390 
(3 or 6 mg/kg, i.p.), or vehicle was administered 15 min before the cocaine 
self-administration session (60 min). The five cocaine intake tests were administered in 
randomized order. The test days were separated by at least two days during which rats 
undertook regular cocaine self-administration sessions until response returned to their 
original response level. The same values for the vehicle pretreatment condition were used in 
the two experiments as control.  
4.2.6 Cocaine PR test (experiment 4) 
Rats (n = 9) were trained to lever press for cocaine (0.5 mg/kg/infusion, 100 µl), being 
sequentially exposed to FR1, FR2, and finally FR3 reinforcement schedules during 
long-access sessions. Schedule progression was dependent upon meeting a criterion (number 
infusions per session ≥ 30). Rats were then transferred to daily FR3 90 min sessions until a 
criterion of stability and consistency was met (number infusions per session ≥ 15 for three 
consecutive days with less than 20% variability). Cocaine infusions were limited to a 
maximum of 40 (20 mg/kg) per session to prevent overdosing. On completion of training, 
each rat was subjected to three PR tests in which RO5203648 (0, 3, or 10 mg/kg, i.p.) was 
administered in counterbalanced fashion 15 min before the start of the session. The PR tests 
were conducted on three different days separated by at least one regular 90 min FR3 cocaine 




lever responses required for each subsequent infusion increased as follows: 1, 2, 4, 6, 9, 12, 
15, 20, etc., following the exponential equation:  
NP (n) = [5e 0.2n]-5,  
with n representing the injection rank (Richardson and Roberts, 1996). After the first FR1 
was achieved, the BP was defined as the largest ratio completed prior to a period lasting for 
60 min or more during which no infusions were obtained.  
4.2.7 METH PR test (experiment 5) 
The procedures for METH self-administration training and PR test were the same as those 
described above for the cocaine PR experiment. Briefly, rats (n = 9) were trained on METH 
self-administration (0.05 mg/kg/infusion, 100 µl) under FR3 reinforcement schedules in 90 
min daily sessions until they achieved a stability criterion (number infusions per session ≥ 17 
for five consecutive days with less than 20% variance in the last three days). METH infusions 
were limited to a maximum of 40 (2 mg/kg) per session to prevent overdosing. The PR tests 
were conducted on three different days during which RO5263397 (0, 3, or 10 mg/kg, i.p.) 
was administered in counterbalanced manner 15 min before the start of the session.  
4.2.8 Food PR test (experiments 4 and 5 cont.) 
The food PR experiment with each of the two partial agonists was respectively conducted 
following the cocaine or METH PR experiment with the same partial agonist used in the drug 
PR test. After the cocaine or METH PR test, an additional group of rats (n = 8) was trained to 
lever press for chocolate-flavored pellets under FR1 reinforcement schedule in daily 60 min 
sessions until a stability criterion was met (number of pellets per session ≥ 20 for three 
consecutive days). Each rat received three food PR tests in which RO5203648 (0, 3, or 10 
mg/kg, i.p.) or RO5263397 (0, 3, or 10 mg/kg, i.p.) was administered 15 min before the start 
of the session. The PR test lasted for 6 h and had identical response requirement as the 
cocaine or METH PR test. The PR tests were conducted on different days separated by one 




4.2.9 FSCV equipment (experiment 6) 
The FSCV setup was custom built, consisting of a slice chamber, stimulating, recording, and 
reference electrodes connected to a computer and amplifier. Recording electrodes were 
manufactured as previously described (Fortin et al., 2015). Reference electrodes were 
manufactured with a piece of silver wire coated in KCl (Ag/AgCl) and attached to a silver pin. 
Bipolar stimulating electrodes were obtained from FHC (ME, USA). The recording and 
reference electrodes were connected to a potentiostat and head-stage circuit (Chemclamp, 
Dagan Instruments, USA) and a computer running DemonVoltammetry software (Wakeforest 
Innovations; NC, USA). Two National Instruments data acquisition cards (NI-DAQ; 
PCI-6711 and PCI-6052e; National Instruments, Austin, TX) were used for interfacing 
Demon Voltammetry with the potentiostat (Dagan Corporation; Minneapolis, MN). The 
recording electrode potential was linearly scanned at a rate of 400V/s as a triangular 
waveform from -0.4 V to 1.3 V and back to -0.4 V vs. the reference electrode. Cyclic 
voltammograms were recorded at the recording electrode every 100 ms by means of the 
voltammeter/amperometer (Dagan Instruments, USA). At this waveform, DA oxidizes at ~ 
0.6 V and reduces at ~ -0.2 V. 
4.2.10 Tissue preparation  
Rats (n = 9) were anaesthetized with isoflurane and sacrificed via a Schedule 1 procedure. 
The brain was rapidly removed and placed in a tube containing pre-carboxygenated (i.e. 
bubbled with 95% O2 and 5% CO2), ice-cold, sodium-free slicing aCSF (SaCSF) consisting 
of 250 mM sucrose, 2.5 mM KCl, 11 mM d-glucose, 1.2 mM NaH2PO4, 25 mM NaHCO3, 
0.4 mM l-ascorbic acid, 0.1 mM CaCl2, and 4 mM MgCl2 adjusted to pH 7.4. The brain was 
then sectioned in ice-cold carboxygenated aCSF on a Vibratome 1000 Classic vibrating 
microtome (The Vibratome Company, MO, USA). Coronal slices (400 µM) through the NAc 
were maintained at room temperature in continuously carboxygenated experimental aCSF 
(EaCSF), which consisted of 126 mM NaCl, 2.5 mM KCl, 11 mM d-glucose, 1.2 mM 
NaH2PO4, 25 mM NaHCO3, 0.4 mM l-ascorbic acid, 2.4 mM CaCl2, and 1.2 mM MgCl2 




before recording. Experimental recordings started 5-10 min after transfer to the FSCV slice 
chamber (see below) to allow slices to equilibrate in warmed aCSF. 
4.2.11 FSCV recordings 
For recordings, a slice was placed in the FSCV slice chamber, held in place with a 
purpose-built grid and superfused with continuously carboxygenated EaCSF at a flow rate of 
1.4 ml/min and heated with a purpose-built Peltier to 32-33°C. The recording electrode was 
positioned ~75 µm below the surface of the slice in the NAc. DA release was electrically 
evoked every 5 min by a 4 ms, one-pulse stimulation (monophasic, 300 µA), using the 
stimulating electrode placed 100 - 200 µm from the recording electrode within the NAc core. 
Current pulses were generated by the acquisition software and applied via an ISo-Flex 
stimulus isolator (AMP Instruments; Jerusalem, Israel). DA was confirmed in each recording 
by observation of the cyclic voltammogram (noting the position of oxidation and reduction 
peaks) and colour plots permitted the visualization of release dynamics over time (Figure 4.5a 
and b). Drugs were applied by superfusion at the same time as the recording was initiated. 
Slices were randomly assigned to the different conditions. Conditions consisted of 20 min 
runs with an electrical stimulation being passed every 5 min with either no drug, 2 µM 
METH, 2 or 4 µM RO5263397 followed by 20 min of co-application of the compound (2 or 
4 µM) with 2 µM METH. Background subtracted cyclic voltammograms were obtained by 
subtracting the current obtained in the first 2 min of every experiment, before drug 
superfusion into the slice chamber. The peak oxidation current (nA) for DA in each 
voltammogram has been deemed an appropriate measure of DA release (Yorgason et al., 
2011). However, these values were also converted into a measure of the DA concentration by 
pre/post-calibration of the electrode using 1-5 µM DA (Sigma Aldrich, MO, USA). DA 
calibrations were performed for each electrode in a flow cell designed from a custom-built 




4.2.12 Statistical analysis 
Data were analysed by ANOVA with repeated measures when a within-subjects design was 
in use, followed by post hoc comparisons with the method of N-K tests using the sampling 
error from the overall ANOVA as denominator. Statistical significance was set at α = 0.05 for 
all experiments. All statistical analyses were performed using StatView 5.0 (SAS Institute, 
NC, USA). 
4.3 Results and Summary   
4.3.1 Experiment 3 results   
Rats were firstly trained to self-administer cocaine at a pre-training dose (0.45 
mg/kg/infusion) before being subsequently divided into five groups that self-administered 
cocaine at five different doses (1.0, 0.45, 0.2, 0.1, or 0.03 mg/kg/infusion). Performance in 
the pre-training phase was matched for the five groups. A repeated measure ANOVA for 
lever presses during the last three pre-training sessions revealed only a significant effect of 
lever (active vs. inactive, F1, 33 = 393.04, p < .0001). Similarly, a one-way ANOVA showed 
no significant differences in the average number infusions obtained by the five groups across 
the last three pre-training sessions (p = .9953). After transfer to the substitute cocaine dose, 
rats re-stabilized response to the new dose. A one-way ANOVA for the average number of 
infusions over the last three training sessions revealed a significant effect of cocaine unit dose 
(F4, 33 = 81.92, p < .0001). The decrease in the number of infusions attained was paralleled by 
a dose-dependent increase in cocaine intake with increasing unit dose. ANOVA for the 
average cocaine intake over the last three training sessions showed a significant main effect 
of cocaine dose (F4, 33 = 9.48, p < .0001).  
In the test, RO5203648 (3 or 6 mg/kg, i.p.) and RO5256390 (3 or 6 mg/kg, i.p.) administered 
15 min prior to the self-administration session dose-dependently shifted the cocaine 
dose-response curve downward. A repeated measure ANOVA for the number of cocaine 
infusions obtained following RO5203648 treatment, with cocaine unit dose as a 




significant main effect of cocaine unit dose (F4, 33 = 54.46, p < .0001) and dose of 
RO5203648 (F2, 66 = 102.07, p < .0001), as well as a significant interaction between those 
factors (F8, 66 = 26.83, p < .0001) (Figure 4.1a). Post hoc comparisons showed a significant 
reduction in cocaine infusions for 0.1 mg/kg and 0.03 mg/kg unit dose of cocaine by 
RO5203648 at both doses (p < .01, by N-K tests) and for 0.2 mg/kg cocaine unit dose by 
RO5203648 at the high dose (p < .01, by N-K tests). ANOVA for the effect of RO5203648 
on amount intake during the test showed a significant main effect of cocaine unit dose (F4, 33 
= 10.19, p < .0001) and dose of RO5203648 (F2, 66 = 144.93, p < .0001) (Figure 4.1c). N-K 
tests showed that RO5203648 at both doses significantly reduced cocaine intake across all 
five cocaine doses (p < .01).  
Similarly, ANOVA for the effect of the full agonist, RO5256390, was conducted with one 
between-subjects factor, cocaine dose, and one within-subjects factor, dose of RO5256390. 
ANOVA for the number cocaine infusions revealed a significant main effect of unit cocaine 
dose (F4, 33 = 43.51, p < .0001) and dose of RO5256390 (F2, 66 = 139.86, p < .0001), as well as 
a significant interaction between those factors (F8, 66 = 36.41, p < .0001) (Figure 4.1b). Means 
comparisons showed a significant reduction in cocaine infusions for 0.03, 0.1, and 0.2 mg/kg 
cocaine unit dose at both the low and the high doses of RO5256390 (p < .01, by N-K tests). 
ANOVA for cocaine intake yielded a significant main effect of cocaine unit dose (F4, 33 = 
9.63, p < .0001) and dose of RO5256390 (F2, 66 = 241.96, p < .0001), as well as a significant 
interaction effect (F8, 66 = 2.75, p = .0111) (Figure 4.1d). Post hoc comparisons indicated a 
significant reduction in cocaine intake across all cocaine unit doses at both doses of 





Figure 4.1 RO5203648 and RO5256390 shifted the cocaine dose-response curve downward 
The number of cocaine infusions decreased as the cocaine unit dose increased. RO5203648 (a) and 
RO5256390 (b) dose-dependently reduced number of infusions at all unit doses of cocaine. The 
decrease in cocaine infusions with increasing cocaine unit dose was paralleled by an increase in 
total amount of cocaine intake, which was dose-dependently attenuated by RO5203648 (c) and 
RO5256390 (d) across all unit doses of cocaine. * p < .01 significantly different from vehicle 





4.3.2 Experiment 3 summary 
Firstly, a dose-response function for cocaine self-administration (0.03, 0.1, 0.2, 0.45, and 1 
mg/kg/infusion) was established such that increases in unit injection dose of cocaine led to 
decreased number of infusions despite an overall increase in the total amount of cocaine 
intake in the session. Both the selective TAAR1 partial and full agonists, RO5203648 and 
RO5256390, respectively, produced a marked downward shift in the cocaine dose-response 
curve, indicating diminished cocaine reinforcement at all doses. These findings demonstrated 
a clear ability of TAAR1 partial and full activation to effectively block the reinforcing 
efficacy of cocaine.  
4.3.3 Experiment 4 results 
After rats were trained to stably self-administer cocaine (0.45 mg/kg/infusion) under a FR3 
reinforcement schedule, they received three PR tests during which RO5203648 (0, 3, or 10 
mg/kg, i.p.) was given 15 min prior to the start of the PR session. One-way ANOVA failed to 
reveal a significant effect of RO5203648 treatment on the number of active lever presses 
made during the test (F2, 16 = 1.16, p = .338) or on the number of infusions obtained (F2, 16 = 
0.59, p = .564).  
However, the temporal parameters of responding for cocaine under the PR schedule were 
markedly altered by RO5203648 treatment. Active lever presses in each 1-h bin, cumulative 
number of cocaine infusions, and time to reach BP were analyzed by ANOVA. RO5203648 
dose-dependently reduced active lever pressing in the early phase of the PR session, 
lengthened the accumulation of cocaine infusions, and delayed the time point to reach BP. A 
repeated measure ANOVA for active lever presses broken down in 1-h bins showed a 
significant effect of time (F5, 40 = 13.37, p < .001) and a significant interaction between 
treatment and time (F10, 80 = 11.08, p < .001). RO5203648 produced a dose-dependent 
temporal shift to the right in the number of active lever presses made during the session. 
Response rate was significantly attenuated by RO5203648 in the 1st h at both doses (p < .01, 




RO5203648 also significantly increased response rate during the 4th time bin (p < .05, by N-K 
tests) (Figure 4.2a).  
RO5203648 dose-dependently delayed the time point at which rats reached each successive 
cocaine infusion. ANOVA was performed for the cumulative number of infusions obtained 
by the end of each 1-h bin, which revealed a significant effect of dose of RO5203648 (F2, 16 = 
6.74, p < .01) and time (F5, 40 = 122.69, p < .0001), as well as a significant interaction 
between time and RO5203648 (F10, 80 = 18.72, p < .001) (Figure 4.2b). Rats receiving vehicle 
injections rapidly obtained the first 10 infusions (FR = 40) by the end of the 1st h bin and 
achieved BP by the 2nd h bin on average. Time to reach BP was significantly delayed by 
RO5203648 (F2, 16 = 20.31, p < .001). Means ± SEM were 1.67 ± 0.24 h, 3.56 ± 0.44 h, and 
4.56 ± 0.34 h to reach BP for control, low and high doses of RO5203648, respectively, with 
both doses of the partial agonist being significantly different from control values (p < .01, by 






Figure 4.2 RO5203648 differentially regulated the reinforcing efficacy of cocaine and food 
In a PR schedule of reinforcement, RO5203648 dose-dependently shifted the cocaine response rate 
curve rightward (a) and delayed the time to reach BP (b). However, RO5203648 enhanced the 
reinforcing efficacy of food in the same PR paradigm (c). # p < .05, ## p < .01 significantly 
different from vehicle pretreatment.  
 
To examine the potential non-specific effects of RO5203648 on motivation to obtain a 
natural reward (i.e. food), an additional group working for food under FR1 reinforcement 
schedule was tested with the same PR procedures. RO5203648 significantly increased the 
number of active lever presses (F2, 14 = 15.06, p = .0003) and the number of pellets obtained 
(F2, 14 = 19.23, p < .0001) in the 6-h food PR test, as revealed by one-way ANOVA tests. Post 
hoc comparisons showed that responses on the active lever were significantly increased by 
RO5203648 at both the low (p < .05, by N-K tests) and the high dose (p < .01, by N-K tests), 
and so was the number of pellets obtained during the test at both doses (p < .01, by N-K tests). 
Similarly, the BP achieved in the PR test was significantly increased by RO5203648 (F2, 14 = 
16.89, p = .0002), with N-K tests revealing a significant effect for both the low (p < .05) and 
the high doses (p < .01). 




A temporal breakdown of the 6-h test showed that RO5203648 changed the pattern of 
responding for food. A repeated measure ANOVA for active lever response in 1-h bins 
revealed a significant effect of treatment (F2, 14 = 15.06, p = .0003) and time (F5, 35 = 12.54, p 
< .0001), as well as a significant interaction between time and treatment (F10, 70 = 7.13, p 
< .0001). Responding under vehicle treatment was high in the 1st h and dropped afterwards. 
At the low dose, RO5203648 upwardly shifted the response rate across the test, with a 
significant increase at the 2nd (p < .01, by N-K tests) and the 3rd time bin (p < .05, by N-K 
tests). At the high dose, RO5203648 significantly reduced response rate during the 1st h (p 
< .01, by N-K tests) but significantly increased it at the 2nd h and subsequent time bins (p 
< .01 at the 2 - 5th time bins, by N-K tests).  
Correspondingly, the cumulative number of pellets obtained by the end of each time bin was 
also altered by RO5203648. A repeated measure ANOVA yielded a significant effect of 
treatment (F2, 14 = 4.85, p = .025) and time (F5, 35 = 351.10, p < .0001), as well as a significant 
interaction between these factors (F10, 70 = 21.23, p < .0001) (Figure 4.2c). RO5203648 at the 
low dose significantly increased the cumulative number of reinforcers from the 2nd h and 
onwards (p < .01 for 2 - 6th time bins, by N-K tests). The high dose of RO5203648 
significantly lowered the number of pellets attained in the 1st h (p < .01, by N-K tests) but 
elevated pellet accumulation from the 3rd time bin to the end of the test (p < .01 from 3 - 6th 
time bins, by N-K tests). Means ± SEM for the total number of pellets obtained at the end of 
the test were 12.50 ± 0.50, 14.88 ± 0.40, and 16.13 ± 0.83 for control, low and high doses of 
RO5203648, respectively.  
4.3.4 Experiment 4 summary 
In the cocaine PR test, RO5203648 treatment did not affect the overall responding rate or the 
total number of infusions earned during the test. However, it produced a significant rightward 
shift in the temporal pattern of responding across time bins, manifested as a significant 
reduction of active lever pressing in the early phase of the test, prolongation of the 




self-administration under the same PR procedure was significantly enhanced by RO5203648 
at both doses, achieving a significantly higher BP than the vehicle treatment. These results 
suggest that the TAAR1 partial agonist is likely to make cocaine less reinforcing and has 
differential regulation on the motivation for cocaine and food reinforcement.  
4.3.5 Experiment 5 results 
RO5263397 administered 15 min before the start of the METH PR session dose-dependently 
reduced the motivation to self-administer METH. A repeated measure ANOVA for active 
lever presses revealed a significant effect of treatment (F2, 16 = 11.45, p < .001) and lever (F1, 8 
= 216.48, p < .0001), as well as a significant interaction between these factors (F2, 16 = 5.88, p 
< .05). Post hoc comparisons showed that responding on the active lever was 
dose-dependently attenuated by RO5263397 at both the low (p < .05) and the high doses (p 
< .01, by N-K tests) (Figure 4.3a). This corresponds to a significant reduction in number of 
infusions obtained (F2, 16 = 7.12, p < .01) and in the BP achieved (F2, 16 = 7.80, p < .01) 
(Figure 4.3b), as revealed by additional one-way ANOVA tests. RO5263397, at the high dose, 
but not the low dose, significantly decreased number of infusions (p < .01) and the BP (p 
< .01, by N-K tests).  
Active lever responses were also analyzed across 1-h bins for a closer examination of the 
effects of RO5263397. A repeated measure ANOVA revealed a significant effect of 
treatment (F2, 16 = 9.21, p < .01) and time (F5, 40 = 10.99, p < .0001), as well as a significant 
interaction between treatment and time (F10, 80 = 9.53, p < .0001). Under the vehicle treatment, 
active lever presses reached peak level at the 3rd h and dropped afterwards. RO5263397 
dose-dependently reduced response rate in the first three h (p < .01 for 1 - 3rd time bins, by 
N-K tests) and produced a downward and rightward shift of the peak response curve (Figure 
4.3c). Similarly, the temporal pattern for the accumulation of infusions was downwardly 








                       
Figure 4.3 RO5263397 reduced the reinforcing efficacy for METH 
RO5263397 significantly reduced the total number of active lever presses (a) and BP (b) for METH 
self-administration under a PR schedule of reinforcement. Time course analysis of active lever 
response showed that RO5263397 significantly attenuated METH-maintained responding in the 
first three h and produced a downward and rightward shift of the peak response curve (c), which 
corresponds with a downward shift of the cumulative number of infusions obtained across the 6-h 







To control for its non-specific effects, RO5263397 was tested in another group of rats that 
worked for food under the same PR requirement. In sharp contrast with METH-maintained 
responding, RO5263397 enhanced the motivation for food. A repeated measure ANOVA for 
active lever presses revealed a significant effect of treatment (F2, 14 = 3.95, p < .05) and a 
significant effect of lever (F1, 7 = 63.77, p < .0001). This was accompanied by an increase in 
the number of pellets earned (F2, 14 = 5.44, p < .05) and in the BP achieved (F2, 14 = 4.86, p 
< .05), as revealed by additional one-way ANOVA. N-K tests showed that RO5263397 at the 
high, but not the low, dose significantly increased active lever presses (p < .01) (Figure 4.4a) 
and number of pellets obtained (p < .05), as well as the BP (p < .05) (Figure 4.4b).  
The temporal breakdown of active lever presses during the 6-h test was analyzed. A repeated 
measure ANOVA showed a significant main effect of treatment (F2, 14 = 3.72, p < .05) and 
time (F5, 35 = 37.39, p < .0001), as well as a significant interaction between these factors (F10, 
70 = 3.51, p < .001). Under the vehicle treatment, response rate was high during the 1
st h 
followed by a rapid decline. RO5263397 significantly increased responding rate during the 
first two h (p < .05 for the low dose at the 1st h; p < .05 for the high dose at the 2nd h, by N-K 















                        
Figure 4.4 RO5263397 increased the reinforcing efficacy for food 
Under a PR schedule of reinforcement, RO5263397 significantly increased the response rate on the 
active lever (a) and the BP (b) maintained by food. Temporal breakdown of the response rate 
revealed that RO5263397 significantly increased active lever responding during the first two h (c), 
which corresponds to an upward shift in the cumulative reinforcers obtained over time (d). * p < 







4.3.6 Experiment 5 summary  
RO5263397 dose-dependently reduced METH self-administration and the BP under a PR 
schedule of reinforcement, suggesting that TAAR1 partial activation decreases the 
reinforcing efficacy of METH and the motivation for METH. On the contrary, RO5263397 
significantly enhanced the BP maintained by food in the same PR procedure, indicating that 
TAAR1’s regulation of the motivational mechanisms underlying drug and food rewards can 
be clearly dissociated.  
4.3.7 Experiment 6 results 
To gain insight into the underlying mechanisms mediating TAAR1’s ability to modulate the 
effects of METH, METH-stimulated DA overflow was measured in NAc slices in the 
presence of RO5263397. Brain slices were perfused with either METH (2 µM), RO5263397 
(2 µM or 4 µM), or combination thereof for 20 min. A two-way repeated measure ANOVA 
revealed a significant main effect of treatment (F5, 32 = 9.073, p < .0001) and time (F19, 608 = 
15.883, p < .0001), and a significant interaction between them (F95, 608 = 5.353, p < .0001). 
Post hoc comparisons for the main effect of treatment showed that METH produced a robust 
and significant increase in DA levels (p < .01, by N-K tests), which was attenuated by both 
doses of RO5263397 (p < .01). RO5263397, when applied alone, failed to affect DA 
overflow at any dose (Figure 4.5d). Analysis of DA concentrations across the 20 min tests 
indicated a rapid and sustained increase following exposure to 2 µM METH (p < .05 at min 
7; p < .01 at min 8 - 20, by N-K tests), reaching a ten-fold elevation relative to baseline after 
12 - 14 min exposure. METH-induced DA accumulation was suppressed by RO5263397 at 
both 2 µM and 4 µM concentrations (p < .05 at min 7; p < .01 at min 8 - 20, by N-K tests) 








              
 
Figure 4.5 RO5263397 reduced METH-induced DA outflow in slices of rat NAc core 
DA calibrations indicated a linear relationship between the peak of the raw current and the specific 
DA concentrations used. The background-subtracted cyclic voltammogram identified the detected 
analyte as DA (a). The colour plots represent the voltammetric currents (encoded in colour in the 
z-axis) plotted against the applied potential (y-axis) and time (x-axis) (b). A representative trace of 
METH demonstrates the effect of METH (2 µM) perfusion on DA outflow in raw current (nA) 
within a 20-min time period (c). Application of 2 µM METH significantly increased DA outflow, 
which was significantly attenuated by both 2 µM and 4 µM RO5263397 (d and e). ** p < .01 








4.3.8 Experiment 6 summary 
RO5263397 effectively blocked METH-evoked DA overflow in the NAc core measured by 
FSCV in rat brain slice, supporting the inhibitory effects of TAAR1 on DA overstimulation 
induced by psychostimulants. When applied on its own, RO5263397 did not affect DA 
concentrations, suggesting that this partial agonist is devoid of METH-like stimulating 
properties.  
4.4 Discussion 
The present chapter described a series of experiments demonstrating that TAAR1 agonists 
display the ability to reduce cocaine and METH reinforcement and prevent METH-induced 
neurochemical changes. Firstly, the full and partial agonists, RO5256390 and RO5203648, 
respectively, shifted the dose-response curve for cocaine self-administration downward, 
suggesting that full and partial activation of TAAR1 block cocaine reinforcement. Secondly, 
in a PR schedule of reinforcement, the partial agonists, RO5203648 and RO5263397, delayed 
the time to reach BP for cocaine self-administration and decreased the BP for METH, 
respectively, suggesting that TAAR1 partial activation reduces the reinforcing value of 
cocaine and METH as well as the motivation for them. Moreover, both partial agonists 
significantly increased food-maintained responding under the same PR requirement, 
indicating differential regulation by TAAR1 on drug and food reward. Finally, FSCV data 
showed that RO5263397 effectively blocked METH-induced increase in DA release in the 
NAc core. Together, these results provided strong evidence for TAAR1 regulation of various 
abuse-related behavioural and neurochemical effects of psychostimulants, supporting TAAR1 
as a potential target for pharmacological development to treat addiction.  
Although the TA system has long been implicated in brain reward function and in 
psychostimulant reinforcement, its functional role in such processes only began to be 
understood with the recent identification of TAAR1 and the latest development of several 
highly selective TAAR1 agonists. TAAR1 KO mice displayed hypersensitivity to 




resistance to extinction (Achat-Mendes et al., 2012), suggesting an inhibitory role of TAAR1 
in the rewarding effects of psychostimulants. An early study with the partial agonist, 
RO5203648, showed a reduced responding rate for a single dose of cocaine under the 
TAAR1 treatment (Revel et al., 2012b), which could be interpreted as either an agonistic or 
antagonistic action of TAAR1 on cocaine reinforcement. The present finding that TAAR1 
partial and full activation produced a downward shift of the dose-response function for 
cocaine self-administration provided explanation for the previous equivocal result. Unlike a 
rightward or leftward shift of the dose-response curve, which represents a mere alteration 
(i.e., decrease or increase, respectively) in the reinforcing potency of the drug, a downward 
shift is best interpreted as a blockade of cocaine reinforcement because responding was 
reduced across all cocaine doses. Thus, a downward shift is the most desirable treatment 
outcome as it cuts the motivation for the drug regardless of doses, which is different from 
lateral shifts that can be easily compensated by self-regulating drug intake (Mello and Negus, 
1996, Veeneman et al., 2012).  
This inhibitory effect of TAAR1 on cocaine reinforcement is likely to depend on the ability 
of TAAR1 to inhibit DA transmission that is potentiated by cocaine. This idea is supported 
by the recent finding that RO5203648 prevented cocaine-stimulated DA overflow in the NAc 
(Pei et al., 2014). However, the molecular mechanisms involved in TAAR1’s regulation on 
DA are less clear. RO5203648 did not affect cocaine-induced changes in the tau measure of 
DA uptake, suggesting that the DAT is not directly involved in such modulation (Pei et al., 
2014). The possible routes of action may include TAAR1 interaction with the D2 
autoreceptors, known to form a mechanism of presynaptic receptor balancing that regulates 
DA activity, or TAAR1’s indirect influence on the DAT.  
In addition to producing augmentation of DA function, cocaine modifies glutamate receptors 
and causes enduring alterations in both pre- and postsynaptic glutamate transmission in the 
VTA and NAc (Fitzgerald et al., 1996, Churchill et al., 1999, Carlezon and Nestler, 2002, 




understanding cocaine reinforcement and relapse. Evidence showed that antagonism of the 
metabotropic glutamate 5 receptor (mGluR5), which is biochemically and structurally 
coupled to NMDA receptor, reduced the place-conditioning effects of cocaine (McGeehan 
and Olive, 2003), decreased cocaine self-administration (Kenny et al., 2005), and attenuated 
cocaine-induced lowering of ICSS thresholds (Kenny et al., 2005), demonstrating a mediating 
role of glutamate in the regulation of cocaine reinforcement. Thus, given the previously 
mentioned implication of TAAR1 in glutamatergic function (Revel et al., 2011, Revel et al., 
2013, Espinoza et al., 2015b), the ability of TAAR1 agonists to downwardly shift the cocaine 
dose-response curve could be linked to TAAR1 modulation of glutamate transmission. 
However, as the interactions between TAAR1 and glutamate systems are largely unknown, 
this possibility awaits future research.  
Our cocaine PR experiment (experiment 4) added further support for TAAR1’s inhibitory 
actions on cocaine reinforcement by showing that the partial agonist, RO5203648, reduced 
cocaine-maintained responding early in the PR session and prolonged the time to reach BP. 
Although the total number of infusions received during the test was not affected by TAAR1 
treatment, the temporal pattern of responding was significantly regulated. The TAAR1 partial 
agonist appeared to have decelerated responding such that responses became more evenly 
spaced, which might reflect an attenuated urge for the drug. Correspondingly, the time it took 
to obtain each successive reinforcer was markedly delayed by TAAR1, suggesting a lessened 
motivation to work for cocaine and a weakened reinforcing power of cocaine.  
The clear suppression on cocaine reinforcement by TAAR1 activation observed here is in 
agreement with reports from more recent behavioural studies examining the same or different 
TAAR1 selective agonists in other animal models of cocaine reward. Firstly, both the full and 
partial agonists, RO5256390 and RO5263397, respectively, dose-dependently prevented 
cocaine-induced lowering of ICSS thresholds in rats (Pei et al., 2015). As mentioned in 
chapter one, abusable drugs are able to decrease ICSS thresholds by acting themselves as 




Thus, this finding indicates that full or partial activation of TAAR1 renders cocaine less 
rewarding. Moreover, the study by Thorn et al. (2014a) found that the partial agonist, 
RO5263397, blocked the expression, but not the development, of cocaine-induced 
conditioned place preference, suggesting that TAAR1 partial activation may suppress the 
conditioned rewarding properties attributed to cocaine-associated cues resulting from their 
repeated pairing with cocaine. However, the lack of effects on the induction of 
cocaine-conditioned place preference is counterintuitive and may reflect a gradually 
diminished ability of the partial agonist to oppose cocaine reward as a consequence of 
chronic stimulation at TAAR1. Finally, using a between-session PR procedure of cocaine 
self-administration, the same group of researchers showed that RO52633397 increased the 
elasticity of cocaine demand curve, causing a faster decline rate in cocaine intake as the 
response requirement increased (Thorn et al., 2014a). According to the authors, their results 
suggest that RO5263397 reduced the essential value of cocaine and the motivation to take 
cocaine (Thorn et al., 2014a). However, RO5263397 did not affect cocaine consumption 
(0.75 mg/kg/infusion) at the minimal price (FR5), which contradicts the findings from the 
present experiments and is difficult to explain. 
The last behavioural experiment in this chapter generalized the reinforcing-decreasing effects 
of TAAR1 to METH, by showing that, the partial agonist, RO5263397, reduced the BP for 
METH self-administration under the PR schedule. Data generated from more recent studies 
reported that METH self-administration under FR schedule of reinforcement was reduced by 
RO5203648 at a single METH unit injection dose (0.05 mg/kg/infusion) (Cotter et al., 2015) 
and by RO5263397 across a range of METH doses (0.03 - 0.1 mg/kg/infusion) (Jing et al., 
2014). These, and the present, data provide straightforward and comprehensive evidence for 
the ability of TAAR1 partial activation to reduce the reinforcing efficacy of METH. Indeed, 
as mentioned previously, TAAR1’s involvement in METH reinforcement was firstly noticed 
in the observation that TAAR1 KO mice were hypersensitive to METH-conditioned place 
preference (Achat-Mendes et al., 2012). Moreover, newer findings indicate that the TAAR1 




genetic difference in voluntary METH intake in mice, suggesting that this gene plays a part in 
influencing the genetic risk for METH use. Mice with a non-functional allele of the TAAR1 
gene displayed heightened METH drinking, accompanied by hyposensitivity to 
METH-induced conditioned taste aversion and hypothermia. On the contrary, expression of 
functional TAAR1 segregated with low METH consumption and increased sensitivity to 
METH-related aversive and hypothermic effects (Harkness et al., 2015, Phillips and Shabani, 
2015). Thus, it has been suggested that an increased TAAR1 function may protect against 
METH consumption through amplifying the unpleasant physiological or subjective effects of 
METH (Harkness et al., 2015, Phillips and Shabani, 2015). 
The physiological mechanisms underlying TAAR1’s dampening effects on METH 
reinforcement may partially overlap with those for cocaine, given the common role of DA 
and glutamate, as well as their interactions, in psychostimulant actions (Wang and 
McGINTY, 1999, Wang et al., 2006, Kalivas, 2007). Acute METH increased extracellular 
concentrations of DA and glutamate in the striatum (O'Dell et al., 1991, Nash and 
Yamamoto, 1992, Ohmori et al., 1996). Moreover, the BP for METH self-administration 
under PR reinforcement was reduced by selective blockade of the DA D3 receptor (Higley et 
al., 2011, Chen et al., 2014) or the mGluR5 receptor (Osborne and Olive, 2008, Gass et al., 
2009), supporting the importance of both DA and glutamate in the reinforcing efficacy of 
METH. Although neurochemical studies are yet to measure the effects of TAAR1 on 
glutamatergic transmission, it might be possible that TAAR1 agonists have the potential to 
modulate glutamatergic response to METH or interfere with glutamatergic afferent to DA 
neurons, either directly or indirectly.  
Experiment 6 was conducted to test if TAAR1 regulates METH-induced alteration in DA 
transmission and found that RO5263397 prevented the robust and sustained increases in DA 
overflow produced by METH treatment. This evidence could, at least in part, account for the 
marked ability of RO5263397 to reduce the acute reinforcing effect of METH that is 




Moreover, this finding is consistent with the inhibitory regulation by RO5203648 on 
cocaine-induced DA accumulation in the NAc (Pei et al., 2014), which together support the 
hypothesis that TAAR1 activation is able to counteract abnormally elevated DA 
neurotransmission, especially DA surges produced by psychostimulants. Besides, experiment 
6 also showed that RO5263397 did not augment DA overflow when applied singly, 
suggesting that the partial agonist does not share the neurochemical properties of METH, 
which is a favourable feature for anti-addiction drugs to have.  
The exact molecular processes underlying the reduction in METH-induced DA release by 
TAAR1 are unclear. As previously described, different from cocaine which has no affinity at 
TAAR1, METH interaction with TAAR1 triggers a series of phosphorylation events to 
inhibit DA uptake, enhance DA efflux, and trigger DAT internalization (Xie and Miller, 
2009a). Thus, given its partial agonist profile, RO5263397 may exert antagonistic action at 
TAAR1 to reduce the TAAR1-dependent effects of METH on DA release. Meanwhile, the 
phosphorylation cascades resulting from METH stimulation of TAAR1 may be opposed by 
D2 autoreceptors, which adds additional inhibitory control over METH-augmented DA 
concentrations (Miller, 2011). In addition, TAAR1 expression was observed in neurons that 
did not co-express DAT but were in approximation to DAT neurons in mouse SNr (Xie et al., 
2007). Activating TAAR1 located in non-DA neurons by METH or TAAR1 selective 
agonists may inhibit the firing frequency of the adjacent DA neurons, leading to decrease in 
terminal DA release (Miller, 2011).  
Lastly, we showed that both RO5203648 and RO5263397 increased response rates and the 
BP for food pellets under the same PR requirement, suggesting that psychostimulant and food 
reinforcement are mediated by different mechanisms in the brain and that TAAR1 treatment 
inhibits drug-related behaviours specifically. The remarkable dissociation is not entirely 
surprising because electrophysiological studies have reported non-overlapping patterned 
discharge of NAc neurons in response to psychostimulants (i.e., cocaine) and natural rewards 




reward conditions is largely segregated within the NAc (Carelli et al., 2000, Carelli, 2002). It 
is interesting to explore the mechanisms by which TAAR1 is able to differentially influence 
such divergent neuronal networks. The fact that stimulant drugs produce more robust 
enhancement in DA transmission, which is larger in magnitude and longer in duration, 
relative to natural reinforcers may be part of the cause (Volkow et al., 2004, Ries et al., 
2009). It is possible that fluctuations in DA transmission modulate the magnitude and 
direction of TAAR1-mediated regulation, which is consistent with the previously proposed 
notion that TAAR1 serves as a stabiliser to “normalize” deviated DA activity, rather than as a 
simple brake on the DA system.  
Taken together, the findings from the present chapter showed that TAAR1 selective agonists 
reduced the reinforcing efficacy of cocaine and METH and blocked METH-induced DA 
release in the NAc without affecting DA level when administered alone. These results 
highlight the therapeutic potential of TAAR1 agonists in influencing abuse-related effects of 








5 TAAR1 Activation Prevents Relapse to Drug Seeking 
5.1 Introduction  
Results obtained from experiments in chapters three and four strongly demonstrated the 
ability of TAAR1 to modulate abuse-related behavioural and neurochemical effects of 
psychostimulants including cocaine- or METH-induced hyperlocomotion, reinforcement, and 
DA release/overflow. These findings, along with early evidence for the involvement of 
TAAR1 in DA transmission and psychostimulant action, support TAAR1 as a promising 
pharmacological target to treat stimulant addiction. Chapter five aimed to further characterize 
the therapeutic potential of TAAR1-based agents in clinically-relevant models of addiction, 
in particular relapse models. Relapse to drug seeking is indeed one of the major obstacles 
addicts encounter on the path to recovery. After a long drug-free period, relapse to drug 
seeking can be triggered by re-experiencing contexts associated with past drug-taking 
behaviour, which can be studied in animal model of context-induced renewal of drug-seeking 
without extinction (Fuchs et al., 2006). Moreover, relapse can be induced by the drug itself 
following a period of forced extinction training, which is best captured in the 
extinction-reinstatement model (Shalev et al., 2002, Shaham and Hope, 2005). Studies have 
implicated an elevated mesolimbic DA transmission in both drug-primed reinstatement and 
context-induced relapse (Self, 1998, Anderson et al., 2003, Crombag et al., 2008). Both the 
drug and drug-associated stimuli increase DA concentration in the striatum including the 
NAc and the dorsal striatum, which is associated with drug craving and drug seeking 
(Shaham and Hope, 2005, Volkow et al., 2006). Therefore, given the inhibitory control of 
TAAR1 over dopaminergic function, TAAR1 activation is expected to suppress drug-seeking 
behaviour in these situations. To test this hypothesis, we firstly examined the effects of 
RO5203648 and RO5256390, the partial and full TAAR1 selective agonists, respectively, on 




The two agonists were also tested against food-taking behaviour in order to control for 
potential motoric and motivational confounds (experiment 7)7. Next, the ability of the partial 
TAAR1 agonists, RO5203648 and RO5263397, to reduce drug-primed reinstatement of 
cocaine (experiment 8)7 and METH (experiment 9)8 seeking, respectively, was investigated. 
The last experiment assessed the potential abuse liability of TAAR1 ligands, which is an 
important issue to consider in evaluating novel anti-addiction medications. A substitution 
procedure was used to test the degree to which the partial agonist, RO5263397, sustained 
self-administration that was previously maintained by METH (experiment 10)8.  
5.2 Materials and Methods 
5.2.1 Subjects 
Long Evans male rats (8-10 weeks-old at the start of the experiments) were obtained from the 
University of Canterbury and maintained on a reversed 12-h light/dark cycle (lights off at 
8:00 a.m.) and standard conditions of temperature and humidity. Rats were given a 
maintenance diet (i.e., kept at 100% of their weight seven days’ post-surgery) and free access 
to water. All procedures were approved by the Animal Ethics Committee of the University of 
Canterbury.  
5.2.2 Pharmacological agents 
Cocaine hydrochloride was obtained from the National Institute on Drug Abuse (USA). 
METH hydrochloride was obtained from BDG synthesis (Wellington, New Zealand). Both 
drugs were dissolved in 0.9% physiological saline for i.p. injection and i.v. 
self-administration. RO5256390, RO5203648, and RO5263397 were synthesized at F. 
                                                 
7 Published paper. Experiment 7 and 8 have been published in the following paper: Pei Y, Lee J, Leo D, 
Gainetdinov RR, Hoener MC, Canales JJ (2014) Activation of the trace amine-associated receptor 1 prevents 
relapse to cocaine seeking. Neuropsychopharmacology 39:2299-2308. doi: 10.1038/npp.2014.88. 
8 Published paper. Experiment 9 and 10 have been published in the following paper: Pei Y, Asif‐Malik A, 
Hoener M, Canales JJ (2016) A partial trace amine‐associated receptor 1 agonist exhibits properties consistent 




Hoffmann-La Roche Ltd (Switzerland) and dissolved in 10% dimethylsulfoxide and 0.9% 
physiological saline for i.p. injection or i.v. self-administration.  
5.2.3 Catheter implantation surgery 
The surgical procedure was the same as previously described in chapter four.  
5.2.4 Apparatus 
The self-administration apparatus was the same as described in chapter four. During the drug 
self-administration training sessions, active lever presses resulted in activation of the infusion 
pump and delivery of the drug (i.e., cocaine or METH) or saline. In the substitution sessions 
(experiment 10), active lever presses led to pump activation and infusion of a dose of 
RO5263397, METH, or saline. In the food assay, response on the active lever resulted in 
delivery of a chocolate-flavoured pellet (45 mg, Bio-Serve, NJ, USA) into a food magazine 
situated between the two levers. The delivery of reinforcers was always paired with 
illumination of a light stimulus for 5 seconds.  
5.2.5 Context-induced relapse of cocaine seeking (experiment 7) 
Rats were trained to self-administer cocaine (0.5 mg/kg/infusion, 100 µl) or saline, being 
sequentially exposed to FR1, FR2, and finally FR3 reinforcement schedules during 
long-access sessions. Schedule progression was dependent upon meeting a criterion (number 
infusions per session ≥ 30). Rats were then transferred to and maintained at daily FR3 90 min 
sessions until meeting a criterion of stability and consistency (number infusions per session ≥ 
15 for five consecutive days with less than 20% variability). Cocaine infusions were limited 
to a maximum of 40 to prevent overdosing. After self-administration training, rats underwent 
withdrawal during which no access was given to the self-administration chambers for 14 
days. Relapse to drug seeking was tested by placing the rats back to the drug-taking context 
(i.e., self-administration chamber with the two levers exposed) for 45 min. Lever presses had 
no programmed consequence (neither the drug delivery nor the light stimulus). Each rat 




mg/kg, i.p.) or RO5256390 (0, 3, or 10 mg/kg, i.p.) was given 15 min before entering the 
chamber.   
5.2.6 Food assay (experiment 7 cont.) 
After completion of the context-induced relapse tests, rats were left undisturbed for two 
weeks and were later trained to lever press for chocolate-flavoured pellets under a FR1 
schedule in daily 45 min sessions. The maximal number of food pellets was limited to 40 per 
session to approximate the response rates obtained in cocaine relapse test. Once a stability 
criterion was met (number of food pellets ≥ 20 for three consecutive days), each rat was 
subjected to three food intake tests by receiving RO5203648 (0, 3, or 10 mg/kg, i.p.) (n = 8) 
or RO5256390 (0, 3, or 10 mg/kg, i.p.) (n = 8) 15 min prior to the test session (45 min) with 
the different doses administered in counterbalanced order.   
5.2.7 Cocaine-primed reinstatement of drug seeking (experiment 8) 
Rats were trained to stably self-administer cocaine (0.5 mg/kg/infusion, 100 µl) on daily FR3 
90 min sessions. The training procedure and stability criterion were the same as above. The 
extinction sessions were then introduced during which lever press was not reinforced either 
by infusions or the stimulus light. The extinction was conducted daily during 90 min sessions 
until a criterion was met (at least ten days of extinction training and the active lever presses 
during the last three extinction sessions being ≤ 15% of the average number of active lever 
presses during the last five drug self-administration sessions). Rats that did not meet this 
criterion after 21 extinction sessions were excluded from this study. After the extinction 
phase, each rat underwent two reinstatement tests, receiving cocaine (10 mg/kg, i.p.) or saline 
in counterbalanced fashion before the start of the sessions. To assess the effects of TAAR1 
partial agonists on drug-induced reinstatement, rats were divided into three experimental 
groups (n = 7-8 per group) receiving a pretreatment of RO5203648 (0, 3, or 10 mg/kg, i.p.) 
15 min prior to cocaine or saline injection. The reinstatement sessions were identical to 
extinction sessions except that they lasted for 3 h. In between the two reinstatement tests rats 




pre-reinstatement levels for two consecutive days. The three experimental groups were 
matched for performance during the drug self-administration sessions and extinction phase. 
To control for potential non-specific responding, a separate group of rats (n = 5) responding 
for saline during the self-administration phase underwent the same extinction procedure and 
received a pretreatment of vehicle 15 min before cocaine or saline injection in the 
reinstatement tests.  
5.2.8 METH-primed reinstatement of drug seeking (experiment 9) 
Rats (n = 27) were trained to lever press for METH (0.05 mg/kg/infusion, 100 µl) in FR3 90 
min daily sessions, with the same training procedures as described above. METH infusions 
were limited to a maximum of 40 per session to prevent overdosing. After response reached 
stability and consistency (number infusions per session ≥ 17 for five consecutive days with 
less than 20% variance in the last three days), rats underwent extinction training followed by 
two reinstatement tests, with the procedure same as that for experiment 8. During the 
reinstatement test, RO5263397 (0, 3, or 10 mg/kg, i.p.) was administered 15 min prior to a 
prime injection of METH (1 mg/kg, i.p.) or saline. An additional group (n = 4) responding for 
saline during the self-administration phase was included to control for non-specific 
responding. The control rats underwent the same extinction procedures and received vehicle 
treatment 15 min before METH or saline injection during the reinstatement tests.  
5.2.9 Substitution assay (experiment 10) 
Rats (n = 26) were trained on METH self-administration (0.05 mg/kg/infusion) under a FR3 
reinforcement schedule in daily 90 min sessions until a stability criterion was met, as above. 
To study the reinforcing property of RO5263397, rats were divided into four groups (n = 6-7 
per group) to receive RO5263397 (0.25 or 0.5 mg/kg/infusion), a lower dose of METH 
(0.017 mg/kg/infusion), or vehicle as the substitute compound. Rats were trained on the same 
substitute treatment for five consecutive days. The average METH intake and response rate 
over the last three METH self-administration pre-training sessions were matched between the 




5.2.10 Statistical analysis 
Data were analysed by ANOVA with repeated measures when a within-subjects design was 
in use, followed by post hoc comparisons with the method of N-K tests using the sampling 
error from the overall ANOVA as denominator. Statistical significance was set at α = 0.05 for 
all experiments. All statistical analyses were performed using StatView 5.0 (SAS Institute, 
NC, USA). 
5.3 Results and Summary  
5.3.1 Experiment 7 results 
Firstly, we tested the ability of the partial TAAR1 agonist, RO5203648, to attenuate 
context-induced cocaine seeking after a 2-week period of abstinence from cocaine 
self-administration. Rats were trained to lever press for cocaine (0.05 mg/kg/infusion) (n = 7) 
or saline (n = 8) on a FR3 schedule of reinforcement. The ANOVA and post hoc comparisons 
showed that rats responding for cocaine produced a significantly higher number of active 
lever presses (ANOVA F1, 13 = 116.98, p < .001; p < .01, by N-K tests) and obtained more 
cocaine infusions (ANOVA F1, 13 = 207.95, p < .001; p < .01, by N-K tests) than rats 
responding for saline (Figure 5.1a and inset).  
After two weeks of abstinence, rats were placed back into the self-administration chambers 
with the two levers exposed but lever pressing was not reinforced either by the drug infusion 
or the light stimulus. Rats previously trained on cocaine self-administration showed robust 
relapse to drug seeking on the active lever upon re-exposure to the chambers, which was 
effectively blocked by RO5203648 pretreatment. ANOVA for lever presses revealed 
significant main effects of drug (cocaine vs. saline, F1, 13 = 44.78, p < .001), lever (active vs. 
inactive, F1, 13 = 25.86, p < .001), and dose of RO5203648 (F2, 26 = 57.33, p < .001), and a 
significant interaction between drug and lever (F1, 13 = 27.40, p < .001), dose and drug (F2, 16 
= 30.62, p < .0001), lever and dose (F2, 26 = 9.61, p < .001), as well as a significant three-way 
interaction between these factors (F2, 26 = 7.77, p < .002) (Figure 5.1b). Post hoc comparisons 




by N-K tests) of RO5203648 on active lever presses. There was a comparatively lower but 
significant increase in the number of inactive lever presses made by cocaine-trained rats. 




Figure 5.1 RO5203648 suppressed context-induced relapse of cocaine seeking 
After consistent cocaine self-administration performance (a) and protracted abstinence, rats showed 
robust drug-seeking behaviour upon exposure to the self-administration chambers, which was 
significantly suppressed by RO5203648 (b). * p < .05, ** p < .01 significantly different from saline 
value; ## p < .01 significantly different from vehicle pretreatment for cocaine value.  
 
To control for potential non-specific effects of RO5203648 on general motivation and motor 
performance, RO5203648 was tested in rats (n = 8) responding for chocolate-flavoured 
pellets under a FR1 reinforcement schedule. The overall responding rate was not affected by 
RO5203648 at any dose. ANOVA did not reveal any significant effects of RO5203648 on 
food-maintained lever presses (F2, 14 = 1.39, p = 0.283). However, analysis of responding rate 
across time bins revealed a significant interaction between TAAR1 treatment and time (F4, 28 




food pellets in the 45 min session (Figure 5.2a) but were slower to initiate responding, 
earning significantly fewer reinforcers in the 1st 15 min (p < .01, by N-K tests) (Figure 5.2b). 
  
 
       
Figure 5.2 RO5203648 delayed food intake only at the high dose 
Rats were trained to stably respond for food pellets under FR1 reinforcement 
schedule. RO5203648 pretreatment did not affect total number of pellets earned (a) 
but slightly delayed response initiation at the high dose only (b). * p < .01 
significantly different from vehicle pretreatment.  
 
Next, we examined the effects of full TAAR1 activation on context-induced cocaine relapse 
by testing RO5256390 under identical conditions. Rats were firstly trained to stably 
self-administer cocaine (n = 8) or saline (n = 6) on a FR3 reinforcement schedule. ANOVA 
revealed a significant effect of the drug (cocaine vs. saline) on active lever presses (F1, 12 = 
196.61, p < .001) and on infusions obtained (F1, 12 = 136.00, p < .001), with both parameters 
being significantly higher for rats responding for cocaine than for saline (p < .01, by N-K 
tests) (Figure 5.3a and inset). In the relapse test, rats previously trained for cocaine showed 
high level of drug seeking only on the active lever, which was dose-dependently blocked by 
RO5256390. ANOVA for lever presses revealed significant effects of drug (cocaine vs. 





RO5256390 (F2, 24 = 33.73, p < .001), as well as a significant interaction between these 
factors (F2, 24 = 13.83, p < .001). RO5256390 significantly reduced active lever presses at 




Figure 5.3 RO5256390 suppressed context-induced relapse of cocaine seeking 
After stable cocaine self-administration training (a) and abstinence, relapse to drug seeking was 
induced by re-exposing to the self-administration chambers. RO5256390 pretreatment significantly 
blocked this context-induced relapse of cocaine seeking (b). ** p < .01, significantly different from 
saline values; ## p < .01 significantly different from vehicle pretreatment for cocaine values. 
 
In the food assay, RO5256390, at the high, but not low, dose, produced nonspecific effects on 
food-maintained responding. The overall number of food pellets earned was significantly 
reduced by the high dose of RO5256390 as revealed by ANOVA (F2, 14 = 5.02, p < .05) and 
post hoc comparisons (p < .05, by N-K tests) (Figure 5.4a). Time course analysis showed a 
significant interaction between RO5256390 and time (F4, 28 = 15.07, p < .001). RO5256390 at 
the high dose delayed response rate and significantly decreased number of reinforcers 







                
Figure 5.4 RO5256390 affected food intake only at the high dose  
Rats were trained to stably respond for food pellets under FR1 reinforcement 
schedule. RO5256390 pretreatment at the high dose reduced food intake (a) and 
delayed response (b). * p < .05 significantly different from vehicle pretreatment.  
 
5.3.2 Experiment 7 summary 
After protracted withdrawal from chronic cocaine self-administration, the partial and full 
TAAR1 agonists, RO5203648 and RO5256390, respectively, prevented relapse of cocaine 
seeking induced by re-exposing the rats to the self-administration chambers. In the food 
assay, RO5203648 at the high dose delayed response initiation without affecting overall 
number of reinforcers earned. RO5256390 at the high dose delayed response and reduced 
number of pellets obtained. Both agonists at the low dose, which was still highly effective in 
attenuating cocaine relapse, did not impair food-maintained behaviour.  
5.3.3 Experiment 8 results 
To test the ability of RO5203648 to reduce cocaine-primed reinstatement of drug seeking, 
three groups of rats (n = 7-8 per group) were firstly trained to self-administer cocaine on a 
FR3 reinforcement schedule. The three groups responded similarly and obtained similar 
number of infusions in the last five days of cocaine self-administration before extinction was 





rate. ANOVA for lever presses during the last five cocaine self-administration sessions 
revealed a significant effect of group (cocaine vs. saline, F3, 23 = 34.56, p < .001) and lever 
(active vs. inactive, F1, 23 = 390.06, p < .001), and a significant interaction between these 
factors (F3, 23 = 35.83, p < .001). Mean comparisons showed a significant difference between 
the control group and each of the three experimental groups in the number of active lever 
presses (p < .01, by N-K tests), but not in the number of inactive lever presses. ANOVA for 
the average number of infusions over the five days showed a significant effect of group (F3, 23 
= 39.32, p < .001), which was due to significantly more infusions obtained by the three 
cocaine groups compared with the control group (p < .01, by N-K tests) (Figure 5.5a and 
inset).  
During extinction, all but seven rats in the experimental groups gradually decreased 
responding on the active lever and reached the extinction criteria within 21 days. These seven 
rats were excluded from further analysis. Responding on the inactive lever was low 
throughout and did not differ between groups. A repeated measure ANOVA for lever presses 
during the last three extinction sessions showed a significant effect of group (F3, 23 = 4.74, p < 
.01) and lever (F1, 23 = 40.74, p < .001), and a significant interaction between these factors (F3, 
23 = 5.34, p < .01). Post hoc comparisons revealed no significant differences between the 
three groups previously responding for cocaine (Figure 5.5b).  
In the reinstatement tests, rats in the experimental groups received RO5203648 (0, 3, or 10 
mg/kg, i.p.) followed 15 min after by cocaine (10 mg/kg, i.p.) or saline injection before 
entering the chambers. The control rats received vehicle pretreatment before cocaine or 
saline. The reinstatement session lasted for 3 h during which lever presses had no 
programmed consequences. ANOVA for the total number of lever presses during the test 
showed a significant main effect of prime injection (saline vs. cocaine, F1, 23 = 18.81, p < 
.001), lever (active vs. inactive, F1, 23 = 47.69, p < .001), and dose of RO5203648 (F3, 23 = 
7.62, p < .001), and a significant interaction between lever and dose of RO5203648 (F3, 23 = 




injection (F1, 23 = 12.17, p < .005), as well as a significant three-way interaction between 
these factors (F3, 23 = 4.69, p < .01). Post hoc comparisons showed that cocaine priming 
induced significantly higher response rates on the active lever, but not on the inactive lever, 
compared with saline treatment (p < .01, by N-K tests). This reinstatement of drug seeking 
was dose-dependently attenuated by RO5203648 at both the low (p < .01, by N-K tests) and 
the high dose (p < .01, by N-K tests). RO5203648 did not in its own right (i.e. when given 
before saline) renew drug seeking at any dose (Figure 5.5c).  
ANOVA analysis for active lever presses in 20 min bins across the reinstatement test for the 
three cocaine groups showed a significant effect of dose of RO5203648 (F2, 12 = 6.33, p < 
.05), cocaine priming (F1, 12 = 9.28, p < .05), and time (F8, 96 = 8.04, p < .001), and a 
significant interaction between RO5203648 and cocaine priming (F2, 12 = 6.55, p < .05), time 
and RO5203648 (F16, 96 = 7.01, p < .0001), cocaine priming and time (F8, 96 = 2.57, p < .05), 
as well as a significant three-way interaction between these factors (F16, 96 = 5.98, p < .001). 
N-K tests indicated that cocaine produced significantly higher number of active lever presses 
in the 1st (p < .01) and the 2nd (p < .01) 20 min bins, and this effect was significantly 
attenuated by RO5203648 at both the low (p < .01) and the high (p < .01) dose (Figure 5.5d).  
5.3.4 Experiment 8 summary  
After extinction of cocaine self-administration, the partial TAAR1 agonist, RO5203648, 
effectively blocked reinstatement of cocaine seeking triggered by a prime injection of 







5.3.5 Experiment 9 results 
To test if partial TAAR1 agonism was also effective in preventing METH-primed 
reinstatement of METH seeking, the partial agonist, RO5263397, was tested in the same 
extinction-reinstatement model. During the self-administration phase, the three experimental 
groups (n = 9 per group) responding for METH (0.05 mg/kg/infusion) showed similar level 
   
           
     
Figure 5.5 RO5203648 prevented cocaine-primed reinstatement of cocaine seeking 
Three groups of rats were trained to stably self-administer cocaine, showing significantly higher 
levels of response than the group self-administering saline (a). This phase was followed by 
extinction during which response rate dropped to low levels in the last three extinction sessions (b). 
A prime injection of cocaine generated strong reinstatement of cocaine seeking, which was 
dose-dependently attenuated by RO5203648 (c and d). ** p < .01, significantly different from 






of response rate and obtained similar number of infusions during the last five METH 
self-administration sessions, which were significantly higher than the control group (n = 4) 
responding for saline. ANOVA for lever presses during the last five METH training sessions 
showed a significant effect of group (METH vs. saline, F3, 27 = 40.37, p < .0001) and lever 
(active vs. inactive, F1, 27 = 334.92, p < .0001), and a significant interaction between them (F3, 
27 = 24.59, p < .0001). Post hoc comparisons showed a significant difference between the 
control group and each of the three experimental groups in active lever presses (p < .01, by 
N-K tests), but not in inactive lever presses (Figure 5.6a). 
During extinction, all the rats in the experimental groups gradually decreased responding on 
the active lever and met the extinction criterion within 21 days. A repeated measure ANOVA 
for lever presses during the last three extinction sessions showed a significant effect of lever 
(F1, 27 = 52.65, p < .0001) and a significant interaction between lever and group (F3, 27 = 3.38, 
p < .05). This was due to a significantly higher response rate on the active lever than on the 
inactive lever in the three METH groups during the last three extinction sessions (p < .05, by 
N-K tests). The three METH groups did not differ in active or inactive lever responding in 
the last three days of extinction training (Figure 5.6b). 
After extinction, reinstatement of drug seeking was examined by giving the rats METH (1 
mg/kg, i.p.) or saline in counterbalanced fashion. The ANOVA for the total number of lever 
presses in the reinstatement test showed a significant main effect of dose of RO5263397 (F3, 
27 = 10.47, p < .0001), lever (F1, 27 = 38.54, p < .0001), and prime injection (F1, 27 = 29.16, p < 
.0001), and a significant interaction between lever and RO5263397 (F3, 27 = 10.14, p < .0001), 
prime injection and RO5263397 (F3, 27 = 9.11, p < .001), lever and prime injection (F1, 27 = 
30.99, p < .0001), as well as a significant three-way interaction between those factors (F3, 27 = 
10.05, p < .001). Post hoc comparisons showed that METH priming induced robust 
responding on the active, but not inactive, lever compared to the saline injection (p < .01, by 
N-K tests). The METH-primed reinstatement was significantly attenuated by RO5263397 at 




drug seeking at any dose (Figure 5.6c). Active lever presses during the reinstatement test 
were further analysed in 1 h bins for the three experimental groups. A repeated measure 
ANOVA showed a significant effect of dose of RO5263397 (F2, 24 = 11.84, p < .001) and 
prime injection (F1, 24 = 44.97, p < .0001), and a significant interaction between RO5263397 
and prime injection (F2, 24 = 11.19, p < .001), time and RO5263397 (F4, 48 = 2.60, p < .05), 
prime injection and time (F2, 48 = 4.89, p < .05), as well as a significant three-way interaction 
between RO5263397, prime injection, and time (F4, 48 = 2.99, p < .05). Drug seeking was 
prevented by RO5263397 at both doses during the 1st (p < .01, by N-K tests) and the 2nd (p < 
.01, by N-K tests) h, but not during the last h, as evidenced by a significant increase in active 
lever presses relative to the preceding time bins (p < .05 for both the 1st and the 2nd time bin 
and for both doses of RO5263397) (Figure 5.6d). 
5.3.6 Experiment 9 summary 
The partial TAAR1 agonist, RO5263397, suppressed METH-primed reinstatement of METH 
seeking after extinction from chronic METH exposure and did not renew drug seeking when 













      
 
Figure 5.6 RO5263397 prevented METH-primed reinstatement of METH seeking 
After rats were trained to stably self-administer METH or saline (a), extinction was introduced 
during which response decreased to low levels in the last three extinction sessions (b). A challenge 
dose of METH produced robust reinstatement of drug seeking, which was significantly reduced by 
RO5263397 (c and d). * p < .01 significantly different from saline values; # p < .01 significantly 
different from METH values.  
 
5.3.7 Experiment 10 results  
To test the abuse potential of RO5263397, we substituted RO5263397 for METH in the 
self-administration task. Four experimental groups were trained to stably self-administer 
METH (n = 6-7 per group; 0.05 mg/kg/infusion) on a FR3 schedule of reinforcement. These 







METH self-administration training sessions. In the substitution tests, two doses of 
RO5263397 (0.25 or 0.5 mg/kg/infusion), a lower dose of METH (0.017 mg/kg/infusion), or 
vehicle were given as the substitute compound for five consecutive days. Unlike the low dose 
of METH, which elevated the response rate, RO5263397 did not sustain responding at either 
dose. A repeated measure ANOVA for active lever presses during the five days revealed a 
significant effect of treatment (F3, 22 = 76.25, p < .0001), lever (F1, 22 = 327.37, p < .0001), and 
day (F4, 88 = 8.34, p < .0001), and a significant interaction between lever and treatment (F3, 22 
= 113.12, p < .0001), lever and day (F4, 88 = 5.71, p < .001), as well as a significant three-way 
interaction between those three factors (F12, 88 = 3.41, p < .001). Means comparisons showed 
that the low dose of METH (0.017 mg/kg/infusion) produced the highest active lever 
responding rate among the four groups in all the five test sessions (p < .01 compared with 
vehicle and both doses of RO5263397, by N-K tests). Response for both doses of 
RO5263397 was significantly lower than that for vehicle on day 1 (p < .01, by N-K tests) 
(Figure 5.7a). For number of infusions obtained during the five sessions, repeated measure 
ANOVA revealed a significant main effect of treatment (F3, 22 = 196.05, p < .0001) and day 
(F4, 88 = 12.77, p < .0001), and a significant interaction between treatment and day (F12, 88 = 
3.36, p < .001). Post hoc comparisons showed that rats obtained most infusions when given 
the low dose of METH for all the five test days (p < .01 compared with vehicle and the two 
RO5263397 substitution groups). RO5263397 at both doses, when substituted for METH, 
produced significantly less infusions than vehicle on the first session (p < .05 for the low 
dose; p < .01 for the high dose of RO5263397, by N-K tests) (Figure 5.7b).  
5.3.8 Experiment 10 summary 
In rats stably self-administering METH, two doses of RO5263397, a lower dose of METH, 
and vehicle were introduced as the substitute drug through i.v. infusions. Unlike the low dose 
of METH which increased response, RO5263397 at both doses led to an immediate drop in 
response rate, which was even lower than that produced by vehicle substitute on the first 




            
 
 
Figure 5.7 RO5263397 did not sustain responding when substituted for METH 
After rats were trained to stably self-administer METH, a lower dose of METH, vehicle, or 
RO5263397 at a high or a low dose was given as substitute infusion for five days. The low dose of 
METH increased and sustained responding. Lever presses and infusions obtained for RO5263397 
remained low at both doses across the five days, and were significantly lower than those for the 
vehicle substitution on day 1 (a and b). * p < .01 significantly different from each of other three 







5.4 Discussion  
The final set of experiments provided strong evidence for the effectiveness of selective 
TAAR1 agonists in two different animal models of relapse, a feature that is highly desirable 
for an efficacious anti-addiction medication to have. Firstly, we determined that the full and 
partial TAAR1 agonists, RO5256390 and RO5203648, respectively, prevented 
context-induced renewal of cocaine seeking in rats after protracted withdrawal from chronic 
cocaine self-administration. Both agonists were highly effective at doses that did not affect 
food-maintained responding. Moreover, after extinction from cocaine self-administration, 
reinstatement of cocaine seeking triggered by a cocaine prime was blocked by the partial 
agonist, RO5203648. Similarly, METH-primed reinstatement of METH seeking was 
significantly reduced by partial TAAR1 agonism with RO5263397. Furthermore, 
RO5263397, when substituted for METH, did not sustain self-administration behaviour, 
displaying low abuse liability. Collectively, these results support TAAR1 agonists as 
potential lead compounds for future development of therapeutic interventions for 
psychostimulant addiction.  
Recurrent cycles of abuse, recovery, and relapse are the defining features of psychostimulant 
addiction, thus developing medications that could aid in recovery and facilitate stable 
abstinence from the drug would be highly beneficial from the medical standpoint. The recent 
discovery of TAAR1, which has shown marked ability to regulate DA transmission and 
psychostimulant action, has generated a great deal of interest in the field of addiction 
pharmacology research. Based on the existing data showing the ability of several highly 
selective TAAR1 agonists to modulate cocaine- or METH-induced locomotor activity and 
inhibit the reinforcing and DA-releasing effects of these drugs, the present work further 
evaluated the potential utility of targeting TAAR1 to treat stimulant addiction by assessing 
the effectiveness of TAAR1 agonists in clinically-relevant animal models of relapse and their 




Firstly, in the model of context-induced renewal of drug seeking, relapse is triggered, after a 
long-term abstinence from cocaine self-administration, by re-entering the self-administration 
chambers that were previously associated with drug taking. This process may involve the 
excitatory Pavlovian conditioning mechanisms through which the chambers acquire 
conditioned stimulus properties and incentive motivational salience during their pairing with 
drug availability, and thus elicit drug craving and drug seeking in abstinent rats upon 
re-exposure (Crombag et al., 2008, Hearing et al., 2008b). It is known that drug-related 
conditioned stimuli are able to produce marked changes in gene expression within the 
corticostriatal circuits including the dorsal striatum, NAc, anterior cingulate cortex, medial 
PFC, and orbitofrontal cortex (Hearing et al., 2008a, Hearing et al., 2008b), and induce 
conditioned increases in mesolimbic DA transmission (Fontana et al., 1993). Studies using 
FSCV have detected a rapid surge of DA in the NAc that coincided with the initiation of 
drug-seeking behaviour, and such behaviour could be reproduced by or/and synchronized to 
electrically evoked DA transients to the NAc (Phillips et al., 2003). Therefore, 
context-induced drug seeking may crucially rely on mesolimbic DA transmission that is 
potentiated by re-exposure to the drug self-administration context. Consistent with this, 
systemic injections of D1-like or D2-like DA receptor antagonists attenuated 
context-renewed cocaine seeking (Crombag et al., 2002a), and this effect has been attributed 
to a decrease in DA transmission in the NAc shell (Crombag et al., 2008).  
In addition to DA, neuroadaptations of the glutamatergic system, mainly within projections 
from the PFC to the NAc, are believed to mediate behavioural neuroplasticity associated with 
relapse (Kalivas, 2004). Changes in both pre- and postsynaptic glutamate transmission in the 
VTA and NAc also play a role (Kalivas, 2004). These adaptations lead to amplified 
biological saliency of glutamate release in the NAc upon exposure to stimulus that triggers 
relapse, which translates into behavioural drive for drug-seeking (Kalivas, 2004). Studies 
have shown that antagonism of AMPA or NMDA receptors in the NAc attenuated cocaine 
relapse induced by cocaine-associated cues (Bäckström and Hyytiä, 2007), whereas 




(Cornish et al., 1999), supporting the engagement of an increased glutamate transmission in 
cocaine relapse. Moreover, it has been suggested that glutamate-mediated effects on drug 
seeking may involve its local interaction with DA in the VTA and NAc (Crombag et al., 
2008), as DA neurons in both regions are controlled in part by glutamatergic input from 
various brain areas (Voorn et al., 2004, Pierce and Kumaresan, 2006, Geisler et al., 2007).  
Therefore, based on the previously mentioned evidence suggesting opposing actions of 
TAAR1 on the DA system, activation of TAAR1 could attenuate context-induced relapse to 
cocaine seeking through preventing the conditioned release of DA upon re-exposure to the 
drug-associated context. TAAR1 may also influence glutamatergic inputs to the NAc, 
especially those from the PFC given the aforementioned implication of TAAR1 in prefrontal 
glutamate transmission, although how this interaction eventually leads to reduced cocaine 
seeking is unknown. Nevertheless, the current results confirmed our prediction of a reduced 
cocaine relapse. Both full and partial TAAR1 activation with RO5256390 and RO5203648, 
respectively, significantly diminished cocaine seeking upon re-entering the 
self-administration chambers. In the experiment in which we tested RO5203648, rats also 
displayed a moderately high level of responding on the inactive lever during the relapse test, 
which might reflect a strategic search for cocaine reinforcement and thus could also be 
interpreted as drug-seeking behaviour. RO5203648 dose-dependently attenuated response not 
only on the active lever but also on the inactive lever, consistent with its anti-relapse profile.  
Besides, both compounds, at the high dose, produced non-specific effects on food intake, 
characterized by slow response initiation and, in the case of the full agonist, decreased overall 
intake as well. This effect is unlikely to be caused by an impaired motoric function, at least 
for RO5203648, as it has been previously shown that 10 mg/kg of this partial agonist did not 
affect locomotor behaviour in rats (Revel et al., 2012b). Alternatively, TAAR1 agonists may 
create a physiological or internal “satisfaction” state in the rats, possibly via balancing the 
activity of neurotransmitters, leading to less interest in external rewards such as food, 




activation increases motivation to seek food in the PR schedule of reinforcement. 
Complementarily, studies have reported the expression of TAAR1 in peripheral organs 
involved in food absorption and control of glucose metabolism, suggesting that TAAR1 may 
regulate metabolic functions (Mitchell et al., 2008, Revel et al., 2013). Although the exact 
functional contribution of TAAR1 in the peripheral system is unclear, it might be possible 
that TAAR1 influences food-intake through mechanisms outside the CNS. As mentioned, in 
the food PR experiments described in the previous chapter, both RO5203648 and 
RO5263397 enhanced the BP for food self-administration, suggesting an increase in the 
motivation for food. However, in the early phase of the PR session, characterized by low 
response requirement, RO5203648 at the high dose delayed responding, mirroring its effects 
in the present food-intake assay. Such discrepant findings (i.e. differential TAAR1 effects on 
food-maintained responding under FR1 and PR schedules of reinforcement) may reflect 
differential regulation by TAAR1 on the appetitive and consummatory aspects of eating, 
which are separable in terms of the underlying neuronal substrates (Foltin, 2005, Gan et al., 
2010, Oleson et al., 2011). Nonetheless, it is important to note that both compounds were 
highly effective in reducing context-induced cocaine seeking at doses (3 mg/kg) that had no 
negative impact on food-maintained responding, suggesting that TAAR1 agonists can act 
within a wide therapeutic window. Due to the propensity of the full agonist to produce a more 
profound non-specific suppression on food taking than the partial agonist, only partial 
TAAR1 agonists were tested in subsequent experiments.  
We next tested TAAR1 agonists in the extinction-reinstatement model of relapse where drug 
seeking is triggered by a challenge dose of the previously self-administered drug. Evidence 
has indicated an important role of both glutamate and DA in drug-induced reinstatement. In 
rats extinguished from METH self-administration, a METH prime produced concurrent 
increases of glutamate efflux in both the dorsal medial PFC and the NAc, accompanied by an 
elevation in DA concentrations only in the dorsal medial PFC (Parsegian and See, 2014). 
Similarly, increased release of glutamate, but not DA, in the NAc, has been specifically 




cocaine-seeking behaviour, was eliminated by inhibition of the dorsal PFC (McFarland et al., 
2003). Moreover, blockade of either D1-like or D2-like DA receptors in the PFC, but not in 
the NAc, decreased cocaine-induced reinstatement (McFarland and Kalivas, 2001, Sun and 
Rebec, 2005), whereas antagonism of the AMPA receptor in the NAc blocked cocaine 
seeking induced by either a systemic injection of cocaine (Cornish and Kalivas, 2000) or 
intra-medial PFC cocaine infusion (Park et al., 2002). Together, these results suggest that the 
glutamatergic projection from the PFC to the NAc in part underlies drug-reinstated drug 
seeking, and that prefrontal DA plays a more enabling role than accumbens DA. In the 
present experiments, following consistent cocaine or METH self-administration and 
extinction, a prime injection of the self-administered drug produced robust reinstatement of 
drug seeking. The TAAR1 partial agonists, RO5203648 and RO5263397, dose-dependently 
prevented cocaine- and METH-primed reinstatement, respectively, consistent with the 
inhibitory control of TAAR1 over augmented drug-induced DA transmission and with a 
potential functional interaction of TAAR1 with the corticoaccumbens glutamatergic pathway 
activated by the drug prime. In agreement with the present findings, studies conducted while 
this thesis was in progress reported that RO5263397 prevented cue- and drug-induced 
reinstatement of cocaine and METH seeking (Jing et al., 2014, Thorn et al., 2014a), which 
further strengthens the evidence for the ability of TAAR1 agonists to prevent relapse.  
However, it is worth noting that the mechanisms involved in TAAR1’s regulation of the 
reinstatement induced by METH may be more complex than that induced by cocaine. While 
TAAR1 partial agonism produced a complete blockade of cocaine-induced drug seeking 
throughout the entire 3-h test, this effect was only observed during the first 2 h of the METH 
reinstatement, with responding recovering in the last part of the session. This later recovery in 
response was not picked up by Jing et al. (2014)’s study as their reinstatement test stopped 
after 2 h. Thus, additional direct interaction between METH and RO5263397 may have 
occurred given the ability of METH, but not cocaine, to stimulate TAAR1 and trigger 
downstream signalling events. Actually, this time-dependent modulation of TAAR1 over 




showing an early attenuation followed by a later potentiation of METH-induced locomotor 
activity by RO5203648. However, while in the locomotor test there was a clear biphasic 
interaction between METH and TAAR1 pretreatment (Figure 3.1), in TAAR1 agonist-treated 
rats the METH-primed drug seeking in the latter part of the test did not exceed the levels 
elicited by METH alone. As discussed earlier, the biphasic modulation by TAAR1 of the 
motor-stimulating effects of METH may fit into the notion of a state-dependent regulation of 
DA transmission by TAAR1 partial agonists. However, in the METH reinstatement model 
which involves prolonged METH exposure and extinction, a subsequent METH prime 
injection may induce a more exaggerated increase in DA release compared with the acute 
METH treatment in the locomotor assay (Yamada et al., 1988, Kazahaya et al., 1989), thus 
promoting a sustained agonistic-like action of the partial agonist to suppress DA 
transmission. In addition, the corticostriatal glutamatergic pathway also undergoes 
neuroadaptations after chronic METH treatment, displaying enhanced stimulated glutamate 
transmission in the PFC and striatum (Stephans and Yamamoto, 1995, Nishioku et al., 1999, 
Bustamante et al., 2002), which did not occur in the acute METH locomotor activity test. 
Moreover, TAAR1 receptor functionality may be affected by repeated METH stimulation, 
resulting in altered responsiveness to subsequent exposure to TAAR1 ligands, including 
METH itself and the selective agonist. Other neuroadaptive consequences following chronic 
TAAR1 activation may include changes in the coordinated interaction between TAAR1 and 
D2 receptors, D2 receptor-mediated autoinhibition, and prefrontal glutamatergic 
transmission. Any of these elements may contribute to the differential TAAR1 modulation of 
the effects induced by acute- and chronic-METH.  
Another important observation in the present reinstatement experiments is that both 
RO5203648 and RO5263397 failed to reinstate drug seeking when administered alone (i.e., 
followed by saline injection). This finding demonstrates a psychopharmacological profile of 
TAAR1-specific compounds that is distinct from some of the psychomotor stimulants and 




and METH, which do produce cross-reinstatement of extinguished drug-seeking behaviour 
(De Wit and Stewart, 1981, Schenk et al., 2008, Nawata et al., 2015).  
The last experiment provided further support for the lack of stimulant-like characteristics of 
TAAR1-selective agonists. We found that RO5263397, at either the low or the high dose, did 
not sustain self-administration when substituted for METH. This is in sharp contrast with the 
elevated responding rate when a lower dose of METH was used as the substitute, which 
possibly reflects the rats’ attempt to maintain an optimal subjective drug effect by 
self-adjusting response according to the unit drug dosage. Consistently, Cotter et al. (2015) 
showed that substitution of different concentrations of RO5203648 for METH did not 
generate varying levels of responding over and above vehicle substitute, while lowering the 
unit injection dose of METH produced a proportional increase in response rate from that 
maintained by the training dose. These results strongly suggest that TAAR1 partial agonists 
do not exhibit METH-like discriminative properties and possess low abuse liability, which is 
a desirable feature for an addiction pharmacotherapy to have. Moreover, in the present 
experiment, response level for RO5263397 was even lower than that for vehicle in the first 
substitution session. This might be an indication that the first couple of RO5263397 
self-infusions reduced METH craving and METH seeking, decreasing the high response rate 
observed early during extinction in animals receiving the vehicle substitution. This 
speculation is consistent with the inhibitory control by TAAR1 over increased DA activity 
such that TAAR1 activation with RO5263397 attenuated DA surges mediated by re-exposure 
to the drug-paired context and cues. In addition, studies found that potentiation of mGluR5 
led to facilitated extinction of cocaine-associated contextual memory (Gass and Olive, 2009) 
and overexpression of GluR1 or GluR2 subunits of AMPA receptors in the NAc shell 
promoted extinction from chronic cocaine self-administration (Sutton et al., 2003), raising the 
possibility that RO5263397 regulation over drug seeking during extinction may also involve 
TAAR1-mediated effects on glutamatergic function in the NAc. In this regard, 
TAAR1-selective agents may have the potential to aid in extinction training, besides its use in 




extinction from chronic cocaine self-administration, daily treatment with RO5263397 before 
each extinction session significantly decreased cocaine seeking, suggesting that TAAR1 
activation may inhibit the expression of cocaine reward memory and could be targeted to 
improve extinction learning.  
Taken together, the results obtained from the last set of experiments demonstrated a 
remarkable ability of TAAR1 agonists to prevent context-induced relapse of cocaine seeking 
and drug-primed reinstatement of cocaine and METH seeking. Moreover, the partial agonist, 
RO5263397, was shown to be devoid of METH-like stimulant properties and possess low 
abuse liability. These data highlight the ideal characteristics of TAAR1 agonist treatment in 
animal models of cocaine and METH addiction that are highly predictive of therapeutic 
efficacy, and support the candidacy and clinical development of novel TAAR1-based 





6 General Discussion 
Each of the previous experimental chapters are self-contained studies with their own 
discussion, therefore this chapter will briefly summarize the major findings, reiterate 
highlights and limitations, and address the implications and future research directions.  
6.1 Summary of Study  
Previous evidence has shown the functional importance of TAAR1, a newly discovered 
GPCR that is responsive to the TAs, in brain monoamine transmission and psychostimulant 
action. Consequently, it has been suggested that pharmacological targeting of TAAR1 may 
present a novel avenue for the treatment of stimulant addiction. The goal of the present thesis 
was to test this idea with the recently generated highly selective TAAR1 agonists in 
clinically-relevant animal models of addiction that are predictive of therapeutic effectiveness. 
The study consisted of three sets of experiments (experiments 1-10) that systematically 
investigated the ability of TAAR1 selective agonists to regulate a broad spectrum of 
psychostimulants effects. The aspects we have examined include locomotor-stimulation, 
behavioural and neuronal sensitization, reinforcement and motivation, neurochemical 
changes, and relapse/reinstatement, which cover several key behavioural and neuronal 
markers of addictive disorder, as measured in animal models.  
The first set of experiments demonstrated a complex modulatory role of TAAR1 in acute and 
repeated METH-induced locomotor hyperactivity, behavioural sensitization, and neuronal 
plasticity. Experiment 1 showed that the selective TAAR1 partial agonist, RO5203648, when 
administered prior to METH, time-dependently modulated METH-stimulated locomotion, 
with an early attenuation followed by a late potentiation, in a 3-h extended test session. 
Experiment 2 involved daily pretreatment with another TAAR1 partial agonist, compound M, 
prior to METH for ten consecutive days followed by a 10-day withdrawal period and a 




concurrent administration of compound M with METH did not affect the early induction or 
the late expression of METH-induced behavioural sensitization, repeated treatment of 
compound M on its own during the acquisition phase produced a dose-dependent effect on 
the probe test such that the high dose group exhibited a significantly higher level of 
locomotor response compared with the low dose group, with the average for saline group 
falling between the two groups receiving compound M alone. At the neuronal level, 
compound M pretreatment potentiated chronic METH-induced changes in c-Fos inducibility 
in both striatal and prefrontal cortical structures after METH challenge. When administered 
alone, compound M also altered subsequent METH-induced expression of c-Fos in the NAc 
core. These findings demonstrate intricate interactions between TAAR1 and METH at both 
behavioural and neuronal levels. They also provide evidence for the ability of TAAR1 to 
regulate some METH-induced neuroadaptations and maladaptive behaviours.  
The second set of experiments demonstrated that full and partial activation of TAAR1 
effectively reduced the reinforcing efficacy of cocaine and METH. Experiment 3 tested the 
effects of the full and the partial agonists, RO5256390 and RO5203648, respectively, on the 
dose-response function of cocaine self-administration. Results suggested a downward shift of 
the dose-response curve, indicating a substantial blockade of cocaine reinforcement. 
Experiments 4 and 5 explored the effects of RO5203648 and another partial agonist, 
RO5263397, on the motivation for cocaine and METH, respectively. While RO5203648 
prolonged the latency to reach BP under a PR schedule of cocaine reinforcement, 
RO5263397 reduced the BP for METH, indicating suppression of the reinforcing and 
motivational effects of these two drugs by TAAR1 partial agonism. Notably, these effects 
could not be attributed to TAAR1’s non-specific influence on general motoric or motivational 
function because RO5203648 and RO5263397 elevated the BP maintained by food under the 
same PR procedure, which additionally suggests differential TAAR1 regulation of drug and 
food reinforcement. Experiment 6 aimed at examining the physiological mechanisms 
underlying TAAR1 regulation of psychostimulants’ effects through the use of FSCV. Our 




which extends previous findings with cocaine, confirming the inhibitory control that TAAR1 
exerts over DA transmission potentiated by psychostimulants.    
The final set of experiments further evaluated the potential clinical utility of TAAR1 agonists 
in treating stimulant addiction by examining the ability of TAAR1 activation to modify 
relapse behaviour. Experiment 7 showed that partial and full activation of TAAR1, with 
RO5203648 and RO5256390, respectively, prevented context-induced relapse of cocaine 
seeking after protracted abstinence from chronic cocaine self-administration. In parallel 
experiments in which rats worked for food under a FR1 reinforcement schedule, these two 
agonists at the high dose delayed response initiation and RO5256390 also reduced the total 
number of reinforcers earned. Notwithstanding, they did not affect food-maintained 
responding at the low dose, which was still highly effective in attenuating cocaine relapse, 
suggesting that TAAR1 agonists may have a wide therapeutic window. Experiments 8 and 9 
employed an extinction-reinstatement model and demonstrated that the partial agonists, 
RO5203648 and RO5263397, reduced drug prime-induced reinstatement of cocaine or 
METH seeking, respectively, without producing cross-reinstatement when given alone, 
further strengthening the anti-relapse properties of TAAR1 agonists. Experiment 10 
examined the abuse liability of TAAR1-selective compounds using a substitution procedure. 
Results revealed that RO5263397 did not sustain self-administration when substituted for 
METH nor evoke extinction-like responses during the substitution sessions, suggesting that 
this compound is devoid of stimulant-like discriminative properties and has low abuse 
potential. Together, the present thesis provided compelling evidence for the remarkable 
ability of TAAR1 to regulate key abuse-related behavioural and physiological effects of 
cocaine and METH, demonstrating highly desirable properties of TAAR1 agonists that are 
consistent with those of an efficacious pharmacotherapy for stimulant addiction. The present 
data, along with others’ findings reported simultaneously during the course of the current 
project, strongly support the development of TAAR1 agonists as a novel generation of 




6.2 Physiology and Regulatory Effects of TAAR1 Activation 
A brain slice electrophysiology study on TAAR1 KO mice revealed elevated spontaneous 
firing rate and depolarized resting membrane potential of DA neurons in the VTA 
(Lindemann et al., 2008). These mutant mice also showed increased levels of extracellular 
DA in the NAc in an in vivo microdialysis study, and enhanced electrically evoked DA 
release in NAc brain slices measured by FSCV (Leo et al., 2014). Therefore, it has been 
suggested that TAAR1 is constitutively active or tonically activated by ambient levels of 
endogenous amines to maintain a negative control over mesolimbic DA activity (Lindemann 
et al., 2008). Importantly, TAAR1 depletion did not change Tau or the half-life of released 
DA in NAc slices, but reduced D2 autoreceptor-mediated autoinhibition in a paired-pulse 
stimulation FSCV test, suggesting that the augmented DA release in the absence of TAAR1 
did not involve alterations in DA reuptake through the DAT, but instead was caused by a less 
effective autoinhibitory regulation by the D2 autoreceptor (Leo et al., 2014). Previous 
evidence has suggested that the D2 autoreceptors maintain tonic activation under 
physiological conditions by basal concentrations of extracellular DA and spontaneous firing 
of DA neurons, which enables a tonic autoinhibitory control over DA activity (Dugast et al., 
1997, Moquin and Michael, 2009). Thus, tonic activation of TAAR1 may support the tonic 
D2 autoreceptor-mediated autoinhibition, through which TAAR1 acts as a homeostatic 
regulator of the DA system.  
Observations of TAAR1 KO mice led to the hypothesis that pharmacologically increasing 
TAAR1 activation may amplify its DA-suppressing effects, possibly through promoting the 
function of D2 autoinhibition; and TAAR1 blockade may produce the opposite effects. In 
agreement with this, the selective full agonists, RO5166017 and RO5256390, decreased the 
firing rate of DA neurons in the VTA (Revel et al., 2011, Revel et al., 2013), whereas the 
selective antagonist, EPPTB, increased it (Bradaia et al., 2009), as measured by brain slice 
electrophysiological recordings. Moreover, while RO5166017 inhibited evoked DA release in 
NAc brain slices in FSCV, EPPTB not only increased it but also blocked the effects of 




confirmation for the constitutive activity or tonic activation status of TAAR1 which 
apparently serves to keep the DA system under control. As expected, none of the treatments 
changed DA uptake kinetics, suggesting that the DAT is not involved in the action of these 
TAAR1 selective compounds (Leo et al., 2014). Subsequent investigation supports 
D2-mediated autoinhibition as a potential alternative mechanism of action by which selective 
TAAR1 agonism reduces DA release. RO5166017 synergized with quinpirole, a D2 class 
receptor agonist, to decrease evoked DA overflow in an additive manner in NAc brain slices 
in a FSCV study (Leo et al., 2014), suggesting the possibility that increasing TAAR1 
activation with selective full agonists may facilitate the autoinhibitory function of D2 
autoreceptors, which might explain their suppressant effects on somatodendritic and axonal 
terminal DA activity. However, as previously discussed, activation of TAAR1 and D2 
receptors have been demonstrated in vitro to regulate DA reuptake through the DAT in 
opposition, with the former inhibiting it and the latter enhancing it. This has led to the 
concept of “presynaptic receptor balancing” that equilibrates DA activity (Xie et al., 2008, 
Xie and Miller, 2009b). This notion appears to be inconsistent with the DAT-independent 
effects of TAAR1 ligands on DA release. Actually, it is worth re-emphasizing that both 
physical and functional interactions between TAAR1 and D2 receptors were observed in vitro 
at both pre- and postsynaptic levels such that they mutually modulate the signalling of each 
other, which is likely to be mediated via receptor heterodimerization (Espinoza et al., 2011, 
Salahpour et al., 2012, Espinoza et al., 2015a, Harmeier et al., 2015). Thus, the 
DA-suppressing effects of full TAAR1 agonism might depend preferentially on TAAR1-D2 
receptor complex formation, circumventing the DA reuptake machinery via the DAT. 
Moreover, D2 autoreceptors can regulate DA activity through several mechanisms that do not 
necessarily involve increasing DAT-mediated uptake. These mechanisms include inhibiting 
DA exocytosis from the axon terminals (Palij et al., 1990, Benoit-Marand et al., 2001, 
Phillips et al., 2002), decreasing DA synthesis through suppressing tyrosine hydroxylase 
(Kehr et al., 1972, Wolf and Roth, 1990), and modulating DA neuronal firing by activating a 




Lacey et al., 1987, Courtney et al., 2012). Nevertheless, it has been suggested that the 
activation of D2 autoreceptor-mediated DAT regulation requires a saturating amount of 
extracellular DA that is beyond the levels raised by tonic background firing of DA neurons 
and by stimulations delivered via single electrical pulse (which was used in the above FSCV 
study) (Kennedy et al., 1992, Benoit‐Marand et al., 2011). Thus, easier detection of changes 
in DA uptake could be expected in situations where prolonged trains of stimulation are 
applied that trigger strong D2 autoreceptor activation, thereby supporting the putative role of 
the DAT in the modulation of DA transmission by selective TAAR1 ligands.  
Further complicating the picture are the findings with partial TAAR1 agonists, which could 
potentially act as net agonists or antagonists depending on the level of receptor stimulation by 
endogenous ligands. Electrophysiological recordings of mice brain slice revealed that the 
TAAR1 partial agonists, RO5263397 and RO5203648, increased the firing rate of VTA DA 
neurons (Revel et al., 2012b, Revel et al., 2013), as did the antagonist, EPPTB (Bradaia et al., 
2009). These findings further support the notion that TAAR1 is constitutively active or 
tonically activated by ambient levels of agonists, whereby partial agonism produces 
antagonistic-like effects at TAAR1. The resultant reduction in TAAR1 activity liberates DA 
neuronal firing from the tonic autoinhibitory control by tonic D2 autoreceptor activation that 
is potentially sustained in part by TAAR1 tonic activity. However, the TAAR1 partial 
agonism-induced enhancement of somatodendritic DA firing activity did not readily translate 
into increased terminal DA transmission in the NAc, as RO5203648 had no effects on NAc 
DA release in an in vivo microdialysis experiment (Cotter et al., 2015) or on electrically 
evoked DA overflow in NAc brain slice in FSCV (Pei et al., 2014). Similarly, in the present 
FSCV study (experiment 6), RO5263397 did not alter evoked DA outflow in the NAc core 
when applied by itself. Several factors might contribute to this dissociation. Firstly, the extent 
to which local TAAR1 regulation observed in brain slice preparations reflects the effects of 
systemic TAAR1 administration on the VTA is unclear. Apart from being regulated by local 
VTA D2 autoreceptors, VTA DA activity is subjected to a long-loop negative feedback 




2001). Thus TAAR1 regulation of NAc DA may provide an additional source of control over 
VTA DA by adjusting the signalling of D1 and D2 receptors which determine the activity of 
the feedback loop. Moreover, the VTA receives a variety of non-DA afferents from other 
brain areas, which also contribute to the regulation of VTA DA activity, including 
serotonergic input from dorsal and median raphe nucleus (Moore et al., 1978, Hervé et al., 
1987, Broderick and Phelix, 1997, Vertes et al., 1999), noradrenergic projections from the 
locus coeruleus (Herve et al., 1982, Grenhoff et al., 1993), cholinergic fibres from the 
pedunculopontine tegmental nucleus and the laterodorsal tegmental nucleus (Oakman et al., 
1995, Blaha et al., 1996), and GABAergic input originating from the NAc, ventral pallidum 
and the pedunculopontine nucleus (Waalas and Fonnum, 1980, Klitenick et al., 1992, Charara 
et al., 1996). Because TAAR1 has been shown to localize in some of those distant regions 
and interact with the respective neurotransmitters, TAAR1 activation therein may have an 
impact on VTA DA through fine-tuning of these non-DA-mediated pathways. Most 
importantly, glutamatergic projections from the medial PFC form the predominant extrinsic 
source of excitatory input to the VTA (Johnson and North, 1992, Adell and Artigas, 2004) 
and stimulation of the PFC causes glutamate release in the VTA and burst firing of VTA DA 
neurons (Murase et al., 1993, Tong et al., 1996, Rossetti et al., 1998). Given the 
aforementioned evidence implicating TAAR1 in prefrontal glutamatergic functioning, 
TAAR1 ligands may influence VTA DA activity through regulating prefrontal glutamatergic 
output into the VTA. Therefore, taken together, TAAR1 is able to regulate VTA DA activity 
both directly through interacting with local DA and indirectly by interfering with distant DA 
or non DA neurotransmitters, which cannot be fully captured in isolated VTA brain slices.  
On the other hand, although the synaptic release of DA in the NAc is thought to originate 
from neuronal firing of DA neurons in the VTA, DA release exhibits a dynamic pattern that 
is controlled by multiple adaptive processes in the terminal (Montague et al., 2004, Sombers 
et al., 2009). Factors such as the rate of DA biosynthesis and vesicular packing, inhibition of 
release through presynaptic D2 autoreceptors, and recycling of released DA through reuptake 




2004, Kita et al., 2007). Accordingly, NAc TAAR1 may exert local effects on DA release 
through interacting with terminal D2 autoreceptors and DAT. In addition, glutamatergic 
afferents from the PFC and the BLA play an important role in regulating DA output in the 
NAc, which might or might not depend on activation of DA cell bodies in the VTA (Taber 
and Fibiger, 1995, Jackson and Moghaddam, 2001, Howland et al., 2002). Thus, TAAR1 
expressed in the amygdala and PFC may act on glutamate efferents to the NAc whereby it 
influences terminal DA activity.  
It is, therefore, reasonable to expect differential effects of TAAR1 ligands on DA activity in 
the somatodendritic and terminal regions. Nevertheless, the fact that the antagonist, EPPTB, 
did increase evoked DA release in NAc brain slices (Leo et al., 2014), which is consistent 
with its potentiating effects on VTA DA neuron firing, implies intrinsic difference in the 
nature of DA regulation by TAAR1 antagonism and partial agonism. While the antagonist in 
principle abolishes TAAR1 activation and thereby reduces D2 autoreceptor-mediated 
autoinhibition, the partial agonist maintains TAAR1 activity within a submaximal range that 
is still sufficient to sustain a functional D2-mediation. Importantly, the partial agonists, 
RO5203648 and RO5263397, effectively prevented cocaine- or METH-induced DA overflow 
in the NAc (Pei et al., 2014, Pei et al., 2016b), demonstrating their ability to suppress DA 
activity in situations of hyperdopaminergia. Similarly, in behavioural models of 
hyperdopaminergia, the two partial agonists blocked locomotor hyperactivity induced by 
psychostimulants or genetic deletion of the DAT, behaving as the full agonists, RO5256390 
and RO5166017 (Revel et al., 2011, Revel et al., 2012b, Revel et al., 2013). In this regard, 
partial TAAR1 agonists may act to stabilize the DA system, decreasing DA when there is 
excessive transmission but also helping maintain DA at sustainable levels under basal or 
hypodopaminergic conditions. This idea of TAAR1 as a biological sentinel fits well with the 
results from experiment 1 showing that RO5203648 time-dependently modulated 
METH-stimulated locomotion, with an early attenuation followed by a late potentiation when 
the effects of METH began to subside. Furthermore, this state-dependent DA regulation by 




addiction over conventional medications, especially given that DA fluctuates dramatically 
during the addiction cycle, encompassing both “high” (intoxication and relapse) and “low” 
phases (withdrawal).  
6.3 TAs vs. Selective TAAR1 Agonists  
It is important to understand the differences between TAAR1’s endogenous ligands and 
selective agonists in the regulation of DA activity. The TAs, such as β-PEA and tyramine, 
inhibited the spontaneous discharge rate of DA neurons in the VTA measured by both in vitro 
and in vivo electrophysiology (Geracitano et al., 2004, Ishida et al., 2005, Lindemann et al., 
2008) and reduced evoked striatal DA release in in vivo voltammetry experiments (Stamford 
et al., 1986). However, in vivo microdialysis revealed that local or systemic β-PEA increased 
extracellular DA levels in the VTA and the striatum including the NAc (Nakamura et al., 
1998, Sotnikova et al., 2004, Ishida et al., 2005, Murata et al., 2009), which contradicts the 
apparent DA-suppressant effects of TAs observed in the electrophysiology and voltammetry 
studies. In fact, as previously described, β-PEA has been considered as an “endogenous 
amphetamine” due to its ability to mimic the major DA-releasing and 
locomotor/stereotypy-stimulating effects of amphetamines (Jackson, 1975, Tinklenberg et al., 
1978, Ortmann et al., 1984, Dourish, 1985, Gianutsos and Chute, 1986, Philips, 1986, Bailey 
et al., 1987, Barroso and Rodriguez, 1996, Janssen et al., 1999). Evidence indicates that 
β-PEA-induced DA release is calcium ion-independent and involves stimulating the efflux of 
newly synthesized DA from reserpine-insensitive pools via carrier-dependent and 
independent mechanisms (Geracitano et al., 2004, Sotnikova et al., 2004, Ishida et al., 2005). 
Therefore, it has been suggested that the inhibition of midbrain DA neuron firing by β-PEA 
and tyramine occurs via indirect activation of D2 autoreceptor-mediated autoinhibition that is 
mediated by an increase in DA release. In support of this, the inhibitory effects of these TAs 
were abolished when D2 receptors were selectively antagonized or the synthesis of DA was 
blocked (Geracitano et al., 2004, Ishida et al., 2005). Similarly, the ability of β-PEA to reduce 
electrically evoked striatal DA release may also involve the activation of D2 autoreceptors, 




However, the mechanisms underlying TAs modulation of dopaminergic activity are complex 
and may involve both inhibitory and excitatory effects. Firstly, β-PEA acting at TAAR1 leads 
to inhibited uptake and increased efflux of DA through the DAT, which may partially 
account for its DA-releasing effects (Xie and Miller, 2008). Intriguingly, the fact that TAAR1 
KO mice exhibited elevated discharge rate of VTA DA neurons suggests that, under 
physiological conditions, TAs may exert tonic inhibitory control over DA neurons through 
TAAR1, which might rely on TAAR1 interaction with the D2 autoreceptors. Moreover, 
β-PEA and tyramine have been shown to depress D2 autoreceptor-activated GIRK currents 
on SNr pars compacta (SNpc) DA cells in a TAAR1-independent manner (Ledonne et al., 
2010). These two TAs also suppressed GABAB-mediated slow inhibitory postsynaptic 
potential and GIRK currents on DA neurons in the VTA and SNpc (Federici et al., 2005). 
Thus, TAs may potentially increase the excitability of midbrain DA neurons by antagonizing 
D2 autoreceptor- and GABAB-mediated inhibition of DA. On the other hand, β-PEA and 
tyramine were able to reduce GABAB-mediated presynaptic inhibition of GABA release to 
SNpc DA neurons, leading to increased GABAergic input and thus enhanced DA inhibition 
(Berretta et al., 2005). It has been suggested that the inhibitory effects of TAs on DA neuron 
prevail over the excitatory effects under normal conditions, but pathological conditions may 
overturn the balance (Ledonne et al., 2011).  
On the contrary, unlike TAs which may exert effects on targets other than TAAR1, rendering 
it extremely difficult to untangle their actions, the selective agonists bind exclusively to 
TAAR1, making it possible to decipher the functional role of TAAR1. As mentioned before, 
the ability of the selective full agonists to inhibit the spontaneous discharge of VTA DA 
neurons and to reduce electrically evoked NAc DA release is most likely mediated by a 
potentiated D2 autoreceptor-mediated autoinhibition as a result of structural and functional 
interactions between TAAR1 and D2 autoreceptors. Moreover, given the ex vivo observation 
that TAAR1 activation releases DA through altering the uptake and efflux function of the 
DAT, it is reasonable to suspect that the triggering of D2-mediated autoinhibition may be due 




action of these selective TAAR1 agonists is not fully supported by current evidence and 
further research should explore this possibility using techniques monitoring DA release in 
real time.   
6.4 Non-Drug Related Effects of TAAR1 Agonists 
Apart from demonstrating the remarkable therapeutic potential of TAAR1 selective agonists 
in modulating effects associated with psychostimulant abuse, the current work also revealed 
several interesting findings that are relevant to the clinical application of TAAR1-based 
pharmacotherapies. Experiments 4 and 5 showed that the partial TAAR1 agonists, 
RO5203648 and RO5263397, enhanced the motivation for food, evidenced by an increased 
BP for food self-administration under the PR reinforcement schedule, in direct contrast with 
the clear-cut inhibition these two agonists produced on cocaine and METH-maintained BP. 
Complicating the picture is the finding from experiment 7 which showed that, under a FR1 
reinforcement schedule, RO5203648 delayed the initiation of responding for food without 
affecting the total number of reinforcers obtained; and the full agonist, RO5256390, not only 
delayed response but also reduced the total number of pellets obtained. It is important to bear 
in mind that these suppressant effects on food-maintained response were absent at the low 
dose, which was still effective at preventing cocaine relapse. Together, the immediate 
message arising from these food experiments is that TAAR1 activation has differential 
regulatory effects on behaviour mediated by drug and natural reward. However, the exact role 
of TAAR1 in food-related process remains to be fully elucidated. A relevant finding showed 
that the selective TAAR1 partial agonist, RO5263397, prevented body weight gain and fat 
accumulation induced by the atypical antipsychotic olanzapine which are noticeable side 
effects produced by this type of drugs that compromise treatment compliance (Revel et al., 
2013). In addition, when administered alone, RO5263397 exhibited a propensity to decrease 
body weight and fat mass (Revel et al., 2013). Thus, it seems that TAAR1 selective agonists 
may possess anti-obesity properties, which would be consistent with the reduced food intake 
observed under a FR1 reinforcement schedule. This reduction is not due to a depression of 




but instead might depend on TAAR1 activation of the peripheral nervous system. Studies 
have identified the expression of TAAR1 mRNA in the rat adipose tissue where TAAR1 
activation facilitates fat depletion (Mitchell et al., 2008). TAAR1 is found in peripheral 
organs that are closely associated with the control of food absorption, energy homeostasis, 
and blood glucose concentration, including the stomach, intestine, and insulin-secreting β 
cells of the pancreas (Revel et al., 2013). Accordingly, it has been postulated that TAAR1 
may be involved in the regulation of insulin secretion and body fat metabolism (Mitchell et 
al., 2008, Revel et al., 2013). Actually, the dysregulation of the TAs, especially PEA, has 
long been implicated in metabolic disorders, such as diabetes (Mosnaim et al., 1979, 
Mosnaim et al., 1982). Moreover, octopamine and synephrine were shown to stimulate 
metabolism and may potentially promote weight loss (Bour et al., 2003, Haaz et al., 2006, de 
Oliveira et al., 2013). Notwithstanding, the body weight regulatory effects of TAAR1 should 
not be considered as a limiting factor that hinders the application of TAAR1-based therapies 
in the treatment of addictive disorders. In our experiments, animals, which were given 
unlimited food or kept on a maintenance diet, did not show significant weight drop following 
either acute or repeated treatment with TAAR1 selective agonists. It is thus possible that the 
role of TAAR1 in weight modulation only becomes apparent under conditions of metabolic 
disturbance, which prompts further evaluation of TAAR1 agonists to treat metabolic diseases 
such as diabetes and obesity and to relieve side effects associated with antipsychotic 
treatment.  
Apart from body weight regulation, other non-drug specific processes have also been 
suggested to involve TAAR1 activity, which encourages the versatile usage of TAAR1-based 
compounds in both clinical and non-clinical contexts beyond the addiction field (Pei et al., 
2016a). For example, given that TAAR1 is expressed in the amygdala, which is a cardinal 
control centre for emotional regulation (Phelps and LeDoux, 2005), and that TA deficiency 
has been historically linked to affective disorders such as depression and bipolar disorder 
(Sandler et al., 1979, Karoum et al., 1982, Wolf and Mosnaim, 1983, Sabelli et al., 1995), it 




in the actions of antidepressants and anxiolytics. Accordingly, TAAR1 selective agonists 
were shown to reduce immobility time in a forced-swim test and prevent stress-induced 
hyperthermia, supporting the anti-depressant and anxiolytic properties of TAAR1 (Revel et 
al., 2011, Revel et al., 2012b, Revel et al., 2013). Moreover, these compounds improved 
performance in tasks requiring sustained attention and response inhibition, and increased 
wakefulness in a manner similar to caffeine without increasing locomotion and core body 
temperature, which are characteristic side effects of caffeine (Revel et al., 2012b, Revel et al., 
2013). Together, these findings support the broad application of TAAR1-selective agents as 
mood stabilisers, cognitive enhancers, and general health supplements.  
Most importantly, cumulative evidence suggests the notion that pharmacologically targeting 
TAAR1 may provide a novel avenue for the treatment of Parkinson’s disease and psychosis. 
Parkinson’s disease is characterized by a progressive degeneration of dopaminergic cells 
along the nigrostriatal pathway and subsequent loss of DA in the striatum (Lotharius and 
Brundin, 2002). L-DOPA treatment remains the gold standard pharmacotherapy for 
Parkinson’s disease due to its ability to partially replenish striatal DA levels. However, 
chronic L-DOPA produces disabling motor side effects such as dyskinesia and motor 
fluctuation (Lloyd et al., 1975, Dauer and Przedborski, 2003). Given the ability of TAAR1 to 
downregulate DA transmission, medications that suppress TAAR1 activation level may hold 
promise for treating this disease.  
In the case of psychosis, it is shown that TAAR1 KO mice exhibited elevated brain 
high-affinity D2 receptors and dopaminergic supersensitivity (Wolinsky et al., 2007), which 
resembles the neurological modifications identified in patients with schizophrenia (Laruelle 
et al., 1996, Abi-Dargham et al., 1998, Seeman, 2011). These TAAR1 mutant mice also had 
significant deficits in sensorimotor gating, which is a known behavioural signature of 
schizophrenia involving both DA- and glutamate-mediated mechanisms (Wan et al., 1995, 
Wan and Swerdlow, 1996, Geyer et al., 2001). Moreover, all human TAAR genes are tightly 




schizophrenia in linkage or association studies (Straub et al., 1995, Cao et al., 1997, 
Lindholm et al., 1999, Borowsky et al., 2001, Bunzow et al., 2001). Together, these findings 
suggest that abnormal TAAR1 function may contribute to the aetiology and neuropathology 
of psychosis, and TAAR1-based treatments may modulate psychotic symptoms through 
interacting with the DA and glutamate system.  
6.5 Limitations and Future Directions  
The current body of work has several limitations that should be addressed in future 
investigations. Firstly, in experiment 2, compound M concurrent administration with METH 
had no effect on METH-induced hyperlocomotion and behaviour sensitization. This finding 
is inconsistent with other studies showing that partial TAAR1 agonism with RO5203648 or 
RO5263397 blocked both the induction and expression of behavioural sensitization induced 
by METH or cocaine (Thorn et al., 2014b, Cotter et al., 2015); and contradicts the notion that 
TAAR1 activation downregulates DA activity that is potentiated by psychostimulants. Apart 
from a different pharmacokinetic/dynamic profile (which is not well suited for rat studies) or 
a therapeutic dose range beyond the tested dosage for compound M, we could not think of 
other explanations for the lack of effect. Thus, one direction for future research is to fully 
characterize the pharmacological properties of compound M (since it is being developed for 
human use) and establish its therapeutic window. Moreover, our data also revealed a 
dose-dependent effect of compound M treatment alone on the subsequent locomotor response 
to a METH probe, suggesting that repeated compound M stimulation at TAAR1 might 
produce neuroadaptive changes that render the neuronal response to METH hypersensitive or 
hyposensitive, depending on the concentration of compound M. This could be linked to the 
cross-sensitization between RO5203648 and METH reported by Cotter et al. (2015), which 
suggests that chronic TAAR1 partial activation may produce neuroadaptations in a way 
similar to METH. In addition, our data also imply the possibility that lower doses of partial 
agonists might produce the opposite effects. In this regard, further research should unravel 




activation/deactivation and its functional implications in relation to the actions of 
psychostimulants.  
Another limitation of the project is that, although we aimed to model in rats some of the 
aspects of the addiction cycle that are characterized by DA fluctuations, we did not capture 
all the situations that human addicts may encounter. Our data strongly support the therapeutic 
potential of TAAR1 selective agonists in modulating behaviours related to drug intoxication 
and relapse to drug seeking, but did not provide information on their effects on the negative 
withdrawal symptoms, which are an important drive for drug craving and drug seeking. Since 
withdrawal from chronic drug use leads to reduced DA transmission, which may underlie 
anhedonia and reward hypofunction (Robertson et al., 1991, Weiss et al., 1992), selective 
partial agonism of TAAR1 may improve the withdrawal state through increasing DA 
transmission. Future studies should be directed to address this question.  
Furthermore, the current study did not test the effects of TAAR1 agonists on the locomotor 
response induced by acute and repeated cocaine. Although both cocaine and METH produce 
their reinforcing and psychostimulating effects by dramatically increasing extracellular DA 
level, they have different mechanisms of action. METH competes with DA at the DAT for 
reuptake, causes transporter internalization, and reverses the transport direction of the DAT 
(Sandoval et al., 2001, Elliott and Beveridge, 2005). METH also depletes DA vesicular 
storage through interfering with vesicular monoamine transporter-2, leading to increased 
cytosolic DA ready for reverse transport by the DAT (Sulzer et al., 2005, Fleckenstein et al., 
2009). On the contrary, cocaine binds directly to the DAT, blocking DA reuptake from the 
extracellular space and thus leading to DA accumulation in the synaptic cleft (Volkow et al., 
1997, Beuming et al., 2008). Critically, METH itself is a potent agonist at TAAR1 but 
cocaine is not. METH stimulation of TAAR1 leads to a series of cellular phosphorylation 
cascades resulting in functional regulation of the DAT, that partially accounts for its 
DA-releasing effects (Xie and Miller, 2009a). Therefore, the regulation of METH’s effects by 




involving direct interaction of the agonist with METH at TAAR1. In experiment 6, we used 
FSCV to show that partial TAAR1 agonism with RO5263397 blocked METH-induced DA 
overflow in the NAc, which is consistent with a recent report using cocaine and RO5203648 
(Pei et al., 2014). However, as revealed in experiment 1, the TAAR1-mediated attenuation of 
METH-induced locomotor response was followed by a potentiation when METH’s effect 
began to subside, which suggests a DA state-dependent modulation by TAAR1 partial 
agonist and potentially reflects the dynamics of TAAR1 activity in response to the 
competition between METH and the partial agonist. This later potentiation effect of TAAR1 
could not be captured in the FSCV experiment because the drug-induced DA accumulation 
was still at a moderately high level at the end of the 20 min recording period (Figure 4.5e). 
Therefore, it is uncertain whether TAAR1 partial agonism would upregulate DA transmission 
after the effects of cocaine wane off. The ideal way to test this question would be to examine 
the effects of RO5203648 on cocaine-induced locomotor response during an extended session 
(3-h), allowing a straightforward comparison with the METH experiment reported here. 
Based on our hypothesis that TAAR1 partial agonism has the unique ability to stabilize DA 
transmission through bidirectional regulation of DA regardless of the drug’s affinity at 
TAAR1, we expect a similar time-dependent modulation as the net behavioural outcome for 
cocaine and METH.  
Finally, while the current project utilized extensive behavioural models to characterize the 
pharmacotherapeutic properties of TAAR1 agonists as treatment for stimulant addiction, less 
attention has been drawn to the neuronal basis of the observed effects. Physiological data was 
collected in experiment 2, where compound M was shown to modulate chronic 
METH-induced changes in early gene inducibility, and in experiment 6, in which we showed 
that RO5263397 prevented acute METH-evoked DA release in the NAc measured by FSCV. 
Although these findings are informative, they could not directly explain all the behavioural 
data, especially those involving chronic METH treatment, including the relapse and 
reinstatement experiments, because the response to drugs is different between naïve and 




psychostimulant-induced behaviour, animals whose brains are used for the FSCV should 
undergo identical chronic METH treatment as those in the behavioural models. Future studies 
should aim at deciphering the underlying neurophysiological mechanisms of 
TAAR1-mediated effects, not only at neurochemical levels but also at cellular and molecular 
levels. Only by doing so will we fully understand the functional role of TAAR1 in regulating 
psychostimulant action and design more efficacious TAAR1-based therapies for the treatment 
of addiction.  
6.6 Conclusion 
To conclude, the current thesis directly tested the hypothesis that pharmacologically targeting 
TAAR1 may present a novel approach for treating psychostimulant addiction. This was 
achieved through a systematic investigation of TAAR1 regulation of key behavioural and 
neuronal markers of METH and cocaine abuse. Our findings provided evidence of the 
complex bidirectional modulation of the locomotor-stimulating effects of METH by TAAR1 
partial agonists, and demonstrated the remarkable ability of full and partial TAAR1 activation 
to block the reinforcing and motivational properties of cocaine and METH. Furthermore, the 
TAAR1 selective agonists effectively prevented cocaine and METH-induced relapse of drug 
seeking, further strengthening the therapeutic potential of TAAR1-based compounds to treat 
addiction disorders. Moreover, our data indicated differential regulation by TAAR1 on food 
and drug reinforcement and suggested a wide therapeutic window for TAAR1-based 
pharmacotherapies. At the neurochemical level, we showed for the first time that TAAR1 
partial agonism completely reduced METH-evoked DA overflow in the NAc, adding to the 
support for TAAR1’s inhibitory control over DA transmission that is potentiated by 
stimulants. Finally, these agonists did not exhibit METH-like discriminative effects or 
produce cross-reinstatement with METH or cocaine, indicating low abuse liability, which is a 
desirable feature for a pharmacotherapy to have. Future research should fully elucidate the 
pharmacological properties and the therapeutic window of compound M as well as other 
selective TAAR1 agonists and further explore the proposed TAAR1 “DA state-dependent 




addition, comparing the ability of TAAR1 partial agonist to modulate the 
locomotor-stimulating effects of cocaine with those of METH in an extended session would 
provide valuable insight into the role of TAAR1 in the actions of METH and cocaine. Lastly, 
more efforts should be devoted to understand the neurophysiological effects of acute and 
repeated TAAR1 agonism and antagonism, the neural basis of TAAR1 ability to prevent 
relapse after protracted withdrawal from chronic drug exposure, and the mechanisms 
mediating the biphasic modulation of DA transmission by TAAR1 partial agonists. However, 
the current study represents an important step towards understanding the pivotal role of 
TAAR1 in the functional regulation of DA transmission and psychostimulant action. The data 
presented here provide new and substantial evidence of potential therapeutic effectiveness of 
TAAR1 agonists in modulating abuse-related effects of METH and cocaine, and strongly 
support the development of TAAR1-based therapies as a new generation of medicines for the 
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